activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	1736609	CHEMBL870945	Inhibition of CDK9	B	Cc1cc(-c2cnc(Nc3cnc(CN4CCN(C)CC4)cn3)s2)nc(OC2CCCCC2)n1		CHEMBL210540	=	IC50	nM	2500.0	CHEMBL3116	Homo sapiens	IC50	nM	2500.0
	1736609	CHEMBL870945	Inhibition of CDK9	B	Cc1cc(-c2cnc(Nc3cnc(CN4CCN(C)CC4)cn3)s2)nc(OC2CCCCC2)n1		CHEMBL210540	=	IC50	nM	2500.0	CHEMBL3116	Homo sapiens	IC50	nM	2500.0
	1736671	CHEMBL870945	Inhibition of CDK9	B	Cc1cc(-c2cnc(Nc3ccccn3)s2)nc(OC2CCCCC2)n1		CHEMBL427045	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	1736690	CHEMBL870945	Inhibition of CDK9	B	Cc1cnc(OC2CCCCC2)nc1-c1cnc(Nc2ccccn2)s1		CHEMBL212049	=	IC50	nM	26.0	CHEMBL3116	Homo sapiens	IC50	nM	26.0
	1736710	CHEMBL870945	Inhibition of CDK9	B	c1ccc(Nc2ncc(-c3ccnc(OC4CCCCC4)n3)s2)nc1		CHEMBL424696	=	IC50	nM	2.5	CHEMBL3116	Homo sapiens	IC50	nM	2.5
	2051602	CHEMBL942743	Inhibition of CDK9	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	1644.0	CHEMBL3116	Homo sapiens	Ki	uM	1.644
	2137304	CHEMBL936787	Inhibition of Cdk9	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
	2250823	CHEMBL1019786	Inhibition of CDK9	B	CCC1CNC(=O)c2cc(-c3ccnc(N)n3)[nH]c21		CHEMBL526092	=	IC50	nM	73.0	CHEMBL3116	Homo sapiens	IC50	uM	0.073
	2250824	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)C(CCC(F)(F)F)CNC3=O)n1		CHEMBL498200	=	IC50	nM	395.0	CHEMBL3116	Homo sapiens	IC50	uM	0.395
	2250825	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)C(CCC(F)(F)F)CNC3=O)n1		CHEMBL498200	=	IC50	nM	218.0	CHEMBL3116	Homo sapiens	IC50	uM	0.218
	2250826	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1		CHEMBL524266	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	uM	0.028
	2250827	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)[C@H](CCF)CNC3=O)n1		CHEMBL451570	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	uM	0.096
	2250828	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)C(C2CCC2)CNC3=O)n1		CHEMBL497995	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	uM	0.096
	2250829	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)C(C2CCC2)CNC3=O)n1		CHEMBL497995	=	IC50	nM	83.0	CHEMBL3116	Homo sapiens	IC50	uM	0.083
	2250830	CHEMBL1019786	Inhibition of CDK9	B	CC(C)C1CNC(=O)c2cc(-c3ccnc(N)n3)[nH]c21		CHEMBL445340	=	IC50	nM	73.0	CHEMBL3116	Homo sapiens	IC50	uM	0.073
	2250831	CHEMBL1019786	Inhibition of CDK9	B	CC(C)C1CNC(=O)c2cc(-c3ccnc(N)n3)[nH]c21		CHEMBL445340	=	IC50	nM	31.0	CHEMBL3116	Homo sapiens	IC50	uM	0.031
	2250832	CHEMBL1019786	Inhibition of CDK9	B	CCC1CNC(=O)c2cc(-c3ccnc(N)n3)[nH]c21		CHEMBL526092	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	uM	0.017
	2250833	CHEMBL1019786	Inhibition of CDK9	B	Nc1nccc(-c2cc3c([nH]2)CCNC3=O)n1		CHEMBL402272	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	uM	0.029
	2250834	CHEMBL1019786	Inhibition of CDK9	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	uM	0.034
	2254188	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	IC50	nM	458.0	CHEMBL3116	Homo sapiens	IC50	uM	0.458
	2254189	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NCC3CCNCC3)s2)o1		CHEMBL524629	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254190	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NCC3CCCCC3)s2)o1		CHEMBL495754	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254191	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](N)CC3)s2)o1		CHEMBL496567	=	IC50	nM	355.0	CHEMBL3116	Homo sapiens	IC50	uM	0.355
	2254192	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@@H](N)CC3)s2)o1		CHEMBL496568	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254193	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](O)CC3)s2)o1		CHEMBL495557	=	IC50	nM	3500.0	CHEMBL3116	Homo sapiens	IC50	uM	3.5
	2254194	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NC3CCCC(N)C3)s2)o1		CHEMBL505474	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254195	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NC3CCCC(O)C3)s2)o1		CHEMBL495558	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254196	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NC3CCCCC3)s2)o1		CHEMBL496785	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254197	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(NC3CCNCC3)s2)o1		CHEMBL509772	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2254198	CHEMBL1002042	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	B	CC(C)(C)c1cnc(CSc2cnc(N)s2)o1		CHEMBL507536	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	2470093	CHEMBL1032235	Inhibition of CDK9 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL3116	Homo sapiens	INH	%	10.0
	2586254	CHEMBL1018128	Inhibition of CDK9	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)ncc2F)n1C(C)C		CHEMBL509406	=	Activity	uM	0.013	CHEMBL3116	Homo sapiens	Activity	uM	0.013
	2586255	CHEMBL1018128	Inhibition of CDK9	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)ncc2F)n1C(C)C		CHEMBL462385	=	Activity	uM	0.003	CHEMBL3116	Homo sapiens	Activity	uM	0.003
	2586256	CHEMBL1018128	Inhibition of CDK9	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CC[C@H](N(C)C)C4)cc3)ncc2F)n1C(C)C		CHEMBL460102	=	Activity	uM	0.005	CHEMBL3116	Homo sapiens	Activity	uM	0.005
	2586257	CHEMBL1018128	Inhibition of CDK9	B	Cc1ncc(-c2nc(Nc3ccc(C(=O)N4CCCN(C)CC4)cc3)ncc2F)n1C(C)C		CHEMBL462192	=	Activity	uM	0.012	CHEMBL3116	Homo sapiens	Activity	uM	0.012
	2592874	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	C[C@@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1		CHEMBL510566	=	IC50	nM	4100.0	CHEMBL3116	Homo sapiens	IC50	uM	4.1
	2592875	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	C[C@@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1		CHEMBL452602	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	uM	0.12
	2592876	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	C[C@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1		CHEMBL452601	=	IC50	nM	770.0	CHEMBL3116	Homo sapiens	IC50	uM	0.77
	2592877	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	C[C@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1		CHEMBL455450	=	IC50	nM	3200.0	CHEMBL3116	Homo sapiens	IC50	uM	3.2
	2592878	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC1CNCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1		CHEMBL454646	=	IC50	nM	270.0	CHEMBL3116	Homo sapiens	IC50	uM	0.27
	2592879	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CN1		CHEMBL454645	=	IC50	nM	370.0	CHEMBL3116	Homo sapiens	IC50	uM	0.37
	2592880	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC1NCCCC1C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1		CHEMBL508506	=	IC50	nM	1600.0	CHEMBL3116	Homo sapiens	IC50	uM	1.6
	2592881	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCCNC3)s2)o1		CHEMBL297570	=	IC50	nM	550.0	CHEMBL3116	Homo sapiens	IC50	uM	0.55
	2592882	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC(C)C1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1		CHEMBL509012	=	IC50	nM	810.0	CHEMBL3116	Homo sapiens	IC50	uM	0.81
	2592883	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CCC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1		CHEMBL455195	=	IC50	nM	680.0	CHEMBL3116	Homo sapiens	IC50	uM	0.68
	2592884	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1		CHEMBL455194	=	IC50	nM	1500.0	CHEMBL3116	Homo sapiens	IC50	uM	1.5
	2592885	CHEMBL965586	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	IC50	nM	550.0	CHEMBL3116	Homo sapiens	IC50	uM	0.55
	2903847	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Kd	nM	3000.0	CHEMBL3116	Homo sapiens	Kd	nM	3000.0
	2903848	CHEMBL1063701	Binding constant for full-length CDK9	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903849	CHEMBL1063701	Binding constant for full-length CDK9	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	190.0	CHEMBL3116	Homo sapiens	Kd	nM	190.0
	2903850	CHEMBL1063701	Binding constant for full-length CDK9	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903851	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903852	CHEMBL1063701	Binding constant for full-length CDK9	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Kd	nM	76.0	CHEMBL3116	Homo sapiens	Kd	nM	76.0
	2903853	CHEMBL1063701	Binding constant for full-length CDK9	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903854	CHEMBL1063701	Binding constant for full-length CDK9	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903855	CHEMBL1063701	Binding constant for full-length CDK9	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903856	CHEMBL1063701	Binding constant for full-length CDK9	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903857	CHEMBL1063701	Binding constant for full-length CDK9	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903858	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903859	CHEMBL1063701	Binding constant for full-length CDK9	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903860	CHEMBL1063701	Binding constant for full-length CDK9	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903861	CHEMBL1063701	Binding constant for full-length CDK9	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	6.4	CHEMBL3116	Homo sapiens	Kd	nM	6.4
	2903862	CHEMBL1063701	Binding constant for full-length CDK9	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903863	CHEMBL1063701	Binding constant for full-length CDK9	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903864	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2903865	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904651	CHEMBL1063701	Binding constant for full-length CDK9	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	470.0	CHEMBL3116	Homo sapiens	Kd	nM	470.0
	2904652	CHEMBL1063701	Binding constant for full-length CDK9	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904653	CHEMBL1063701	Binding constant for full-length CDK9	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904654	CHEMBL1063701	Binding constant for full-length CDK9	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904655	CHEMBL1063701	Binding constant for full-length CDK9	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904656	CHEMBL1063701	Binding constant for full-length CDK9	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904657	CHEMBL1063701	Binding constant for full-length CDK9	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904658	CHEMBL1063701	Binding constant for full-length CDK9	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904659	CHEMBL1063701	Binding constant for full-length CDK9	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904660	CHEMBL1063701	Binding constant for full-length CDK9	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904661	CHEMBL1063701	Binding constant for full-length CDK9	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904662	CHEMBL1063701	Binding constant for full-length CDK9	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904663	CHEMBL1063701	Binding constant for full-length CDK9	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904664	CHEMBL1063701	Binding constant for full-length CDK9	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	100.0	CHEMBL3116	Homo sapiens	Kd	nM	100.0
	2904665	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904666	CHEMBL1063701	Binding constant for full-length CDK9	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904667	CHEMBL1063701	Binding constant for full-length CDK9	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904668	CHEMBL1063701	Binding constant for full-length CDK9	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2904669	CHEMBL1063701	Binding constant for full-length CDK9	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	2921403	CHEMBL1052889	Inhibition of CDK9 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	97.0	CHEMBL3116	Homo sapiens	Activity	%	97.0
	3062452	CHEMBL1048645	Binding affinity to human CDK9 at 200 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595545	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	3063587	CHEMBL1045173	Binding affinity to human CDK9 at 500 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595546	=	Activity	%	92.0	CHEMBL3116	Homo sapiens	Activity	%	92.0
	3063677	CHEMBL1038888	Binding affinity to human CDK9 at 50 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL609010	=	Activity	%	99.0	CHEMBL3116	Homo sapiens	Activity	%	99.0
	3065857	CHEMBL1069289	Inhibition of CDK9 at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	0.0	CHEMBL3116	Homo sapiens	INH	%	0.0
	3066923	CHEMBL1069289	Inhibition of CDK9 at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	0.0	CHEMBL3116	Homo sapiens	INH	%	0.0
	3203241	CHEMBL1103003	Inhibition of CDK9	B	Cn1cc(C2=C(c3cccc(NCC(O)CO)c3)C(=O)NC2=O)c2cc(F)ccc21		CHEMBL1082152	=	Kd	nM	410.0	CHEMBL3116	Homo sapiens	Kd	uM	0.41
	3213897	CHEMBL1114045	Inhibition of CDK9 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	0.0	CHEMBL3116	Homo sapiens	INH	%	0.0
	3253945	CHEMBL1111591	Inhibition of CDK9 at 10 uM	B	O=C(Nc1ccccc1)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12		CHEMBL1092134	=	Inhibition	%	81.0	CHEMBL3116	Homo sapiens	INH	%	81.0
	3304937	CHEMBL1119484	Inhibition of CDK9	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	480.0	CHEMBL3116	Homo sapiens	Ki	nM	480.0
	3304938	CHEMBL1119484	Inhibition of CDK9	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)n2)s1		CHEMBL1083484	=	Ki	nM	1472.0	CHEMBL3116	Homo sapiens	Ki	nM	1472.0
	3304939	CHEMBL1119484	Inhibition of CDK9	B	CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(C)nc4C)n3)cc2)CC1		CHEMBL1083786	=	Ki	nM	1153.0	CHEMBL3116	Homo sapiens	Ki	nM	1153.0
	3304940	CHEMBL1119484	Inhibition of CDK9	B	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1083785	=	Ki	nM	448.0	CHEMBL3116	Homo sapiens	Ki	nM	448.0
	3304941	CHEMBL1119484	Inhibition of CDK9	B	CC(=O)N1CCN(c2ccc(Nc3nccc(-c4sc(N)nc4C)n3)cc2)CC1		CHEMBL1084969	=	Ki	nM	264.0	CHEMBL3116	Homo sapiens	Ki	nM	264.0
	3304942	CHEMBL1119484	Inhibition of CDK9	B	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1		CHEMBL1084630	=	Ki	nM	559.0	CHEMBL3116	Homo sapiens	Ki	nM	559.0
	3304943	CHEMBL1119484	Inhibition of CDK9	B	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1		CHEMBL1084629	=	Ki	nM	2605.0	CHEMBL3116	Homo sapiens	Ki	nM	2605.0
	3304944	CHEMBL1119484	Inhibition of CDK9	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)s1		CHEMBL1085626	>	Ki	nM	10000.0	CHEMBL3116	Homo sapiens	Ki	nM	10000.0
	3304945	CHEMBL1119484	Inhibition of CDK9	B	CCNc1nc(C)c(-c2ccnc(Nc3ccc(CNC(C)=O)cc3)n2)s1		CHEMBL1084715	=	Ki	nM	9.0	CHEMBL3116	Homo sapiens	Ki	nM	9.0
	3304946	CHEMBL1119484	Inhibition of CDK9	B	CCNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1		CHEMBL1086088	=	Ki	nM	564.0	CHEMBL3116	Homo sapiens	Ki	nM	564.0
	3304947	CHEMBL1119484	Inhibition of CDK9	B	CNc1nc(C)c(-c2ccnc(Nc3cc(OC)c(OC)c(OC)c3)n2)s1		CHEMBL1083152	=	Ki	nM	6.0	CHEMBL3116	Homo sapiens	Ki	nM	6.0
	3304948	CHEMBL1119484	Inhibition of CDK9	B	COc1cc(Nc2nccc(-c3sc(C)nc3C)n2)cc(OC)c1OC		CHEMBL1083151	=	Ki	nM	11.0	CHEMBL3116	Homo sapiens	Ki	nM	11.0
	3304949	CHEMBL1119484	Inhibition of CDK9	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N)cc3)n2)s1		CHEMBL1084454	=	Ki	nM	337.0	CHEMBL3116	Homo sapiens	Ki	nM	337.0
	3304950	CHEMBL1119484	Inhibition of CDK9	B	CNc1ccc(Nc2nccc(-c3sc(C)nc3C)n2)cc1		CHEMBL1083150	=	Ki	nM	348.0	CHEMBL3116	Homo sapiens	Ki	nM	348.0
	3304951	CHEMBL1119484	Inhibition of CDK9	B	Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1		CHEMBL46817	=	Ki	nM	575.0	CHEMBL3116	Homo sapiens	Ki	nM	575.0
	3304952	CHEMBL1119484	Inhibition of CDK9	B	Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1		CHEMBL298445	=	Ki	nM	4.0	CHEMBL3116	Homo sapiens	Ki	nM	4.0
	3331866	CHEMBL1168825	Inhibition of CDK9 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	3333281	CHEMBL1168825	Inhibition of CDK9 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	3334686	CHEMBL1168825	Inhibition of CDK9 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	3336106	CHEMBL1168825	Inhibition of CDK9 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	3340634	CHEMBL1168825	Inhibition of CDK9 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	3342050	CHEMBL1168825	Inhibition of CDK9 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	3358497	CHEMBL1174169	Inhibition of CDK9 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	52.0	CHEMBL3116	Homo sapiens	INH	%	52.0
	3358939	CHEMBL1174169	Inhibition of CDK9 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	31.0	CHEMBL3116	Homo sapiens	INH	%	31.0
	3420190	CHEMBL1226911	Inhibition of cdk9	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
Active	3420211	CHEMBL1225145	Inhibition of cdk9-mediated RNA pol2 CTD phosphorylation at ser2 in human A2780 cells after 24 hrs	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	3420217	CHEMBL1226911	Inhibition of cdk9	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
Active	3420357	CHEMBL1225140	Inhibition of cdk9 human A2780 cells after 24 hrs	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	3445061	CHEMBL1244763	Binding affinity to CDK9	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	530.0	CHEMBL3116	Homo sapiens	Kd	nM	530.0
	3448375	CHEMBL1244763	Binding affinity to CDK9	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	3448712	CHEMBL1244763	Binding affinity to CDK9	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	3449599	CHEMBL1244763	Binding affinity to CDK9	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	3450025	CHEMBL1244763	Binding affinity to CDK9	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	3450306	CHEMBL1244763	Binding affinity to CDK9	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
	3450940	CHEMBL1244763	Binding affinity to CDK9	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	uM	10.0
Active	6274469	CHEMBL1805554	Inhibition of CDK9-mediated phosphorylation at Ser2 in C-terminal domain of RNA polymerase 2 in human HCT116 cells after 4 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	6274470	CHEMBL1805555	Inhibition of CDK9-mediated phosphorylation at Ser2 in C-terminal domain of RNA polymerase 2 in human HCT116 cells after 24 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	6274478	CHEMBL1805563	Inhibition of CDK9-mediated phosphorylation of RB protein in human HCT116 cells after 4 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	6274489	CHEMBL1805626	Inhibition of CDK9-mediated phosphorylation of RNA pol3 in human HCT116 cells after 4 hrs by immunoblotting analysis	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	6340981	CHEMBL1827567	Activity of CDK9 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	97.0	CHEMBL3116	Homo sapiens	Activity	%	97.0
Dose-dependent effect	6352183	CHEMBL1825638	Inhibition of CDK9-catalyzed RNA polymerase 2 phosphorylation at Ser2 in human MCF7 cells after 2 hrs by immunoblotting	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	6352184	CHEMBL1825639	Inhibition of CDK9-catalyzed RNA polymerase 2 phosphorylation at Ser2 in human HMEC1 cells after 2 hrs by immunoblotting	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	6352187	CHEMBL1825642	Inhibition of CDK9 by [33P]gamma-ATP incorporation assay	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	IC50	nM	350.0	CHEMBL3116	Homo sapiens	IC50	uM	0.35
	6384509	CHEMBL1837580	Inhibition of human CDK9 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	6384510	CHEMBL1837580	Inhibition of human CDK9 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	6384511	CHEMBL1837580	Inhibition of human CDK9 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	6384512	CHEMBL1837580	Inhibition of human CDK9 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	6384513	CHEMBL1837580	Inhibition of human CDK9 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	7567225	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7567684	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7568155	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7568623	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	1800.0	CHEMBL3116	Homo sapiens	Kd	nM	1800.0
	7569198	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7569658	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7570130	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7570578	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7571174	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7571631	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7572128	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7572544	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7573155	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7573646	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7574115	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7574523	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7575133	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7575152	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7575623	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7576088	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7576496	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	8800.0	CHEMBL3116	Homo sapiens	Kd	nM	8800.0
	7577124	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	1600.0	CHEMBL3116	Homo sapiens	Kd	nM	1600.0
	7577602	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7578072	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7578477	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7578673	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	180.0	CHEMBL3116	Homo sapiens	Kd	nM	180.0
	7579047	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7579497	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	6.4	CHEMBL3116	Homo sapiens	Kd	nM	6.4
	7579971	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7580440	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7580843	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7581031	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7581416	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Kd	nM	1900.0	CHEMBL3116	Homo sapiens	Kd	nM	1900.0
	7581861	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7582332	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	Kd	nM	1300.0	CHEMBL3116	Homo sapiens	Kd	nM	1300.0
	7582796	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7583196	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7583377	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Kd	nM	3000.0	CHEMBL3116	Homo sapiens	Kd	nM	3000.0
	7583774	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Kd	nM	76.0	CHEMBL3116	Homo sapiens	Kd	nM	76.0
	7584219	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7584690	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7585707	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7586115	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7586561	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7587044	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Kd	nM	15.0	CHEMBL3116	Homo sapiens	Kd	nM	15.0
	7587668	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7588087	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	530.0	CHEMBL3116	Homo sapiens	Kd	nM	530.0
	7588540	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7588569	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7589020	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7589633	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7590057	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7590556	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7591007	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7591606	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	190.0	CHEMBL3116	Homo sapiens	Kd	nM	190.0
	7592058	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7592531	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7592984	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7593566	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7594038	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7594511	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7594963	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7595099	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	=	Kd	nM	5.8	CHEMBL3116	Homo sapiens	Kd	nM	5.8
	7595543	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7596017	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7596488	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7596935	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	100.0	CHEMBL3116	Homo sapiens	Kd	nM	100.0
	7597071	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7597524	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7597997	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7598467	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7598909	CHEMBL1908527	Binding constant for CDK9 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL3116	Homo sapiens	Kd	nM	10000.0
	7951315	CHEMBL1926149	Inhibition of CDK9 in human HT29 cells assessed as reduction in RNA polymerase 2 expression	B	CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL1922219	=	IC50	nM	107.0	CHEMBL3116	Homo sapiens	IC50	nM	107.0
	8003440	CHEMBL1944421	Inhibition of human CDK9 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	8003441	CHEMBL1944421	Inhibition of human CDK9 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	8003442	CHEMBL1944421	Inhibition of human CDK9 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	8003443	CHEMBL1944421	Inhibition of human CDK9 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
Active	8024282	CHEMBL1947634	Inhibition of CDK9-mediated phosphorylation of RNA polymerase 2 at Ser2 in human HCT116 cells at GI50 after 24 hrs by Western blot analysis	B	Cc1nc2cc(Cl)c(Cl)cc2n1C1CCCC1		CHEMBL1946633		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	8024283	CHEMBL1947635	Inhibition of CDK9 in human HCT116 cells assessed as reduction in Mcl-1 protein level at GI50 after 24 hrs by Western blot analysis	B	Cc1nc2cc(Cl)c(Cl)cc2n1C1CCCC1		CHEMBL1946633		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	8024284	CHEMBL1947636	Inhibition of CDK9 in human HCT116 cells assessed as reduction in MDM2 protein level at GI50 after 24 hrs by Western blot analysis	B	Cc1nc2cc(Cl)c(Cl)cc2n1C1CCCC1		CHEMBL1946633		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	8024289	CHEMBL1947625	Inhibition of CDK9-mediated phosphorylation of RNA polymerase 2 at Ser2 in human HCT116 cells after 24 hrs by Western blot analysis	B	Cc1nc2cc(Cl)c(Cl)cc2n1C1CCCC1		CHEMBL1946633		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
inactive	9661596	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661597	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661598	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661599	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661600	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661601	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1nc(=O)[nH]c2sccc12		CHEMBL2007097	=	Ki	nM	5011.87	CHEMBL3116	Homo sapiens	pKi		5.3
inactive	9661602	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661603	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
inactive	9661604	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661605	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661606	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(F)c2)n1		CHEMBL243298	=	Ki	nM	31.62	CHEMBL3116	Homo sapiens	pKi		7.5
inactive	9661607	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661608	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1980435	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661609	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1ccccc1)Nc1ccccn1		CHEMBL143703	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661610	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
inactive	9661611	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661612	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
active	9661613	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	=	Ki	nM	31.62	CHEMBL3116	Homo sapiens	pKi		7.5
active	9661614	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(F)cc1		CHEMBL1966204	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
inactive	9661615	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661616	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	1258.93	CHEMBL3116	Homo sapiens	pKi		5.9
active	9661617	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	=	Ki	nM	15.85	CHEMBL3116	Homo sapiens	pKi		7.8
inactive	9661618	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661619	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
inactive	9661620	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661621	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	1.259	CHEMBL3116	Homo sapiens	pKi		8.9
inactive	9661622	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1ccc(Nc2ncnc3ccccc23)cc1		CHEMBL289959	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661623	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncc2cccc(-c3ccccc3)n12		CHEMBL1997119	=	Ki	nM	15848.93	CHEMBL3116	Homo sapiens	pKi		4.8
active	9661624	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9661625	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1ccc(C2CCc3[nH]ncc3C2)cc1		CHEMBL2000879	=	Ki	nM	50118.72	CHEMBL3116	Homo sapiens	pKi		4.3
inactive	9661626	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661627	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	=	Ki	nM	79.43	CHEMBL3116	Homo sapiens	pKi		7.1
inactive	9661628	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1nc(-c2ccc3c(c2)OCO3)c2cc[nH]c2n1		CHEMBL2004515	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661629	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	=	Ki	nM	251.19	CHEMBL3116	Homo sapiens	pKi		6.6
inactive	9661630	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661631	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)CNS(C)(=O)=O		CHEMBL1971172	=	Ki	nM	31.62	CHEMBL3116	Homo sapiens	pKi		7.5
inactive	9661632	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Fc1ccc(-c2ccc3nccn3n2)cn1		CHEMBL1967211	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661633	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
inactive	9661634	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661635	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661636	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661637	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661638	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1NCc2c1cccc2-c1cccs1		CHEMBL1991782	<	Ki	nM	31622.78	CHEMBL3116	Homo sapiens	pKi		4.5
active	9661639	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1n[nH]c2ncc(Br)cc12		CHEMBL2002105	=	Ki	nM	15848.93	CHEMBL3116	Homo sapiens	pKi		4.8
inactive	9661640	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661641	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9661642	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661643	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cccc(-c2ccc3c(c2)C(=O)NC3)c1		CHEMBL1968394	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9661644	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661645	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661646	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCOC(=O)Cc1nc2c3cc(Br)ccc3[nH]c(=O)n2n1		CHEMBL1974480	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9661647	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661648	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncnc2c1C(=O)Nc1ccccc1N2		CHEMBL1980671	=	Ki	nM	3981.07	CHEMBL3116	Homo sapiens	pKi		5.4
inactive	9661649	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661650	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661651	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661652	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
active	9661653	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1983589	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
inactive	9661654	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661655	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1ccc2c(c1)Cc1c[nH]nc1-2		CHEMBL1989423	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661656	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	=	Ki	nM	316.23	CHEMBL3116	Homo sapiens	pKi		6.5
inactive	9661657	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9661658	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	=	Ki	nM	316.23	CHEMBL3116	Homo sapiens	pKi		6.5
active	9661659	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	=	Ki	nM	12.59	CHEMBL3116	Homo sapiens	pKi		7.9
active	9661660	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2005718	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
inactive	9661661	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	31622.78	CHEMBL3116	Homo sapiens	pKi		4.5
inactive	9661662	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661663	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661664	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=CN(O)C(CS(=O)(=O)c1ccc(-c2ccc(C(F)(F)F)cc2)cc1)c1ccc(O)cc1		CHEMBL1971227	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661665	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
active	9661666	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	=	Ki	nM	1258.93	CHEMBL3116	Homo sapiens	pKi		5.9
inactive	9661667	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661668	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
active	9661669	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccc(Cl)cc1		CHEMBL1987073	=	Ki	nM	251.19	CHEMBL3116	Homo sapiens	pKi		6.6
active	9661670	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	12589.25	CHEMBL3116	Homo sapiens	pKi		4.9
active	9661671	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661672	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661673	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661674	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1995712	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
active	9661675	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
inactive	9661676	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661677	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1ccc(-c2cccc3nccn23)cc1		CHEMBL1992723	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661678	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
inactive	9661679	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661680	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661681	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
inactive	9661682	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661683	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
active	9661684	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
inactive	9661685	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661686	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661687	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	251.19	CHEMBL3116	Homo sapiens	pKi		6.6
active	9661688	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
inactive	9661689	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9661690	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661691	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661692	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(F)n1		CHEMBL1987261	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
inactive	9661693	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661694	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
active	9661695	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC1c2cccn2CCN1Cc1nc2scc(-c3ccco3)c2c(=O)[nH]1		CHEMBL2003119	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661696	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661697	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	=	Ki	nM	251.19	CHEMBL3116	Homo sapiens	pKi		6.6
inactive	9661698	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661699	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Ki	nM	12.59	CHEMBL3116	Homo sapiens	pKi		7.9
inactive	9661700	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661701	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661702	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661703	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661704	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661705	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1n[nH]c2cccc(-c3ccc(F)cc3)c12		CHEMBL1971519	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661706	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1980562	=	Ki	nM	2.512	CHEMBL3116	Homo sapiens	pKi		8.6
active	9661707	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
inactive	9661708	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661709	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661710	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661711	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(CN)CNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1985723	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
inactive	9661712	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661713	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	=	Ki	nM	12589.25	CHEMBL3116	Homo sapiens	pKi		4.9
active	9661714	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ncnc(Nc2cccc(F)c2)n1		CHEMBL1979933	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
active	9661715	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
inactive	9661716	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661717	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(O)c1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL2001641	=	Ki	nM	10000.0	CHEMBL3116	Homo sapiens	pKi		5.0
active	9661718	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OC1CCCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1976936	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
inactive	9661719	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661720	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9661721	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1cccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL1977128	=	Ki	nM	79.43	CHEMBL3116	Homo sapiens	pKi		7.1
inactive	9661722	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661723	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1cc(-c2c[nH]c3ncccc23)ncn1		CHEMBL1972988	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9661724	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)C1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1965702	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
inactive	9661725	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661726	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661727	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
active	9661728	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	=	Ki	nM	50.12	CHEMBL3116	Homo sapiens	pKi		7.3
inactive	9661729	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661730	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1987448	=	Ki	nM	3.981	CHEMBL3116	Homo sapiens	pKi		8.4
inactive	9661731	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661732	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661733	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661734	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)NC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2005216	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9661735	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661736	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)c1ccccc1-c1ncnc2[nH]ccc12		CHEMBL1977931	=	Ki	nM	50118.72	CHEMBL3116	Homo sapiens	pKi		4.3
inactive	9661737	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)Nc1cc2ccccn2n1		CHEMBL1976872	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661738	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)CNC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2006456	=	Ki	nM	15.85	CHEMBL3116	Homo sapiens	pKi		7.8
inactive	9661739	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1nccc2cnc(-c3ccccc3)n12		CHEMBL1969156	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661740	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OCC1OC(n2cnc3cc(Cl)c(Cl)cc32)C(O)C1O		CHEMBL267071	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
inactive	9661741	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661742	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9661743	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1964340	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
inactive	9661744	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661745	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
inactive	9661746	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661747	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)c1cc(=O)[nH]c2[nH][nH]c(=O)c12		CHEMBL1999120	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
inactive	9661748	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661749	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1972583	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9661750	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661751	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9661752	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(CO)CCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1967662	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
inactive	9661753	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661754	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	=	Ki	nM	3981.07	CHEMBL3116	Homo sapiens	pKi		5.4
inactive	9661755	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661756	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
inactive	9661757	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661758	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1		CHEMBL1983070	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661759	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661760	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661761	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	=	Ki	nM	15848.93	CHEMBL3116	Homo sapiens	pKi		4.8
active	9661762	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
inactive	9661763	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661764	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
active	9661765	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Ki	nM	10.0	CHEMBL3116	Homo sapiens	pKi		8.0
inactive	9661766	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661767	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1nn(C)c2sc3c(=O)[nH]cnc3c12		CHEMBL1967538	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9661768	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661769	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9661770	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1CN2C(=NN1)COc1ccccc12		CHEMBL1968515	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9661771	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661772	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661773	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9661774	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661775	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1ccccc1Nc1nc(Nc2ccccc2)ncc1C(F)(F)F		CHEMBL1997554	=	Ki	nM	39.81	CHEMBL3116	Homo sapiens	pKi		7.4
active	9661776	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccccc1-c1cccc2nccn12		CHEMBL1980003	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
inactive	9661777	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9661778	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)Nc1ccc(-n2nc3ccc(N)nc3n2)cc1		CHEMBL2002723	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9661779	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9661780	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665747	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1980178	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
inactive	9665748	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665749	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
inactive	9665750	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665751	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665752	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
inactive	9665753	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665754	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncnc2sccc12		CHEMBL1972934	=	Ki	nM	7943.28	CHEMBL3116	Homo sapiens	pKi		5.1
inactive	9665755	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665756	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665757	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	1258.93	CHEMBL3116	Homo sapiens	pKi		5.9
active	9665758	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
active	9665759	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	12589.25	CHEMBL3116	Homo sapiens	pKi		4.9
active	9665760	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	C=Cc1ccc(-c2cccc3nnc(N)n23)cc1		CHEMBL1983573	=	Ki	nM	3981.07	CHEMBL3116	Homo sapiens	pKi		5.4
inactive	9665761	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9665762	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21		CHEMBL1984847	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665763	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)c1c(-c2ccccc2)nn(C)c(=O)c1N		CHEMBL1984402	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665764	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	=	Ki	nM	1258.93	CHEMBL3116	Homo sapiens	pKi		5.9
inactive	9665765	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665766	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665767	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665768	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc2ccncc2s1		CHEMBL1971534	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
inactive	9665769	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665770	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)c1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1992363	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9665771	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	79.43	CHEMBL3116	Homo sapiens	pKi		7.1
inactive	9665772	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665773	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665774	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)CC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1982271	=	Ki	nM	5.012	CHEMBL3116	Homo sapiens	pKi		8.3
active	9665775	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9665776	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665777	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	39.81	CHEMBL3116	Homo sapiens	pKi		7.4
active	9665778	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9665779	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665780	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665781	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9665782	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	=	Ki	nM	6.31	CHEMBL3116	Homo sapiens	pKi		8.2
inactive	9665783	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)n1ncc2cc(N)ccc21		CHEMBL1972454	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665784	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12		CHEMBL1990590	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665785	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665786	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	=	Ki	nM	5011.87	CHEMBL3116	Homo sapiens	pKi		5.3
inactive	9665787	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665788	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	3.981	CHEMBL3116	Homo sapiens	pKi		8.4
active	9665789	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NCCNc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1972290	=	Ki	nM	79.43	CHEMBL3116	Homo sapiens	pKi		7.1
inactive	9665790	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665791	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665792	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665793	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1		CHEMBL1973016	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9665794	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665795	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	=	Ki	nM	19952.62	CHEMBL3116	Homo sapiens	pKi		4.7
active	9665796	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	12.59	CHEMBL3116	Homo sapiens	pKi		7.9
inactive	9665797	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665798	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1cc(Nc2ncc(Cl)c(Nc3ccccc3C(N)=O)n2)cn1		CHEMBL1984548	=	Ki	nM	2.512	CHEMBL3116	Homo sapiens	pKi		8.6
active	9665799	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	=	Ki	nM	158.49	CHEMBL3116	Homo sapiens	pKi		6.8
active	9665800	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL1986666	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
inactive	9665801	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665802	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665803	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
inactive	9665804	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665805	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	=	Ki	nM	251.19	CHEMBL3116	Homo sapiens	pKi		6.6
inactive	9665806	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C		CHEMBL1233887	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665807	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1nnc2cncc(Cl)n12		CHEMBL1968130	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665808	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665809	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665810	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665811	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	2511.89	CHEMBL3116	Homo sapiens	pKi		5.6
active	9665812	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1972339	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
inactive	9665813	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665814	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665815	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665816	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665817	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
active	9665818	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Ki	nM	15.85	CHEMBL3116	Homo sapiens	pKi		7.8
active	9665819	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	39.81	CHEMBL3116	Homo sapiens	pKi		7.4
active	9665820	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(Cl)c1		CHEMBL1983595	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
active	9665821	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
active	9665822	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	19.95	CHEMBL3116	Homo sapiens	pKi		7.7
active	9665823	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1		CHEMBL1990162	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
inactive	9665824	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665825	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCNC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1992220	=	Ki	nM	3.981	CHEMBL3116	Homo sapiens	pKi		8.4
inactive	9665826	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665827	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	1.259	CHEMBL3116	Homo sapiens	pKi		8.9
active	9665828	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCOCC2)n1		CHEMBL1980253	=	Ki	nM	25.12	CHEMBL3116	Homo sapiens	pKi		7.6
active	9665829	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
inactive	9665830	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665831	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
inactive	9665832	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665833	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	=	Ki	nM	0.631	CHEMBL3116	Homo sapiens	pKi		9.2
active	9665834	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1		CHEMBL243664	=	Ki	nM	1258.93	CHEMBL3116	Homo sapiens	pKi		5.9
inactive	9665835	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665836	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	Ki	nM	10.0	CHEMBL3116	Homo sapiens	pKi		8.0
inactive	9665837	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)c1cccc(-c2ccc3nccn3n2)c1		CHEMBL1994159	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665838	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665839	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	C(=Cc1ccc2nccn2n1)c1ccccc1		CHEMBL1988622	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665840	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9665841	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1ccc(-c2ccncc2)cc1N1CCCC1		CHEMBL1986722	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
inactive	9665842	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665843	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665844	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9665845	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9665846	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNCC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1996980	=	Ki	nM	3.162	CHEMBL3116	Homo sapiens	pKi		8.5
active	9665847	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665848	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1987948	=	Ki	nM	50.12	CHEMBL3116	Homo sapiens	pKi		7.3
active	9665849	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
active	9665850	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Cc2cc(-c3ccccc3)cnc2N1		CHEMBL1983630	=	Ki	nM	15848.93	CHEMBL3116	Homo sapiens	pKi		4.8
active	9665851	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1cc(Nc2ncc(Br)c(Nc3ccccc3C(N)=O)n2)cn1		CHEMBL1994669	=	Ki	nM	1.995	CHEMBL3116	Homo sapiens	pKi		8.7
active	9665852	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	=	Ki	nM	31.62	CHEMBL3116	Homo sapiens	pKi		7.5
inactive	9665853	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665854	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1NCc2ccc(-c3ccccc3)cc21		CHEMBL1973795	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665855	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665856	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
inactive	9665857	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665858	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665859	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665860	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1csc2nc(N)nn12		CHEMBL1965838	=	Ki	nM	50118.72	CHEMBL3116	Homo sapiens	pKi		4.3
active	9665861	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	=	Ki	nM	39.81	CHEMBL3116	Homo sapiens	pKi		7.4
active	9665862	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	3981.07	CHEMBL3116	Homo sapiens	pKi		5.4
inactive	9665863	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(-c2ccc3c(c2)CNC3=O)ccc1F		CHEMBL1976290	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665864	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665865	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665866	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COCCN(CCOC)c1nc(OC)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2003856	<	Ki	nM	2511.89	CHEMBL3116	Homo sapiens	pKi		5.6
inactive	9665867	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	3981.07	CHEMBL3116	Homo sapiens	pKi		5.4
inactive	9665868	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665869	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665870	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9665871	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665872	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccccc1Nc1ncnc(Nc2ccc(F)cc2)n1		CHEMBL1992231	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9665873	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNC(=O)c1cc(-c2ccccc2)[nH]n1		CHEMBL1995916	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665874	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	316.23	CHEMBL3116	Homo sapiens	pKi		6.5
active	9665875	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	50.12	CHEMBL3116	Homo sapiens	pKi		7.3
active	9665876	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
inactive	9665877	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665878	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665879	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(CN)CNc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1968930	=	Ki	nM	5.012	CHEMBL3116	Homo sapiens	pKi		8.3
inactive	9665880	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc2c(c1)C(=O)Nc1ccccc1N2		CHEMBL1970873	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665881	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665882	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665883	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
active	9665884	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	=	Ki	nM	630.96	CHEMBL3116	Homo sapiens	pKi		6.2
inactive	9665885	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(-c2ccc(N)cc2)c2cnoc12		CHEMBL2002450	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665886	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncnc2scc(-c3ccccc3)c12		CHEMBL1975212	=	Ki	nM	10000.0	CHEMBL3116	Homo sapiens	pKi		5.0
active	9665887	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	5011.87	CHEMBL3116	Homo sapiens	pKi		5.3
inactive	9665888	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665889	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665890	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665891	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665892	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC1CCCCC1Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL1994438	=	Ki	nM	79.43	CHEMBL3116	Homo sapiens	pKi		7.1
inactive	9665893	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665894	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cccc(-c2cccc3onc(N)c23)c1		CHEMBL1980376	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
inactive	9665895	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12		CHEMBL2000724	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665896	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665897	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	3.981	CHEMBL3116	Homo sapiens	pKi		8.4
active	9665898	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
active	9665899	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
active	9665900	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(=O)[nH]c2[nH]n(-c3ccccc3)c(=O)c12		CHEMBL1985042	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
inactive	9665901	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665902	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	=	Ki	nM	3981.07	CHEMBL3116	Homo sapiens	pKi		5.4
active	9665903	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9665904	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665905	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665906	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1cc(-c2cccs2)n2nccc2n1		CHEMBL1987815	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665907	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	=	Ki	nM	0.7943	CHEMBL3116	Homo sapiens	pKi		9.1
inactive	9665908	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665909	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9665910	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	=	Ki	nM	199.53	CHEMBL3116	Homo sapiens	pKi		6.7
active	9665911	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	=	Ki	nM	501.19	CHEMBL3116	Homo sapiens	pKi		6.3
inactive	9665912	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665913	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665914	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=c1[nH]c2ccc(Cl)cc2c2ncnn12		CHEMBL1992673	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
active	9665915	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	=	Ki	nM	0.631	CHEMBL3116	Homo sapiens	pKi		9.2
inactive	9665916	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665917	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	5.012	CHEMBL3116	Homo sapiens	pKi		8.3
active	9665918	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
active	9665919	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
active	9665920	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COC(=O)c1c(N)nc2ccccn12		CHEMBL1981492	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
inactive	9665921	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665922	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	=	Ki	nM	12.59	CHEMBL3116	Homo sapiens	pKi		7.9
inactive	9665923	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665924	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	=	Ki	nM	1258.93	CHEMBL3116	Homo sapiens	pKi		5.9
inactive	9665925	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665926	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(C=Cc1ccc(Br)cc1)Nc1cccc2cnccc12		CHEMBL1967719	=	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665927	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(OC)cc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)c1		CHEMBL2002613	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665928	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNC(=O)NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL2005509	=	Ki	nM	3.162	CHEMBL3116	Homo sapiens	pKi		8.5
inactive	9665929	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665930	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665931	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	=	Ki	nM	794.33	CHEMBL3116	Homo sapiens	pKi		6.1
inactive	9665932	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665933	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ccc(-c2cccn3c(=O)[nH]nc23)cc1		CHEMBL1975503	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
inactive	9665934	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665935	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CN(C)c1cc(-c2ccncc2)cc2[nH]nc(N)c12		CHEMBL2003229	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
active	9665936	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1ccc(CNc2cc(-c3c[nH]c4ncccc34)cc(F)n2)cc1		CHEMBL1986855	=	Ki	nM	7.943	CHEMBL3116	Homo sapiens	pKi		8.1
inactive	9665937	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665938	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC1CCCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)C1		CHEMBL1998432	=	Ki	nM	15.85	CHEMBL3116	Homo sapiens	pKi		7.8
inactive	9665939	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665940	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665941	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665942	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665943	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	=	Ki	nM	125.89	CHEMBL3116	Homo sapiens	pKi		6.9
active	9665944	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
active	9665945	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1ccc(-c2ccnc3[nH]ccc23)cc1		CHEMBL482538	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9665946	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665947	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	63.1	CHEMBL3116	Homo sapiens	pKi		7.2
inactive	9665948	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	NC(=O)c1csc2c1NCCC2=O		CHEMBL1973399	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665949	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
inactive	9665950	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665951	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
active	9665952	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1nn(C)c2sc(C(N)=O)c(N)c12		CHEMBL1996837	=	Ki	nM	31622.78	CHEMBL3116	Homo sapiens	pKi		4.5
active	9665953	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	=	Ki	nM	1000.0	CHEMBL3116	Homo sapiens	pKi		6.0
active	9665954	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	c1ccc(C2CCc3[nH]ncc32)cc1		CHEMBL1965683	=	Ki	nM	31622.78	CHEMBL3116	Homo sapiens	pKi		4.5
active	9665955	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CC1=CN2CC(=O)NN=C2C=C1		CHEMBL1964718	=	Ki	nM	39810.72	CHEMBL3116	Homo sapiens	pKi		4.4
active	9665956	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	100.0	CHEMBL3116	Homo sapiens	pKi		7.0
inactive	9665957	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665958	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665959	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665960	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	1584.89	CHEMBL3116	Homo sapiens	pKi		5.8
inactive	9665961	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	Cc1cc(C(N)=O)n2nc(C(C)(C)C)cc2n1		CHEMBL1986684	<	Ki	nM	63095.73	CHEMBL3116	Homo sapiens	pKi		4.2
active	9665962	CHEMBL1963831	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDK9	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	=	Ki	nM	398.11	CHEMBL3116	Homo sapiens	pKi		6.4
	10863756	CHEMBL2024911	Inhibition of CDK9 by TR-FRET assay	B	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	10910719	CHEMBL2040159	Inhibition of CDK9	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1		CHEMBL2035185	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
	12173694	CHEMBL2209331	Inhibition of CDK9 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	57.0	CHEMBL3116	Homo sapiens	Activity	%	57.0
	12183908	CHEMBL2211476	Inhibition of CDK9	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	pIC50		5.0
	12622858	CHEMBL2321003	Inhibition of CDK9 (unknown origin)	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Ki	nM	4.0	CHEMBL3116	Homo sapiens	Ki	nM	4.0
	12622859	CHEMBL2321003	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Ki	nM	3.0	CHEMBL3116	Homo sapiens	Ki	nM	3.0
Active	12715052	CHEMBL2350503	Inhibition of CDK9 in human A2780 cells assessed as downregulation of MCL1 at GI50 to 5XGI50 concentration after 24 hrs by Western blotting analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	12715080	CHEMBL2350504	Inhibition of CDK9 in human A2780 cells assessed as downregulation of HDM2 at GI50 to 5XGI50 concentration after 24 hrs by Western blotting analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	12715081	CHEMBL2350504	Inhibition of CDK9 in human A2780 cells assessed as downregulation of HDM2 at GI50 to 5XGI50 concentration after 24 hrs by Western blotting analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCCNCC4)c3)ncc2C#N)s1		CHEMBL2312185		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	12715082	CHEMBL2350503	Inhibition of CDK9 in human A2780 cells assessed as downregulation of MCL1 at GI50 to 5XGI50 concentration after 24 hrs by Western blotting analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCCNCC4)c3)ncc2C#N)s1		CHEMBL2312185		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	12715083	CHEMBL2350495	Inhibition of CDK9 in human A2780 cells assessed as reduction of RNAPII CTD phosphorylation at Ser2 at 5XGI50 concentration after 24 hrs by Western blotting analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCCNCC4)c3)ncc2C#N)s1		CHEMBL2312185		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	12715084	CHEMBL2350496	Inhibition of CDK9 in human A2780 cells assessed as reduction of RNAPII CTD phosphorylation at Ser2 at GI50 concentration after 24 hrs by Western blotting analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	12715085	CHEMBL2350496	Inhibition of CDK9 in human A2780 cells assessed as reduction of RNAPII CTD phosphorylation at Ser2 at GI50 concentration after 24 hrs by Western blotting analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCCNCC4)c3)ncc2C#N)s1		CHEMBL2312185		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	13352096	CHEMBL2399034	Inhibition of CDK9 (unknown origin)	B	Cc1nc(NC(=O)[C@@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1		CHEMBL2397315	=	IC50	nM	5300.0	CHEMBL3116	Homo sapiens	IC50	uM	5.3
Active	13372527	CHEMBL2406204	Inhibition of CDK9-mediated RNA polymerase 2 phosphorylation at ser2 in human G361 cells at 300 nM after 24 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-n4cccn4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403088		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13372528	CHEMBL2406204	Inhibition of CDK9-mediated RNA polymerase 2 phosphorylation at ser2 in human G361 cells at 300 nM after 24 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4cccc(F)c4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403093		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13372529	CHEMBL2406204	Inhibition of CDK9-mediated RNA polymerase 2 phosphorylation at ser2 in human G361 cells at 300 nM after 24 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccco4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403094		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13372530	CHEMBL2406204	Inhibition of CDK9-mediated RNA polymerase 2 phosphorylation at ser2 in human G361 cells at 300 nM after 24 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccoc4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403095		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13372531	CHEMBL2406204	Inhibition of CDK9-mediated RNA polymerase 2 phosphorylation at ser2 in human G361 cells at 300 nM after 24 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4cccs4)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2403096		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13372567	CHEMBL2406204	Inhibition of CDK9-mediated RNA polymerase 2 phosphorylation at ser2 in human G361 cells at 300 nM after 24 hrs by immunoblotting analysis	B	NC1CCC(Nc2nc(NCc3ccc(-c4ccccc4O)nc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL2402946		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	13414838	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414839	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414840	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	=	Inhibition	%	49.8	CHEMBL3116	Homo sapiens	INH	%	49.8
	13414841	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414842	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414843	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414844	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414845	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414846	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414847	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	=	Inhibition	%	42.0	CHEMBL3116	Homo sapiens	INH	%	42.0
	13414848	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	=	Inhibition	%	98.6	CHEMBL3116	Homo sapiens	INH	%	98.6
	13414849	CHEMBL2424244	Inhibition of CDK9 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	=	Inhibition	%	97.9	CHEMBL3116	Homo sapiens	INH	%	97.9
	13414926	CHEMBL2424258	Inhibition of CDK9 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O[C@H]1CC[C@H](Nc2nc3ccccc3n3ccnc23)CC1		CHEMBL2420582	=	Inhibition	%	90.7	CHEMBL3116	Homo sapiens	INH	%	90.7
	13414927	CHEMBL2424258	Inhibition of CDK9 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	c1ccc(CNc2nc3ccccc3n3ccnc23)cc1		CHEMBL2420578	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414928	CHEMBL2424258	Inhibition of CDK9 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	c1ccc(CCNc2nc3ccccc3n3ccnc23)cc1		CHEMBL2420577	<	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	13414929	CHEMBL2424258	Inhibition of CDK9 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	c1ccc2c(c1)nc(NC1CCCCC1)c1nccn12		CHEMBL2420576	=	Inhibition	%	50.7	CHEMBL3116	Homo sapiens	INH	%	50.7
	13418820	CHEMBL2422672	Inhibition of CDK9 (unknown origin)	B	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	IC50	nM	630.96	CHEMBL3116	Homo sapiens	pIC50		6.2
	13418845	CHEMBL2422672	Inhibition of CDK9 (unknown origin)	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	IC50	nM	794.33	CHEMBL3116	Homo sapiens	pIC50		6.1
	13418848	CHEMBL2422672	Inhibition of CDK9 (unknown origin)	B	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	pIC50		8.0
	13433612	CHEMBL2421777	Inhibition of CDK9 (unknown origin)	B	O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl		CHEMBL2387224	=	Ki	nM	111.0	CHEMBL3116	Homo sapiens	Ki	nM	111.0
	13439881	CHEMBL2428171	Competitive binding affinity to CDK9 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	=	Inhibition	%	85.0	CHEMBL3116	Homo sapiens	INH	%	85.0
	13448446	CHEMBL2428171	Competitive binding affinity to CDK9 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	82.0	CHEMBL3116	Homo sapiens	INH	%	82.0
	13451701	CHEMBL2428171	Competitive binding affinity to CDK9 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	96.0	CHEMBL3116	Homo sapiens	INH	%	96.0
Active	13833572	CHEMBL3089272	Inhibition of CDK9 in human HCT116 cells assessed as downregulation of Mcl-1 protein expression at 1 to 5 uM after 24 hrs by Western blot analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(C(=O)NC4CCN(C)CC4)c3)ncc2C#N)s1		CHEMBL3087432		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13833574	CHEMBL3089274	Inhibition of CDK9 in human HCT116 cells assessed as decrease in RNAP2 CTD phosphorylation at Ser5 at 10 uM after 24 hrs by Western blot analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(C(=O)NC4CCN(C)CC4)c3)ncc2C#N)s1		CHEMBL3087432		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	13833575	CHEMBL3089275	Inhibition of CDK9 in human HCT116 cells assessed as decrease in RNAP2 CTD phosphorylation at Ser2 at 1 to 5 uM after 24 hrs by Western blot analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(C(=O)NC4CCN(C)CC4)c3)ncc2C#N)s1		CHEMBL3087432		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	13859799	CHEMBL3101304	Inhibition of active state of CDK9 (unknown origin) at 1 uM	B	COC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cc(C(=O)O)c2cc(-c3cccc(Cl)c3)ccc2n1		CHEMBL3099755		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	15037183	CHEMBL3368332	Inhibition of CDK9 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1OC		CHEMBL3102948	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	15037184	CHEMBL3368332	Inhibition of CDK9 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1cc(-c2c[nH]c3ncc(-c4cccc(N)c4)cc23)cc(OC)c1OC		CHEMBL3319457	=	Inhibition	%	83.0	CHEMBL3116	Homo sapiens	INH	%	83.0
	15037185	CHEMBL3368332	Inhibition of CDK9 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4ccc(C(=O)N5CCOCC5)c(N)c4)cc23)cc1OC		CHEMBL3319467	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	15037186	CHEMBL3368332	Inhibition of CDK9 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4cc(OC)c(OC)c(OC)c4)cc23)cc1OC		CHEMBL3319468	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	15037187	CHEMBL3368332	Inhibition of CDK9 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1N		CHEMBL3319470	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	15101469	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1O		CHEMBL3343033	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101470	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(C)nc2cc1O		CHEMBL3343034	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101471	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCO		CHEMBL3343037	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101472	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(=O)O		CHEMBL3343038	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101473	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCC(N)=O		CHEMBL3343039	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101474	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(N)nc2cc1O		CHEMBL3343040	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101475	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)nc(NCCc3ccccn3)nc2cc1O		CHEMBL3343042	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101476	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)ccc1O		CHEMBL3343044	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101477	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1ccc(O)c([N+](=O)[O-])c1		CHEMBL3343045	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101478	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1O		CHEMBL3343046	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101479	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)c(N)cc1O		CHEMBL3343047	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101480	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccc3)cc2)ccc1OCC(=O)O		CHEMBL3343048	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101481	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1		CHEMBL3341771	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101482	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	O=C(Nc1ccc(NC(=O)c2ccccn2)cc1)c1cccc(-c2c[nH]c(=O)[nH]c2=O)c1		CHEMBL3343051	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101483	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1ccc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc1-c1c[nH]c(=O)[nH]c1=O		CHEMBL3343052	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101484	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)c3ccccn3)cc2)cc(N2CCC(=O)NC2=O)c1		CHEMBL3343055	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101485	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	COc1cc(C(=O)Nc2ccc(NC(=O)C3CCCCN3)cc2)cc(-c2c[nH]c(=O)[nH]c2=O)c1		CHEMBL3343057	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15101486	CHEMBL3380808	Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay	B	CCNC(=O)Nc1ccc(NC(=O)c2cc(OC)cc(-c3c[nH]c(=O)[nH]c3=O)c2)cc1		CHEMBL3343058	>	IC50	nM	30000.0	CHEMBL3116	Homo sapiens	IC50	uM	30.0
	15643361	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccccc2c2[nH]c3c(Cl)cccc3c12		CHEMBL3589660	=	IC50	nM	15000.0	CHEMBL3116	Homo sapiens	IC50	uM	15.0
	15643362	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccccc2c2[nH]c3c(Br)cccc3c12		CHEMBL3589661	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	uM	0.16
	15643363	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccccc2c2[nH]c3c(I)cccc3c12		CHEMBL3589662	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	15643364	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1cccc2c1[nH]c1c3ccccc3nc(C(=O)O)c21		CHEMBL3589663	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	uM	0.12
	15643365	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(F)c3[nH]c21		CHEMBL3589664	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	15643366	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(Cl)c3[nH]c21		CHEMBL3589665	=	IC50	nM	1000.0	CHEMBL3116	Homo sapiens	IC50	uM	1.0
	15643367	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(Br)c3[nH]c21		CHEMBL3589666	=	IC50	nM	1500.0	CHEMBL3116	Homo sapiens	IC50	uM	1.5
	15643368	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1ccc2c(c1)nc(C(=O)O)c1c3cccc(I)c3[nH]c21		CHEMBL3589667	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	15643369	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(F)cccc3c12		CHEMBL3589670	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	15643370	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(Cl)cccc3c12		CHEMBL3589671	=	IC50	nM	2200.0	CHEMBL3116	Homo sapiens	IC50	uM	2.2
	15643371	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccc(I)cc2c2[nH]c3c(Br)cccc3c12		CHEMBL3589672	=	IC50	nM	1500.0	CHEMBL3116	Homo sapiens	IC50	uM	1.5
	15643372	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1ccc2nc(C(=O)O)c3c4cccc(Cl)c4[nH]c3c2c1		CHEMBL3589673	=	IC50	nM	210.0	CHEMBL3116	Homo sapiens	IC50	uM	0.21
	15643373	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1cccc(-c2ccc3nc(C(=O)O)c4c5cccc(Cl)c5[nH]c4c3c2)c1		CHEMBL3589674	=	IC50	nM	3100.0	CHEMBL3116	Homo sapiens	IC50	uM	3.1
	15643374	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	COc1ccc(-c2ccc3nc(C(=O)O)c4c5cccc(Cl)c5[nH]c4c3c2)cc1		CHEMBL3589675	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	15643375	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2ccsc2c2[nH]c3c(Cl)cccc3c12		CHEMBL3589774	=	IC50	nM	350.0	CHEMBL3116	Homo sapiens	IC50	uM	0.35
	15643376	CHEMBL3591180	Inhibition of human recombinant CDK9 expressed in insect cells using CDK7/9 tide as substrate after 30 mins by scintillation counting analysis	B	O=C(O)c1nc2cccnc2c2[nH]c3c(Br)cccc3c12		CHEMBL3589775	=	IC50	nM	2000.0	CHEMBL3116	Homo sapiens	IC50	uM	2.0
	15654952	CHEMBL3599524	Inhibition of CDK9 (unknown origin) at 0.5 uM relative to control	B	Nc1nccc(-c2c[nH]c3ccccc23)n1		CHEMBL48082	=	Inhibition	%	3.8	CHEMBL3116	Homo sapiens	INH	%	3.8
	15654953	CHEMBL3599524	Inhibition of CDK9 (unknown origin) at 0.5 uM relative to control	B	Nc1nccc(-c2cn(C(=O)N3CCOCC3)c3ccc(Br)cc23)n1		CHEMBL3133762	=	Inhibition	%	12.6	CHEMBL3116	Homo sapiens	INH	%	12.6
	15654954	CHEMBL3599524	Inhibition of CDK9 (unknown origin) at 0.5 uM relative to control	B	Cc1noc(C)c1Cn1cc(-c2ccnc(N)n2)c2ccccc21		CHEMBL3133770	=	Inhibition	%	14.0	CHEMBL3116	Homo sapiens	INH	%	14.0
	15755223	CHEMBL3630643	Inhibition of CDK9 (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control	B	O=C1c2ccccc2-c2c1oc1ccccc1c2=O		CHEMBL3629616	=	Activity	%	71.0	CHEMBL3116	Homo sapiens	Activity	%	71.0
226153	16263804	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CCC(Nc1nc(NCc2cccnc2)c2ncn(C(C)C)c2n1)C(O)C(F)(F)F		CHEMBL3655777	=	IC50	nM	2140.0	CHEMBL3116	Homo sapiens	IC50	nM	2140.0
226139	16265751	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2ccc(C)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655763	=	IC50	nM	3630.0	CHEMBL3116	Homo sapiens	IC50	nM	3630.0
308356	16270823	CHEMBL3707939	In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).	B	COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1		CHEMBL3673434	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
226141	16273121	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2cccc(F)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655765	=	IC50	nM	80.0	CHEMBL3116	Homo sapiens	IC50	nM	80.0
226138	16273378	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655762	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
226146	16273434	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2ccncc2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655770	=	IC50	nM	610.0	CHEMBL3116	Homo sapiens	IC50	nM	610.0
226148	16274192	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2ccc(C(F)(F)F)nc2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655772	=	IC50	nM	250.0	CHEMBL3116	Homo sapiens	IC50	nM	250.0
226152	16280574	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC(C)n1cnc2c(NCc3cccnc3)nc(NCC(O)C(F)(F)F)nc21		CHEMBL3655776	=	IC50	nM	7400.0	CHEMBL3116	Homo sapiens	IC50	nM	7400.0
226142	16289488	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2cccnc2)c2ncn(CC3CC3)c2n1)[C@@H](C)O		CHEMBL3655766	=	IC50	nM	7890.0	CHEMBL3116	Homo sapiens	IC50	nM	7890.0
226145	16292885	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NC2CCC2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655769	=	IC50	nM	500.0	CHEMBL3116	Homo sapiens	IC50	nM	500.0
308357	16301173	CHEMBL3707939	In Vitro Kinase Inhibition Assay: In vitro kinase assay analysis may be performed using standard techniques described in the art. These techniques are also used by commercial services providers in order to offer in vitro kinase activity assay services, e.g. the assays offered by Millipore Inc. (worldwide website www(dot)millipore.com), ProQinase GmbH (worldwide website www(dot)proqinase.de) and others. All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50ul reaction volume. The reaction mixture was pipetted in four steps in the following order: 20ul of assay buffer (standard buffer),5ul of ATP solution (in H2O, 5 ul of test compound (in 10% DMSO), 10ul of substrate/10ul of enzyme solution (premixed)The assay for all enzymes contained 60 mM HEPES-NaOH (pH 7.5), 3 mM MgCl2, 3 mM MnCl2, 3uM Na-Orthovanadate, 1.2 mM DTT, 50 ug/ml PEG2000, 1 uM [33P]-ATP (approx. 5x1005 cpm per well).	B	COc1cc(F)ccc1-c1ccnc(NC(=O)C2CCC(NC(C)=O)C2)c1		CHEMBL3673435	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
226140	16302568	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2cccc(Cl)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655764	=	IC50	nM	60.0	CHEMBL3116	Homo sapiens	IC50	nM	60.0
226149	16307817	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2cccc(C)n2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655773	=	IC50	nM	2040.0	CHEMBL3116	Homo sapiens	IC50	nM	2040.0
226144	16310045	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCC2CC2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655768	=	IC50	nM	380.0	CHEMBL3116	Homo sapiens	IC50	nM	380.0
226150	16319910	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2ncccc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655774	=	IC50	nM	5840.0	CHEMBL3116	Homo sapiens	IC50	nM	5840.0
226151	16330794	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC(C)n1cnc2c(NCc3cccnc3)nc(NC[C@@H](C)O)nc21		CHEMBL3655775	=	IC50	nM	6530.0	CHEMBL3116	Homo sapiens	IC50	nM	6530.0
226143	16333102	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NC2CC2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655767	=	IC50	nM	270.0	CHEMBL3116	Homo sapiens	IC50	nM	270.0
226147	16345479	CHEMBL3707641	Kinase Assay: To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins generated at Cyclacel. Ltd Dundee, UK.	B	CC[C@H](Nc1nc(NCc2cc(C)nc(C)c2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL3655771	=	IC50	nM	1040.0	CHEMBL3116	Homo sapiens	IC50	nM	1040.0
	16485711	CHEMBL3771439	Inhibition of human recombinant CDK9 assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	16507261	CHEMBL3777660	Inhibition of CDK9 (unknown origin)	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	IC50	nM	892.0	CHEMBL3116	Homo sapiens	IC50	uM	0.892
	16507262	CHEMBL3777660	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12		CHEMBL1801932	=	IC50	nM	2180.0	CHEMBL3116	Homo sapiens	IC50	uM	2.18
	16507263	CHEMBL3777660	Inhibition of CDK9 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	178.0	CHEMBL3116	Homo sapiens	IC50	uM	0.178
	16507264	CHEMBL3777660	Inhibition of CDK9 (unknown origin)	B	CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1		CHEMBL3774632	=	IC50	nM	240.0	CHEMBL3116	Homo sapiens	IC50	uM	0.24
Not Active	16514110	CHEMBL3782158	Inhibition of partial length human CDK9 expressed in bacterial system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	16566182	CHEMBL3803172	Inhibition of CDK9 (unknown origin)	B	C[C@H]1CN(c2cccc3nc(-c4nc(-c5cc(C(=O)N(C)C)ccn5)cnc4N)n(C)c23)CCN1		CHEMBL3800585	>	IC50	nM	25000.0	CHEMBL3116	Homo sapiens	IC50	uM	25.0
	16594904	CHEMBL3812235	Inhibition of full length human CDK9 expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	16636715	CHEMBL3825313	Inhibition of CDK9 (unknown origin)	B	CC(=O)N1CCC(n2cc(Nc3ncc(Cl)c(-c4cnc5ccccn45)n3)cn2)CC1		CHEMBL3823659	=	IC50	nM	37.0	CHEMBL3116	Homo sapiens	IC50	uM	0.037
	16636716	CHEMBL3825313	Inhibition of CDK9 (unknown origin)	B	Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1		CHEMBL3823030	=	IC50	nM	450.0	CHEMBL3116	Homo sapiens	IC50	uM	0.45
	16737068	CHEMBL3856530	Binding affinity to full length human CDK9 (1 to 372 residues) expressed in bacterial expression system by KINOMEscan competition assay	B	Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12		CHEMBL393525	=	Kd	nM	4.1	CHEMBL3116	Homo sapiens	Kd	nM	4.1
	16737072	CHEMBL3856527	Inhibition of human CDK9 (unknown origin)	B	COc1ccccc1-c1cc(Nc2ccc(F)c(NS(C)(=O)=O)c2)ncn1		CHEMBL3895785	=	Ki	nM	17.0	CHEMBL3116	Homo sapiens	Ki	nM	17.0
	16737082	CHEMBL3856518	Inhibition of recombinant CDK9 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated Histone H1 as substrate after 1 hr in presence of 33P-ATP by liquid scintillation counting analysis	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nmol/L	4.0
	16737097	CHEMBL3856509	Inhibition of CDK9 (unknown origin)	B	Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12		CHEMBL393525	=	IC50	nM	1.4	CHEMBL3116	Homo sapiens	IC50	nM	1.4
	16737144	CHEMBL3856553	Inhibition of human GST-tagged CDK9	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
	16844140	CHEMBL3877186	Inhibition of CDK9 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
217630	17606282	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	[O-][n+]1cccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3919070	=	IC50	nM	60.0	CHEMBL3116	Homo sapiens	IC50	nM	60.0
217631	17606283	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCCCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3974193	=	IC50	nM	35.0	CHEMBL3116	Homo sapiens	IC50	nM	35.0
217635	17606287	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CCN4CCOCC4)CC3)cc12		CHEMBL3949793	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	nM	40.0
217636	17606288	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CCC(C3)N4S(C)(=O)=O)cc12		CHEMBL3965720	=	IC50	nM	38.0	CHEMBL3116	Homo sapiens	IC50	nM	38.0
217641	17606293	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCNCC3S(C)(=N)=O)cc12		CHEMBL3928559	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
217644	17606296	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CCC(C3)N4CC(=O)N(C)C)cc12		CHEMBL3918885	=	IC50	nM	114.0	CHEMBL3116	Homo sapiens	IC50	nM	114.0
217646	17606298	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3C[C@@H]4CN(S(C)(=O)=O)C[C@@H]4C3)cc12		CHEMBL3924904	=	IC50	nM	70.0	CHEMBL3116	Homo sapiens	IC50	nM	70.0
217650	17606302	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3=CC4CCC(C3)N4CC(=O)N(C)C)cc12		CHEMBL3943237	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
218799	17607456	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CC4CCC(C3)N4CC(=O)N(C)C)cc12		CHEMBL3969365	=	IC50	nM	90.0	CHEMBL3116	Homo sapiens	IC50	nM	90.0
218819	17607476	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CCC(C3)N4C(=O)CN3CC(O)C3)cc12		CHEMBL3902691	=	IC50	nM	131.0	CHEMBL3116	Homo sapiens	IC50	nM	131.0
218850	17607507	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CCC(C3)N4C(=O)Cn3c(OC)cc4cccnc43)cc12		CHEMBL3930674	=	IC50	nM	61.0	CHEMBL3116	Homo sapiens	IC50	nM	61.0
218881	17607538	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CCC(C3)N4CC(=O)N(C)CCO)cc12		CHEMBL3925253	=	IC50	nM	114.0	CHEMBL3116	Homo sapiens	IC50	nM	114.0
218942	17607631	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CC=C(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3986015	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
249032	17632268	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccccc1-c1cc(N(C)C(=O)[C@@H]2CCCNC2)ncn1		CHEMBL3694399	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
249033	17632269	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccc(F)cc1-c1cc(NC(=O)C2CCCNC2)ncn1		CHEMBL3694400	=	IC50	nM	0.018	CHEMBL3116	Homo sapiens	IC50	nM	0.018
249034	17632270	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1cccc(F)c1-c1cc(NC(=O)C2CCCNC2)ncn1		CHEMBL3694401	=	IC50	nM	0.039	CHEMBL3116	Homo sapiens	IC50	nM	0.039
249035	17632271	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccccc1-c1cc(NC(=O)C2CCC(=O)NC2)ncn1		CHEMBL3694402	=	IC50	nM	0.019	CHEMBL3116	Homo sapiens	IC50	nM	0.019
249036	17632272	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccccc1-c1cc(NC(=O)C2CCC(=O)NC2)ncn1		CHEMBL3694402	=	IC50	nM	0.173	CHEMBL3116	Homo sapiens	IC50	nM	0.173
249037	17632273	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccccc1-c1cc(NC(=O)c2ccc(NS(C)(=O)=O)cc2)ncn1		CHEMBL3694403	=	IC50	nM	1.25	CHEMBL3116	Homo sapiens	IC50	nM	1.25
249038	17632274	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccccc1-c1cc(NC(=O)c2ccc(C)c(NS(C)(=O)=O)c2)ncn1		CHEMBL3694404	=	IC50	nM	0.116	CHEMBL3116	Homo sapiens	IC50	nM	0.116
249039	17632275	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccccc1-c1cc(NC(=O)c2cccc(NS(C)(=O)=O)c2)ncn1		CHEMBL3694405	=	IC50	nM	1.08	CHEMBL3116	Homo sapiens	IC50	nM	1.08
249040	17632276	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccc(F)cc1-c1cc(NC(=O)Cc2cccnc2)ncn1		CHEMBL3694406	=	IC50	nM	0.015	CHEMBL3116	Homo sapiens	IC50	nM	0.015
249041	17632277	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccc(F)cc1-c1cc(NC(=O)Cc2ccncc2)ncn1		CHEMBL3694407	=	IC50	nM	0.029	CHEMBL3116	Homo sapiens	IC50	nM	0.029
249042	17632278	CHEMBL3706262	In Vitro Kinase Inhibition Assays: All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixture was pipetted in four steps in the following order:20 μl of assay buffer (standard buffer),5 μl of ATP solution (in H2O),5 μl of test compound (in 10% DMSO),10 μl of substrate/10 μl of enzyme solution (premixed),The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-Orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [-33P]-ATP (approx. 5×1005 cpm per well).	B	COc1ccc(F)cc1-c1cc(NC(=O)COc2ccc(Cl)cn2)ncn1	Outside typical range	CHEMBL3694408	=	IC50	nM	0.005	CHEMBL3116	Homo sapiens	IC50	nM	0.005
311299	17691776	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663743	=	IC50	nM	16.0	CHEMBL3116	Homo sapiens	IC50	nM	16.0
311300	17691777	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663744	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
311301	17691778	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@H]3CCCNC3)cc12		CHEMBL3663745	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311302	17691779	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@@H]3CCCNC3)cc12		CHEMBL3663746	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311303	17691780	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(N)nc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663747	=	IC50	nM	6900.0	CHEMBL3116	Homo sapiens	IC50	nM	6900.0
311304	17691781	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(C2=NCCN2)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663748	>	IC50	nM	12500.0	CHEMBL3116	Homo sapiens	IC50	nM	12500.0
311305	17691782	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(C2CC2)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663749	=	IC50	nM	4700.0	CHEMBL3116	Homo sapiens	IC50	nM	4700.0
311306	17691783	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CCCN(C)C3)cc12		CHEMBL3663750	=	IC50	nM	49.0	CHEMBL3116	Homo sapiens	IC50	nM	49.0
311307	17691784	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN(C)C3)cc12		CHEMBL3663751	=	IC50	nM	35.0	CHEMBL3116	Homo sapiens	IC50	nM	35.0
311308	17691785	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN(C(C)=O)C3)cc12		CHEMBL3663752	=	IC50	nM	320.0	CHEMBL3116	Homo sapiens	IC50	nM	320.0
311309	17691786	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccccc2)nc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663753	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311310	17691787	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCCC(c2cc3c(-c4nc(NCc5ccccc5)ccc4Cl)ccnc3[nH]2)C1		CHEMBL3663754	=	IC50	nM	93.0	CHEMBL3116	Homo sapiens	IC50	nM	93.0
311311	17691788	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCCC(c2cc3c(-c4cccc(NCc5ccccc5)n4)ccnc3[nH]2)C1		CHEMBL3663755	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
311312	17691789	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(NCc2ccccc2)nc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3663756	=	IC50	nM	490.0	CHEMBL3116	Homo sapiens	IC50	nM	490.0
311313	17691790	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CC(C)S(=O)(=O)N1CCCC(c2cc3c(-c4nc(NCc5ccccc5)ccc4Cl)ccnc3[nH]2)C1		CHEMBL3663757	=	IC50	nM	1400.0	CHEMBL3116	Homo sapiens	IC50	nM	1400.0
311314	17691791	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COC(=O)N1CCCC(c2cc3c(-c4nc(NCc5ccccc5)ccc4Cl)ccnc3[nH]2)C1		CHEMBL3663758	=	IC50	nM	770.0	CHEMBL3116	Homo sapiens	IC50	nM	770.0
311315	17691792	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663759	=	IC50	nM	11.0	CHEMBL3116	Homo sapiens	IC50	nM	11.0
311316	17691793	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663760	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311317	17691794	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(Cl)ccc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663761	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311318	17691795	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cccnc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663762	=	IC50	nM	31.0	CHEMBL3116	Homo sapiens	IC50	nM	31.0
311319	17691796	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(N)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663763	=	IC50	nM	6600.0	CHEMBL3116	Homo sapiens	IC50	nM	6600.0
311320	17691797	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)c(F)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663764	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
311321	17691798	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(Cl)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663765	=	IC50	nM	77.0	CHEMBL3116	Homo sapiens	IC50	nM	77.0
311322	17691799	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(C)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663766	=	IC50	nM	68.0	CHEMBL3116	Homo sapiens	IC50	nM	68.0
311323	17691800	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1c(Cl)cccc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3639626	=	IC50	nM	300.0	CHEMBL3116	Homo sapiens	IC50	nM	300.0
311324	17691801	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663767	=	IC50	nM	77.0	CHEMBL3116	Homo sapiens	IC50	nM	77.0
311325	17691802	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccccc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663768	=	IC50	nM	27.0	CHEMBL3116	Homo sapiens	IC50	nM	27.0
311326	17691803	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C)CC3)cc12		CHEMBL3663769	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311327	17691804	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CCN(C)CC3)cc12		CHEMBL3663770	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311328	17691805	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(C)cc1-c1ccnc2[nH]c(C3CCN(C)CC3)cc12		CHEMBL3663771	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
311329	17691806	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccncc1-c1ccnc2[nH]c(C3CCN(C)CC3)cc12		CHEMBL3663772	=	IC50	nM	2600.0	CHEMBL3116	Homo sapiens	IC50	nM	2600.0
311330	17691807	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccccc2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663773	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311331	17691808	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3663774	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311332	17691809	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2cccnc2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663775	=	IC50	nM	18.0	CHEMBL3116	Homo sapiens	IC50	nM	18.0
311333	17691810	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)cc1		CHEMBL3663776	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311334	17691811	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(F)c(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3663777	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311335	17691812	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cncc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3663778	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
311336	17691813	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccccc1CNc1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1		CHEMBL3663779	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311337	17691814	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)cc1F		CHEMBL3663780	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311338	17691815	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccncc2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663781	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311339	17691816	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCC2CCNCC2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663782	=	IC50	nM	550.0	CHEMBL3116	Homo sapiens	IC50	nM	550.0
311340	17691817	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCC2CCCNC2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663783	=	IC50	nM	170.0	CHEMBL3116	Homo sapiens	IC50	nM	170.0
311341	17691818	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(-c2ccccc2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663784	=	IC50	nM	5100.0	CHEMBL3116	Homo sapiens	IC50	nM	5100.0
311342	17691819	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(Nc1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1)c1ccccc1		CHEMBL3663785	=	IC50	nM	19000.0	CHEMBL3116	Homo sapiens	IC50	nM	19000.0
311343	17691820	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN(Cc1ccccc1)c1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1		CHEMBL3663786	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311344	17691821	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCN(Cc1ccccc1)c1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1		CHEMBL3663787	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	nM	48.0
311345	17691822	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCC2CCOCC2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663788	=	IC50	nM	81.0	CHEMBL3116	Homo sapiens	IC50	nM	81.0
311346	17691823	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCC2CCCOC2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663789	=	IC50	nM	87.0	CHEMBL3116	Homo sapiens	IC50	nM	87.0
311347	17691824	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=S(=O)(Nc1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)c1)c1ccccc1		CHEMBL3663790	=	IC50	nM	570.0	CHEMBL3116	Homo sapiens	IC50	nM	570.0
311348	17691825	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663791	=	IC50	nM	49.0	CHEMBL3116	Homo sapiens	IC50	nM	49.0
311349	17691826	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1cnc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663792	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311350	17691827	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663793	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311351	17691828	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5ccccc5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3663794	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311352	17691829	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	C[C@H](Nc1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1)c1ccccc1		CHEMBL3663795	=	IC50	nM	49.0	CHEMBL3116	Homo sapiens	IC50	nM	49.0
311353	17691830	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3663796	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311354	17691831	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5cccc(F)c5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3663797	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311355	17691832	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(OCc2ccccc2)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3663798	=	IC50	nM	24.0	CHEMBL3116	Homo sapiens	IC50	nM	24.0
311356	17691833	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCNC3)cc12		CHEMBL3663799	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311357	17691834	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CCNC3)cc12		CHEMBL3663800	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311358	17691835	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@H]3CCNC3)cc12		CHEMBL3663801	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311359	17691836	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@@H]3CCNC3)cc12		CHEMBL3663802	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311360	17691837	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C)C3)cc12		CHEMBL3663803	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
311361	17691838	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccccc2)nc1-c1ccnc2[nH]c(C3CCNC3)cc12		CHEMBL3663804	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311362	17691839	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCC2CCOCC2)nc1-c1ccnc2[nH]c(C3CCNC3)cc12		CHEMBL3663805	=	IC50	nM	200.0	CHEMBL3116	Homo sapiens	IC50	nM	200.0
311363	17691840	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CNCCO3)cc12		CHEMBL3663806	=	IC50	nM	42.0	CHEMBL3116	Homo sapiens	IC50	nM	42.0
311364	17691841	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CNCCO3)cc12		CHEMBL3663807	=	IC50	nM	37.0	CHEMBL3116	Homo sapiens	IC50	nM	37.0
311365	17691842	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CN(C)CCO3)cc12		CHEMBL3663808	=	IC50	nM	510.0	CHEMBL3116	Homo sapiens	IC50	nM	510.0
311366	17691843	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(C)CCO3)cc12		CHEMBL3668343	=	IC50	nM	250.0	CHEMBL3116	Homo sapiens	IC50	nM	250.0
311367	17691844	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccccc2)nc1-c1ccnc2[nH]c(C3CNCCO3)cc12		CHEMBL3668344	=	IC50	nM	65.0	CHEMBL3116	Homo sapiens	IC50	nM	65.0
311368	17691845	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CNC(C)(C)CO3)cc12		CHEMBL3668345	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	nM	63.0
311369	17691846	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)ccc1-c1ccnc2[nH]c(C3CNC(C)(C)CO3)cc12		CHEMBL3668346	=	IC50	nM	360.0	CHEMBL3116	Homo sapiens	IC50	nM	360.0
311370	17691847	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(Cl)ccc1-c1ccnc2[nH]c(C3CNC(C)(C)CO3)cc12		CHEMBL3668347	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
311371	17691848	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCC(N)CC3)cc12		CHEMBL3668348	=	IC50	nM	24.0	CHEMBL3116	Homo sapiens	IC50	nM	24.0
311372	17691849	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCC(N)C3)cc12		CHEMBL3668349	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311373	17691850	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCNCC3)c(C)c12		CHEMBL3668350	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311374	17691851	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1cnc2[nH]c(C3CCNCC3)cc2c1-c1cccc(NCc2ccccc2)n1		CHEMBL3668351	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311375	17691852	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(-c2c(Cl)cnc3[nH]c(C4CCCNC4)cc23)c1		CHEMBL3668352	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	nM	63.0
311376	17691853	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(-c2c(Cl)cnc3[nH]c(C4CCCNC4)cc23)n1		CHEMBL3668353	=	IC50	nM	840.0	CHEMBL3116	Homo sapiens	IC50	nM	840.0
311377	17691854	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1cnc2[nH]c(C3CCCNC3)cc2c1-c1cccc(NCc2ccccc2)n1		CHEMBL3668354	=	IC50	nM	39.0	CHEMBL3116	Homo sapiens	IC50	nM	39.0
311378	17691855	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1cnc2[nH]c(C3CCCNC3)cc2c1-c1cccc(NCC2CCOCC2)n1		CHEMBL3668355	=	IC50	nM	640.0	CHEMBL3116	Homo sapiens	IC50	nM	640.0
311379	17691856	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCCC(c2cc3c(-c4cccc(NCc5ccccc5)n4)c(Cl)cnc3[nH]2)C1		CHEMBL3668356	=	IC50	nM	180.0	CHEMBL3116	Homo sapiens	IC50	nM	180.0
311380	17691857	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COC(=O)N1CCCC(c2cc3c(-c4cccc(NCc5ccccc5)n4)c(Cl)cnc3[nH]2)C1		CHEMBL3668357	=	IC50	nM	1300.0	CHEMBL3116	Homo sapiens	IC50	nM	1300.0
311381	17691858	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CC(C)S(=O)(=O)N1CCCC(c2cc3c(-c4cccc(NCc5ccccc5)n4)c(Cl)cnc3[nH]2)C1		CHEMBL3668358	=	IC50	nM	600.0	CHEMBL3116	Homo sapiens	IC50	nM	600.0
311382	17691859	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	NC1CCCC(c2cc3c(-c4cccc(F)c4)c(Cl)cnc3[nH]2)C1		CHEMBL3668359	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
311383	17691860	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	NC1CCCC(c2cc3c(-c4cccc(NCc5ccccc5)n4)c(Cl)cnc3[nH]2)C1		CHEMBL3668360	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
311384	17691861	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCNCC3)cc12		CHEMBL3668361	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
311385	17691862	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1cc(NCC2CCOCC2)nc(-c2ccnc3[nH]c(C4CCNCC4)cc23)c1		CHEMBL3668362	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
311386	17691863	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCC5CCOCC5)n4)ccnc3[nH]2)CC1		CHEMBL3668363	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
311387	17691864	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5cccnc5)n4)ccnc3[nH]2)CC1		CHEMBL3668364	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
311388	17691865	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCCSc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3668365	=	IC50	nM	51.0	CHEMBL3116	Homo sapiens	IC50	nM	51.0
311389	17691866	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCC5CC5)n4)ccnc3[nH]2)CC1		CHEMBL3668366	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
311390	17691867	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN3)cc12		CHEMBL3668367	=	IC50	nM	580.0	CHEMBL3116	Homo sapiens	IC50	nM	580.0
311391	17691868	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCC5CCOC(C)(C)C5)n4)ccnc3[nH]2)CC1		CHEMBL3668368	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
311392	17691869	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(N(C)Cc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3668369	=	IC50	nM	50.0	CHEMBL3116	Homo sapiens	IC50	nM	50.0
311393	17691870	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5cccc(Cl)c5)n4)ccnc3[nH]2)CC1		CHEMBL3668370	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311394	17691871	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCCC3)cc12		CHEMBL3668371	=	IC50	nM	270.0	CHEMBL3116	Homo sapiens	IC50	nM	270.0
311395	17691872	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN3C(C)=O)cc12		CHEMBL3668372	=	IC50	nM	1300.0	CHEMBL3116	Homo sapiens	IC50	nM	1300.0
311396	17691873	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(C)=O)CC3)cc12		CHEMBL3668373	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311397	17691874	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)CO)CC3)cc12		CHEMBL3668374	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
311398	17691875	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5c(F)cccc5F)n4)ccnc3[nH]2)CC1		CHEMBL3668375	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
311399	17691876	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN3C)cc12		CHEMBL3668376	=	IC50	nM	430.0	CHEMBL3116	Homo sapiens	IC50	nM	430.0
311400	17691877	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	C[C@H](Nc1cccc(-c2ccnc3[nH]c(C4CCN(C)CC4)cc23)n1)c1ccccc1		CHEMBL3668377	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
311401	17691878	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5ccc6c(c5)OCO6)n4)ccnc3[nH]2)CC1		CHEMBL3668378	=	IC50	nM	13.0	CHEMBL3116	Homo sapiens	IC50	nM	13.0
311402	17691879	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Nc1ccc(Cl)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1		CHEMBL3668379	=	IC50	nM	180.0	CHEMBL3116	Homo sapiens	IC50	nM	180.0
311403	17691880	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1ccc(SCCNc2cccc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)cc1		CHEMBL3668380	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
311404	17691881	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(C)=O)C3)cc12		CHEMBL3668381	=	IC50	nM	74.0	CHEMBL3116	Homo sapiens	IC50	nM	74.0
311405	17691882	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CCO)C3)cc12		CHEMBL3668382	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
311406	17691883	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C4CCOCC4)C3)cc12		CHEMBL3668383	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
311407	17691884	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(Cc4ccccn4)C3)cc12		CHEMBL3668384	=	IC50	nM	38.0	CHEMBL3116	Homo sapiens	IC50	nM	38.0
311408	17691885	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(Cc4cccnc4)C3)cc12		CHEMBL3668385	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311409	17691886	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(Cc4ccncc4)C3)cc12		CHEMBL3668386	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311410	17691887	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC4CCCOC4)C3)cc12		CHEMBL3668387	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
311411	17691888	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CCNC(=O)OC(C)(C)C)C3)cc12		CHEMBL3668388	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
311412	17691889	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C4CCN(C(=O)OC(C)(C)C)C4)C3)cc12		CHEMBL3668389	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
311413	17691890	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC4CCOCC4)C3)cc12		CHEMBL3668390	=	IC50	nM	61.0	CHEMBL3116	Homo sapiens	IC50	nM	61.0
311414	17691891	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CCN4CCOCC4)C3)cc12		CHEMBL3668391	=	IC50	nM	43.0	CHEMBL3116	Homo sapiens	IC50	nM	43.0
311415	17691892	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)cc12		CHEMBL3668392	=	IC50	nM	37.0	CHEMBL3116	Homo sapiens	IC50	nM	37.0
311416	17691893	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COC(=O)CCCN[C@H]1CC[C@H](c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668393	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
311417	17691894	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCOC(=O)C1CC1CN[C@H]1CC[C@H](c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668394	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
311418	17691895	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@H]3CC[C@H](NCC(O)CO)CC3)cc12		CHEMBL3668395	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	nM	28.0
311419	17691896	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CCN)C3)cc12		CHEMBL3668396	=	IC50	nM	39.0	CHEMBL3116	Homo sapiens	IC50	nM	39.0
311420	17691897	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C4CCNC4)C3)cc12		CHEMBL3668397	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
311421	17691898	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3(O)CCNCC3)cc12		CHEMBL3668398	=	IC50	nM	75.0	CHEMBL3116	Homo sapiens	IC50	nM	75.0
311422	17691899	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN(CCCNC(=O)OCc4ccccc4)C3)cc12		CHEMBL3668399	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311423	17691900	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN(CCO)C3)cc12		CHEMBL3668400	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311424	17691901	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCN(CCCN)C3)cc12		CHEMBL3668401	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311425	17691902	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COCCN1CCCC(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)C1		CHEMBL3668402	=	IC50	nM	50.0	CHEMBL3116	Homo sapiens	IC50	nM	50.0
311426	17691903	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@H]3CC[C@H](NCCCC(=O)O)CC3)cc12		CHEMBL3668403	=	IC50	nM	64.0	CHEMBL3116	Homo sapiens	IC50	nM	64.0
311427	17691904	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(N)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668404	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
311428	17691905	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(Nc5nc(N)ccc5Cl)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668405	=	IC50	nM	1500.0	CHEMBL3116	Homo sapiens	IC50	nM	1500.0
311429	17691906	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCC5CCOCC5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668406	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
311430	17691907	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(C)=O)CC3)cc12		CHEMBL3668407	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
311431	17691908	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(=O)CO)CC3)cc12		CHEMBL3668408	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311432	17691909	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(C#N)ccc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668409	=	IC50	nM	39.0	CHEMBL3116	Homo sapiens	IC50	nM	39.0
311433	17691910	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1ccc(CCNc2cccc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)cc1		CHEMBL3668410	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311434	17691911	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(N(C)CCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3668411	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
311435	17691912	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccccc1CNc1cccc(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1		CHEMBL3668412	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
311436	17691913	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5ccccc5Cl)n4)ccnc3[nH]2)CC1		CHEMBL3668413	=	IC50	nM	24.0	CHEMBL3116	Homo sapiens	IC50	nM	24.0
311437	17691914	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(N(C)Cc5ccccc5Cl)n4)ccnc3[nH]2)CC1		CHEMBL3668414	=	IC50	nM	69.0	CHEMBL3116	Homo sapiens	IC50	nM	69.0
311438	17691915	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C1CCCN1CCNc1cccc(-c2ccnc3[nH]c(C4CCNCC4)cc23)n1		CHEMBL3668415	=	IC50	nM	320.0	CHEMBL3116	Homo sapiens	IC50	nM	320.0
311439	17691916	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(N(C)CCN5CCCC5=O)n4)ccnc3[nH]2)CC1		CHEMBL3668416	=	IC50	nM	370.0	CHEMBL3116	Homo sapiens	IC50	nM	370.0
311440	17691917	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c([C@H]3CC[C@H](NCC4CC4C(=O)O)CC3)cc12		CHEMBL3668417	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
311441	17691918	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CNC3)cc12		CHEMBL3668418	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
311442	17691919	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(=O)CN4CCC(O)CC4)CC3)cc12		CHEMBL3668419	=	IC50	nM	31.0	CHEMBL3116	Homo sapiens	IC50	nM	31.0
311443	17691920	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(S(C)(=O)=O)CC3)cc12		CHEMBL3639672	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311444	17691921	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(O)CO)CC3)cc12		CHEMBL3668420	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311445	17691922	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3668421	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311446	17691923	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCCN5CCCC5=O)n4)ccnc3[nH]2)CC1		CHEMBL3668422	=	IC50	nM	340.0	CHEMBL3116	Homo sapiens	IC50	nM	340.0
311447	17691924	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCC5CC5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668423	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	nM	96.0
311448	17691925	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN(C)CCOc1ccc(CNc2cccc(-c3ccnc4[nH]c(C5CCN(C)CC5)cc34)n2)cc1		CHEMBL3668424	=	IC50	nM	47.0	CHEMBL3116	Homo sapiens	IC50	nM	47.0
311449	17691926	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCC5CCOC(C)(C)C5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668425	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
311450	17691927	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5ccncc5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668426	=	IC50	nM	51.0	CHEMBL3116	Homo sapiens	IC50	nM	51.0
311451	17691928	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5cc[nH]n5)n4)ccnc3[nH]2)CC1		CHEMBL3668427	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311452	17691929	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5ccc6c(c5)CNC6)n4)ccnc3[nH]2)CC1		CHEMBL3668428	=	IC50	nM	49.0	CHEMBL3116	Homo sapiens	IC50	nM	49.0
311453	17691930	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCC5CCN(C)C5)n4)ccnc3[nH]2)CC1		CHEMBL3668429	=	IC50	nM	91.0	CHEMBL3116	Homo sapiens	IC50	nM	91.0
311454	17691931	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCc5ccc6cc[nH]c6c5)n4)ccnc3[nH]2)CC1		CHEMBL3668430	=	IC50	nM	86.0	CHEMBL3116	Homo sapiens	IC50	nM	86.0
311455	17691932	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5ccc(S(C)(=O)=O)cc5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668431	=	IC50	nM	41.0	CHEMBL3116	Homo sapiens	IC50	nM	41.0
311456	17691933	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5ccc(S(N)(=O)=O)cc5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668432	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
311457	17691934	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5ccc(C(N)=O)cc5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668433	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	nM	28.0
311458	17691935	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCCN5CCOCC5)n4)ccnc3[nH]2)CC1		CHEMBL3668434	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
311459	17691936	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cccc(NCCO)n4)ccnc3[nH]2)CC1		CHEMBL3668435	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
311460	17691937	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCC5CCNCC5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668436	=	IC50	nM	450.0	CHEMBL3116	Homo sapiens	IC50	nM	450.0
311461	17691938	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3(O)CCOCC3)cc12		CHEMBL3668437	=	IC50	nM	270.0	CHEMBL3116	Homo sapiens	IC50	nM	270.0
311462	17691939	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(Cc4ccncc4)C3)cc12		CHEMBL3668438	=	IC50	nM	73.0	CHEMBL3116	Homo sapiens	IC50	nM	73.0
311463	17691940	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(C(C)=O)C3)cc12		CHEMBL3668439	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	nM	160.0
311464	17691941	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(CCN)C3)cc12		CHEMBL3668440	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
311465	17691942	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(CC4CCOCC4)C3)cc12		CHEMBL3668441	=	IC50	nM	290.0	CHEMBL3116	Homo sapiens	IC50	nM	290.0
311466	17691943	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(CCN4CCOCC4)C3)cc12		CHEMBL3668442	=	IC50	nM	90.0	CHEMBL3116	Homo sapiens	IC50	nM	90.0
311467	17691944	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(CCO)C3)cc12		CHEMBL3668443	=	IC50	nM	76.0	CHEMBL3116	Homo sapiens	IC50	nM	76.0
311468	17691945	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCC5CCN(C(=O)OC(C)(C)C)C5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668444	=	IC50	nM	75.0	CHEMBL3116	Homo sapiens	IC50	nM	75.0
311469	17691946	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCC5CCS(=O)(=O)CC5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668445	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311470	17691947	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5cccc(OCC(=O)O)c5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668446	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
311471	17691948	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5ccc(OCC(=O)O)cc5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668447	=	IC50	nM	35.0	CHEMBL3116	Homo sapiens	IC50	nM	35.0
311472	17691949	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CC(=O)N1CCC(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCN(C)CC5)cc34)n2)CC1		CHEMBL3668448	=	IC50	nM	55.0	CHEMBL3116	Homo sapiens	IC50	nM	55.0
311473	17691950	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5nnc[nH]5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668449	=	IC50	nM	78.0	CHEMBL3116	Homo sapiens	IC50	nM	78.0
311474	17691951	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cc(NCC5CCOCC5)ccc4F)ccnc3[nH]2)CC1		CHEMBL3668450	=	IC50	nM	52.0	CHEMBL3116	Homo sapiens	IC50	nM	52.0
311475	17691952	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(=O)CN4CCCCC4)CC3)cc12		CHEMBL3668451	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311476	17691953	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(=O)CN4CCOCC4)CC3)cc12		CHEMBL3668452	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311477	17691954	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(=O)CNC4CCC(O)CC4)CC3)cc12		CHEMBL3668453	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
311478	17691955	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(C(=O)CNCCO)CC3)cc12		CHEMBL3668454	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
311479	17691956	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(C)C3)cc12		CHEMBL3668455	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
311480	17691957	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CN(S(C)(=O)=O)C3)cc12		CHEMBL3668456	=	IC50	nM	140.0	CHEMBL3116	Homo sapiens	IC50	nM	140.0
311481	17691958	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(O)CO)CC3)cc12		CHEMBL3668457	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
311482	17691959	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Nc1ccc(F)c(-c2ccnc3[nH]c(C4CCNCC4)cc23)c1		CHEMBL3668458	=	IC50	nM	67.0	CHEMBL3116	Homo sapiens	IC50	nM	67.0
311483	17691960	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4nc(NCc5cccc(S(C)(=O)=O)c5)ccc4Cl)ccnc3[nH]2)CC1		CHEMBL3668459	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
311484	17691961	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cc(NCc5ccncc5)ccc4F)ccnc3[nH]2)CC1		CHEMBL3668460	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311485	17691962	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cc(NCc5ccc(S(C)(=O)=O)cc5)ccc4F)ccnc3[nH]2)CC1		CHEMBL3668461	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
311486	17691963	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cc(NCc5ccc(C(N)=O)cc5)ccc4F)ccnc3[nH]2)CC1		CHEMBL3668462	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311487	17691964	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O[C@@H]1CN[C@@H](CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)C1		CHEMBL3668463	=	IC50	nM	810.0	CHEMBL3116	Homo sapiens	IC50	nM	810.0
311488	17691965	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCCCNC3)cc12		CHEMBL3668464	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311489	17691966	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(NCc2ccccc2)cc1-c1c(Cl)cnc2[nH]c(C3CCNCC3)cc12		CHEMBL3668465	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311490	17691967	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	F[C@@H]1CN[C@H](CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)C1		CHEMBL3668466	=	IC50	nM	910.0	CHEMBL3116	Homo sapiens	IC50	nM	910.0
311491	17691968	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	N#CC1(CNc2cc(-c3ccnc4[nH]c(C5CCNCC5)cc34)c(Cl)cn2)CCOCC1		CHEMBL3668467	=	IC50	nM	730.0	CHEMBL3116	Homo sapiens	IC50	nM	730.0
311492	17691969	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	FC1(F)CN[C@H](CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)C1		CHEMBL3668468	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	nM	160.0
311493	17691970	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668469	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
311494	17691971	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN(Cc1ccccc1)c1ccc(Cl)c(-c2ccnc3[nH]c(C4CCCNC4)cc23)n1		CHEMBL3668470	=	IC50	nM	55.0	CHEMBL3116	Homo sapiens	IC50	nM	55.0
311495	17691972	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1cc(F)c(F)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668471	=	IC50	nM	26.0	CHEMBL3116	Homo sapiens	IC50	nM	26.0
311496	17691973	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCCNC5)cc34)n2)cc1F		CHEMBL3668472	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
311497	17691974	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCCNC5)cc34)n2)c1		CHEMBL3668473	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
311498	17691975	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCCNC5)cc34)n2)cc1		CHEMBL3668474	=	IC50	nM	27.0	CHEMBL3116	Homo sapiens	IC50	nM	27.0
311499	17691976	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1cnc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668475	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311500	17691977	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668476	=	IC50	nM	11.0	CHEMBL3116	Homo sapiens	IC50	nM	11.0
311501	17691978	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccccc1CNc1ccc(Cl)c(-c2ccnc3[nH]c(C4CCCNC4)cc23)n1		CHEMBL3668477	=	IC50	nM	66.0	CHEMBL3116	Homo sapiens	IC50	nM	66.0
311502	17691979	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(NCc2cccnc2)nc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668478	=	IC50	nM	43.0	CHEMBL3116	Homo sapiens	IC50	nM	43.0
311503	17691980	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1ccc(OCc2cccnc2)nc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668479	=	IC50	nM	80.0	CHEMBL3116	Homo sapiens	IC50	nM	80.0
311504	17691981	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cncc(CNc2ccc(Cl)c(-c3ccnc4[nH]c(C5CCCNC5)cc34)n2)c1		CHEMBL3668480	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311505	17691982	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cnc(NCc2ccccc2)cc1-c1ccnc2[nH]c(C3CCCNC3)cc12		CHEMBL3668481	=	IC50	nM	18.0	CHEMBL3116	Homo sapiens	IC50	nM	18.0
311506	17691983	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cc(NCc2ccccc2)nc(-c2ccnc3[nH]c(C4CCCNC4)cc23)c1		CHEMBL3668482	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311507	17691984	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Clc1cnc2[nH]c(C3CCCNC3)cc2c1-c1ccnc(NCc2ccccc2)c1		CHEMBL3668483	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
311508	17691985	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2ccc(F)c(-c3ccnc4[nH]c(C5CCCNC5)cc34)c2)c1		CHEMBL3668484	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311509	17691986	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668485	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311510	17691987	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(N)(=O)=O)CC3)cc12		CHEMBL3668486	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
311511	17691988	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(Cc4ccc(NC(C)=O)cc4)CC3)cc12		CHEMBL3668487	=	IC50	nM	56.0	CHEMBL3116	Homo sapiens	IC50	nM	56.0
311512	17691989	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(=O)(=O)N(C(=O)O)C(C)(C)C)CC3)cc12		CHEMBL3668488	=	IC50	nM	64.0	CHEMBL3116	Homo sapiens	IC50	nM	64.0
311513	17691990	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C(=O)O)CC3)cc12		CHEMBL3668489	=	IC50	nM	62.0	CHEMBL3116	Homo sapiens	IC50	nM	62.0
311514	17691991	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(F)c4F)ccnc3[nH]2)CC1		CHEMBL3668490	=	IC50	nM	53.0	CHEMBL3116	Homo sapiens	IC50	nM	53.0
311515	17691992	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)CC#N)CC3)cc12		CHEMBL3668491	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311516	17691993	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2cc3c(-c4cccc(F)c4F)ccnc3[nH]2)CC1		CHEMBL3668492	=	IC50	nM	84.0	CHEMBL3116	Homo sapiens	IC50	nM	84.0
311517	17691994	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668493	=	IC50	nM	39.0	CHEMBL3116	Homo sapiens	IC50	nM	39.0
311518	17691995	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)Nc4cnn(C)c4)CC3)cc12		CHEMBL3668494	=	IC50	nM	37.0	CHEMBL3116	Homo sapiens	IC50	nM	37.0
311519	17691996	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)O)CC3)cc12		CHEMBL3668495	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
311520	17691997	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(N)=O)CC3)cc12		CHEMBL3668496	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	nM	28.0
311521	17691998	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCN(C(=O)O)S(=O)(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668497	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311522	17691999	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)c(Cl)cnc3[nH]2)CC1		CHEMBL3668498	=	IC50	nM	101.0	CHEMBL3116	Homo sapiens	IC50	nM	101.0
311523	17692000	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668499	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
311524	17692001	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2cc3c(-c4cc(F)c(F)cc4OC)ccnc3[nH]2)CC1		CHEMBL3668500	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311525	17692002	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN(C)C(=O)CN1CC=C(c2cc3c(-c4cccc(F)c4F)ccnc3[nH]2)CC1		CHEMBL3668501	=	IC50	nM	47.0	CHEMBL3116	Homo sapiens	IC50	nM	47.0
311526	17692003	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668502	=	IC50	nM	38.0	CHEMBL3116	Homo sapiens	IC50	nM	38.0
311527	17692004	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3=CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668503	=	IC50	nM	126.0	CHEMBL3116	Homo sapiens	IC50	nM	126.0
311528	17692005	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCN(C(=O)O)S(=O)(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)c(F)cnc3[nH]2)CC1		CHEMBL3668504	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
311529	17692006	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N4CC(O)C4)CC3)cc12		CHEMBL3668505	=	IC50	nM	62.0	CHEMBL3116	Homo sapiens	IC50	nM	62.0
311530	17692007	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N4CCC[C@H]4CO)CC3)cc12		CHEMBL3668506	=	IC50	nM	53.0	CHEMBL3116	Homo sapiens	IC50	nM	53.0
311531	17692008	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)[C@H]4C[C@@H](O)CN4)CC3)cc12		CHEMBL3668507	=	IC50	nM	56.0	CHEMBL3116	Homo sapiens	IC50	nM	56.0
311532	17692009	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N[C@@H](C(=O)O)C(C)C)CC3)cc12		CHEMBL3668508	=	IC50	nM	80.0	CHEMBL3116	Homo sapiens	IC50	nM	80.0
311533	17692010	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCC[C@H]4C(=O)O)CC3)cc12		CHEMBL3668509	=	IC50	nM	70.0	CHEMBL3116	Homo sapiens	IC50	nM	70.0
311534	17692011	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)NC#N)CC3)cc12		CHEMBL3668510	=	IC50	nM	27.0	CHEMBL3116	Homo sapiens	IC50	nM	27.0
311535	17692012	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N4CCC[C@H]4C(N)=O)CC3)cc12		CHEMBL3668511	=	IC50	nM	118.0	CHEMBL3116	Homo sapiens	IC50	nM	118.0
311536	17692013	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(N)=O)CC3)cc12		CHEMBL3668512	=	IC50	nM	32.0	CHEMBL3116	Homo sapiens	IC50	nM	32.0
311537	17692014	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)CN1CCC(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668513	=	IC50	nM	39.0	CHEMBL3116	Homo sapiens	IC50	nM	39.0
311538	17692015	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(=O)N4CCC[C@H]4CO)CC3)cc12		CHEMBL3668514	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
311539	17692016	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)c(C#N)c12		CHEMBL3668515	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
311540	17692017	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2[nH]c3nccc(-c4cc(F)ccc4OC)c3c2C#N)CC1		CHEMBL3668516	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	nM	28.0
311541	17692018	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCN(C(=O)O)S(=O)(=O)NC1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668517	=	IC50	nM	47.0	CHEMBL3116	Homo sapiens	IC50	nM	47.0
311542	17692019	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(=O)N(C)CCO)CC3)cc12		CHEMBL3668518	=	IC50	nM	56.0	CHEMBL3116	Homo sapiens	IC50	nM	56.0
311543	17692020	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(=O)NC4CC(O)C4)CC3)cc12		CHEMBL3639673	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
311544	17692021	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(=O)N4CC(O)C4)CC3)cc12		CHEMBL3668519	=	IC50	nM	77.0	CHEMBL3116	Homo sapiens	IC50	nM	77.0
311545	17692022	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N[C@H](C(=O)O)C(C)(C)C)CC3)cc12		CHEMBL3668520	=	IC50	nM	95.0	CHEMBL3116	Homo sapiens	IC50	nM	95.0
311546	17692023	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668521	=	IC50	nM	90.0	CHEMBL3116	Homo sapiens	IC50	nM	90.0
311547	17692024	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N(C)C)CC3)c(C#N)c12		CHEMBL3668522	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
311548	17692025	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccccc1-c1ccnc2[nH]c(C3CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668523	=	IC50	nM	82.0	CHEMBL3116	Homo sapiens	IC50	nM	82.0
311549	17692026	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=C[C@H](C)N(S(C)(=O)=O)CC3)cc12		CHEMBL3668524	=	IC50	nM	85.0	CHEMBL3116	Homo sapiens	IC50	nM	85.0
311550	17692027	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3CCN(CC(=O)N4CC(O)C4)CC3)cc12		CHEMBL3668525	=	IC50	nM	102.0	CHEMBL3116	Homo sapiens	IC50	nM	102.0
311551	17692028	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N(C)C)[C@H](CO)C3)cc12		CHEMBL3668526	=	IC50	nM	111.0	CHEMBL3116	Homo sapiens	IC50	nM	111.0
311552	17692029	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=C[C@@H](CO)N(CC(=O)N(C)C)CC3)cc12		CHEMBL3668527	=	IC50	nM	93.0	CHEMBL3116	Homo sapiens	IC50	nM	93.0
311553	17692030	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=C[C@H]4CN(S(C)(=O)=O)C[C@H]4C3)cc12		CHEMBL3668528	=	IC50	nM	91.0	CHEMBL3116	Homo sapiens	IC50	nM	91.0
311554	17692031	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(CC(=O)N(C)C)CC3)c(C#N)c12		CHEMBL3668529	=	IC50	nM	101.0	CHEMBL3116	Homo sapiens	IC50	nM	101.0
311555	17692032	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)c(C#N)c12		CHEMBL3668530	=	IC50	nM	49.0	CHEMBL3116	Homo sapiens	IC50	nM	49.0
311556	17692033	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2[nH]c3ncc(F)c(-c4cc(F)ccc4OC)c3c2C#N)CC1		CHEMBL3668531	=	IC50	nM	85.0	CHEMBL3116	Homo sapiens	IC50	nM	85.0
311557	17692034	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(CC(=O)N4CC(O)C4)CC3)c(C#N)c12		CHEMBL3668532	=	IC50	nM	135.0	CHEMBL3116	Homo sapiens	IC50	nM	135.0
311558	17692035	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(CC(=O)N4CCC[C@@H]4CO)CC3)c(C#N)c12		CHEMBL3668533	=	IC50	nM	149.0	CHEMBL3116	Homo sapiens	IC50	nM	149.0
311559	17692036	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=C[C@H](CO)N(CC(=O)N(C)C)CC3)cc12		CHEMBL3668534	=	IC50	nM	115.0	CHEMBL3116	Homo sapiens	IC50	nM	115.0
311560	17692037	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N(C)C)[C@@H](CO)C3)cc12		CHEMBL3668535	=	IC50	nM	82.0	CHEMBL3116	Homo sapiens	IC50	nM	82.0
311561	17692038	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC(C)(C)N(S(C)(=O)=O)CC3)cc12		CHEMBL3668536	=	IC50	nM	104.0	CHEMBL3116	Homo sapiens	IC50	nM	104.0
311562	17692039	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(C)(=O)=O)C(C)(C)C3)cc12		CHEMBL3668537	=	IC50	nM	122.0	CHEMBL3116	Homo sapiens	IC50	nM	122.0
311563	17692040	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N(C)C)C(C)(C)C3)cc12		CHEMBL3668538	=	IC50	nM	81.0	CHEMBL3116	Homo sapiens	IC50	nM	81.0
311564	17692041	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COCCS(=O)(=O)N1CC2C=C(c3cc4c(-c5cc(F)ccc5OC)ccnc4[nH]3)CC2C1		CHEMBL3668539	=	IC50	nM	78.0	CHEMBL3116	Homo sapiens	IC50	nM	78.0
311565	17692042	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3CCN(CC(=O)N(C)C)CC3)cc12		CHEMBL3668540	=	IC50	nM	90.0	CHEMBL3116	Homo sapiens	IC50	nM	90.0
311566	17692043	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3CCN(CC(=O)N(C)C4CC(O)C4)CC3)cc12		CHEMBL3668541	=	IC50	nM	66.0	CHEMBL3116	Homo sapiens	IC50	nM	66.0
311567	17692044	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3=CC4CN(S(C)(=O)=O)CC4C3)cc12		CHEMBL3668542	=	IC50	nM	87.0	CHEMBL3116	Homo sapiens	IC50	nM	87.0
311568	17692045	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3=CC4CN(CC(=O)N(C)C)CC4C3)cc12		CHEMBL3668543	=	IC50	nM	86.0	CHEMBL3116	Homo sapiens	IC50	nM	86.0
311569	17692046	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCC(C(=O)O)CC3)cc12		CHEMBL3668544	=	IC50	nM	124.0	CHEMBL3116	Homo sapiens	IC50	nM	124.0
311570	17692047	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CN(C(=O)CO)CC4C3)cc12		CHEMBL3668545	=	IC50	nM	71.0	CHEMBL3116	Homo sapiens	IC50	nM	71.0
311571	17692048	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CN(C(=O)CC#N)CC4C3)cc12		CHEMBL3668546	=	IC50	nM	77.0	CHEMBL3116	Homo sapiens	IC50	nM	77.0
311572	17692049	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CC4CN(S(C)(=O)=O)CC4C3)cc12		CHEMBL3668547	=	IC50	nM	117.0	CHEMBL3116	Homo sapiens	IC50	nM	117.0
311573	17692050	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3=CCN(CC(=O)N4CCC[C@H]4CO)CC3)cc12		CHEMBL3668548	=	IC50	nM	172.0	CHEMBL3116	Homo sapiens	IC50	nM	172.0
311574	17692051	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1C[C@H]2C=C(c3cc4c(-c5cc(F)ccc5OC)ccnc4[nH]3)C[C@H]2C1		CHEMBL3668549	=	IC50	nM	71.0	CHEMBL3116	Homo sapiens	IC50	nM	71.0
311575	17692052	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1C[C@H]2CC(c3cc4c(-c5cc(F)ccc5OC)ccnc4[nH]3)=C[C@H]2C1		CHEMBL3668550	=	IC50	nM	93.0	CHEMBL3116	Homo sapiens	IC50	nM	93.0
311576	17692053	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC2C=C(c3cc4c(-c5cc(F)ccc5OC)c(F)cnc4[nH]3)CC2C1		CHEMBL3668551	=	IC50	nM	201.0	CHEMBL3116	Homo sapiens	IC50	nM	201.0
311577	17692054	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CC4CN(CC(=O)N(C)C)CC4C3)cc12		CHEMBL3668552	=	IC50	nM	104.0	CHEMBL3116	Homo sapiens	IC50	nM	104.0
311578	17692055	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)cc12		CHEMBL3668553	=	IC50	nM	71.0	CHEMBL3116	Homo sapiens	IC50	nM	71.0
311579	17692056	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)cc12		CHEMBL3668554	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
311580	17692057	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3CCN(CC(=O)N4CCC[C@H]4CO)CC3)cc12		CHEMBL3668555	=	IC50	nM	78.0	CHEMBL3116	Homo sapiens	IC50	nM	78.0
311581	17692058	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNS(=O)(=O)CC(=O)N1CC2C=C(c3cc4c(-c5cc(F)ccc5OC)ccnc4[nH]3)CC2C1		CHEMBL3668556	=	IC50	nM	93.0	CHEMBL3116	Homo sapiens	IC50	nM	93.0
311582	17692059	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C4CCC(C(=O)O)CC4)CC3)cc12		CHEMBL3668557	=	IC50	nM	139.0	CHEMBL3116	Homo sapiens	IC50	nM	139.0
311583	17692060	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CC4CN(CC(=O)N5CC(O)C5)CC4C3)cc12		CHEMBL3668558	=	IC50	nM	70.0	CHEMBL3116	Homo sapiens	IC50	nM	70.0
311584	17692061	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(CC(=O)N4CC(O)C4)CC3)cc12		CHEMBL3668559	=	IC50	nM	42.0	CHEMBL3116	Homo sapiens	IC50	nM	42.0
311585	17692062	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CN(CC(=O)N5CC(O)C5)CC4C3)cc12		CHEMBL3668560	=	IC50	nM	119.0	CHEMBL3116	Homo sapiens	IC50	nM	119.0
311586	17692063	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CN(CC(=O)N5CCC[C@H]5CO)CC4C3)cc12		CHEMBL3668561	=	IC50	nM	125.0	CHEMBL3116	Homo sapiens	IC50	nM	125.0
311587	17692064	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(CC(=O)N4CCC(O)CC4)CC3)cc12		CHEMBL3668562	=	IC50	nM	83.0	CHEMBL3116	Homo sapiens	IC50	nM	83.0
311588	17692065	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN(C4CCC(CC(=O)O)CC4)CC3)cc12		CHEMBL3668563	=	IC50	nM	99.0	CHEMBL3116	Homo sapiens	IC50	nM	99.0
311589	17692066	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)N4CC(O)C4)C(C)(C)C3)cc12		CHEMBL3673490	=	IC50	nM	83.0	CHEMBL3116	Homo sapiens	IC50	nM	83.0
311590	17692067	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CC4CN(C(=O)C5CC(O)C5)CC4C3)cc12		CHEMBL3673491	=	IC50	nM	115.0	CHEMBL3116	Homo sapiens	IC50	nM	115.0
311591	17692068	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1c(C#N)cnc2[nH]c(C3=CC4CN(CC(=O)N5CCC[C@H]5CO)CC4C3)cc12		CHEMBL3673492	=	IC50	nM	138.0	CHEMBL3116	Homo sapiens	IC50	nM	138.0
311592	17692069	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2cc(-c3ccnc4[nH]c(C5CCNCC5)cc34)c(Cl)cn2)c1		CHEMBL3673493	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311593	17692070	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	NC1CCCC(c2cc3c(-c4cccc(NCc5cccc(F)c5)n4)ccnc3[nH]2)C1		CHEMBL3673494	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
311594	17692071	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(-c2ccnc3[nH]c(C4=CCNCC4)cc23)n1		CHEMBL3673495	=	IC50	nM	240.0	CHEMBL3116	Homo sapiens	IC50	nM	240.0
311595	17692072	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(F)n4)ccnc3[nH]2)CC1		CHEMBL3673496	=	IC50	nM	250.0	CHEMBL3116	Homo sapiens	IC50	nM	250.0
311596	17692073	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(NCc5c(F)cccc5F)n4)ccnc3[nH]2)CC1		CHEMBL3673497	=	IC50	nM	170.0	CHEMBL3116	Homo sapiens	IC50	nM	170.0
311597	17692074	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(NCc5ccccc5Cl)n4)ccnc3[nH]2)CC1		CHEMBL3673498	=	IC50	nM	490.0	CHEMBL3116	Homo sapiens	IC50	nM	490.0
311598	17692075	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(NCC5CC5)n4)ccnc3[nH]2)CC1		CHEMBL3673499	=	IC50	nM	260.0	CHEMBL3116	Homo sapiens	IC50	nM	260.0
311599	17692076	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673500	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311600	17692077	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1ccc(CNc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)cc1		CHEMBL3673501	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
311601	17692078	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1cc(-c2cncc(NCC3CCOCC3)n2)c2cc(C3CCNCC3)[nH]c2n1		CHEMBL3673502	=	IC50	nM	31.0	CHEMBL3116	Homo sapiens	IC50	nM	31.0
311602	17692079	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cc(F)cc(CNc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3673503	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
311603	17692080	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3673504	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
311604	17692081	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1cncc(CNc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3673505	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
311605	17692082	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	c1cc(CNc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)ccn1		CHEMBL3673506	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
311606	17692083	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(CNc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)cc1F		CHEMBL3673507	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
311607	17692084	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CCC(c2cc3c(-c4cncc(NCc5cc(F)cc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673508	=	IC50	nM	31.0	CHEMBL3116	Homo sapiens	IC50	nM	31.0
311608	17692085	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CCC(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673509	=	IC50	nM	11.0	CHEMBL3116	Homo sapiens	IC50	nM	11.0
311609	17692086	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673510	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	nM	40.0
311610	17692087	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cncc(N(C)Cc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673511	=	IC50	nM	620.0	CHEMBL3116	Homo sapiens	IC50	nM	620.0
311611	17692088	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673512	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
311612	17692089	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CC(=O)N1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673513	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
311613	17692090	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	OCC(O)CN1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673514	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	nM	28.0
311614	17692091	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCN(C(=O)O)S(=O)(=O)N1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673515	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311615	17692092	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1ccc(Cl)nc1-c1ccnc2[nH]c(C3CCNCC3)cc12		CHEMBL3673516	=	IC50	nM	2600.0	CHEMBL3116	Homo sapiens	IC50	nM	2600.0
311616	17692093	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(COc2cncc(-c3ccnc4[nH]c(C5CCNCC5)cc34)n2)c1		CHEMBL3673517	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
311617	17692094	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673518	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311618	17692095	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CC(=O)N1CCC(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673519	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311619	17692096	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673520	=	IC50	nM	13.0	CHEMBL3116	Homo sapiens	IC50	nM	13.0
311620	17692097	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	C1=C(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CCNC1		CHEMBL3673521	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
311621	17692098	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CCC(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673522	=	IC50	nM	27.0	CHEMBL3116	Homo sapiens	IC50	nM	27.0
311622	17692099	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	OCC(O)CN1CCC(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673523	=	IC50	nM	11.0	CHEMBL3116	Homo sapiens	IC50	nM	11.0
311623	17692100	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CCOC(=O)NS(=O)(=O)N1CCC(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673524	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311624	17692101	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CCC(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673525	=	IC50	nM	35.0	CHEMBL3116	Homo sapiens	IC50	nM	35.0
311625	17692102	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CCC(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673526	=	IC50	nM	19.0	CHEMBL3116	Homo sapiens	IC50	nM	19.0
311626	17692103	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CCC(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673527	=	IC50	nM	60.0	CHEMBL3116	Homo sapiens	IC50	nM	60.0
311627	17692104	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CC(=O)N1CCC(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673528	=	IC50	nM	24.0	CHEMBL3116	Homo sapiens	IC50	nM	24.0
311628	17692105	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CCC(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673529	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
311629	17692106	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2cncc(-c3ccnc4[nH]c(C5=CCNCC5)cc34)n2)c1		CHEMBL3673530	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
311630	17692107	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	OCC(O)CN1CC=C(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673531	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
311631	17692108	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(COc2cncc(-c3ccnc4[nH]c(C5=CCNCC5)cc34)n2)c1		CHEMBL3673532	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
311632	17692109	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673533	=	IC50	nM	17.0	CHEMBL3116	Homo sapiens	IC50	nM	17.0
311633	17692110	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CN1CCC(c2cc3c(-c4cncc(NCc5cccnc5)n4)ccnc3[nH]2)CC1		CHEMBL3673534	=	IC50	nM	41.0	CHEMBL3116	Homo sapiens	IC50	nM	41.0
311634	17692111	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	OCC(O)CN1CCC(c2cc3c(-c4cncc(NCc5cccnc5)n4)ccnc3[nH]2)CC1		CHEMBL3673535	=	IC50	nM	43.0	CHEMBL3116	Homo sapiens	IC50	nM	43.0
311635	17692112	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CCC(c2cc3c(-c4cncc(NCc5cccnc5)n4)ccnc3[nH]2)CC1		CHEMBL3673536	=	IC50	nM	81.0	CHEMBL3116	Homo sapiens	IC50	nM	81.0
311636	17692113	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CCC(c2cc3c(-c4cncc(NCc5cccnc5)n4)ccnc3[nH]2)CC1		CHEMBL3673537	=	IC50	nM	66.0	CHEMBL3116	Homo sapiens	IC50	nM	66.0
311637	17692114	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CC=C(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673538	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
311638	17692115	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673539	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
311639	17692116	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	Fc1cccc(CNc2nc(-c3ccnc4[nH]c(C5CCNCC5)cc34)c(F)cc2F)c1		CHEMBL3673540	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
311640	17692117	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CC=C(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673541	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
311641	17692118	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CC=C(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673542	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
311642	17692119	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4nc(NCc5cccc(F)c5)c(F)cc4F)ccnc3[nH]2)CC1		CHEMBL3673543	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
311643	17692120	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)N1CCC(c2cc3c(-c4nc(NCc5cccc(F)c5)c(F)cc4F)ccnc3[nH]2)CC1		CHEMBL3673544	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
311644	17692121	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(CO)N1CCC(c2cc3c(-c4nc(NCc5cccc(F)c5)c(F)cc4F)ccnc3[nH]2)CC1		CHEMBL3673545	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
311645	17692122	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(O)C1CC=C(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673546	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
311646	17692123	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)C1CC=C(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673547	=	IC50	nM	11.0	CHEMBL3116	Homo sapiens	IC50	nM	11.0
311647	17692124	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(O)C1CC=C(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673548	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
311648	17692125	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	O=C(O)C1CC=C(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673549	=	IC50	nM	18.0	CHEMBL3116	Homo sapiens	IC50	nM	18.0
311649	17692126	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	CNC(=O)C1CC=C(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673550	=	IC50	nM	84.0	CHEMBL3116	Homo sapiens	IC50	nM	84.0
311650	17692127	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	NC(=O)C1CC=C(c2cc3c(-c4cncc(OCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673551	=	IC50	nM	87.0	CHEMBL3116	Homo sapiens	IC50	nM	87.0
311651	17692128	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	NC(=O)C1CC=C(c2cc3c(-c4cncc(NCc5cccc(F)c5)n4)ccnc3[nH]2)CC1		CHEMBL3673552	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
311652	17692129	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	NC(=O)C1CC=C(c2cc3c(-c4cncc(NCc5ccccc5)n4)ccnc3[nH]2)CC1		CHEMBL3673553	=	IC50	nM	2200.0	CHEMBL3116	Homo sapiens	IC50	nM	2200.0
311653	17692130	CHEMBL3706310	LANCE ULight TR-FRET Kinase Assay: CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in 100% DMSO to white low volume assay plates (Perkin Elmer Proxiplate 6008289) using a Labcyte Echo acoustic dispenser. Assay reagents in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. were added for final reaction mixture concentrations of 1000 uM ATP, 100 nM U-light MBP peptide (Perkin Elmer TRF0109M) and reaction initiated with 4 nM CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 30 minutes before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer (PerkinElmer CR97-100). The reaction was equilibrated for 1 hour and the signal read in the Perkin Elmer Envision in TR-FRET mode.	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)OC(C)(C)C)CC3)cc12		CHEMBL3673554	=	IC50	nM	570.0	CHEMBL3116	Homo sapiens	IC50	nM	570.0
327464	17706191	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3906489	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327465	17706192	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3965161	=	IC50	nM	15.0	CHEMBL3116	Homo sapiens	IC50	nM	15.0
327466	17706193	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3900262	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327467	17706194	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3927078	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327468	17706195	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1		CHEMBL3949057	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
327469	17706196	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1		CHEMBL3978185	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327470	17706197	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1)=NC#N		CHEMBL3892285	=	IC50	nM	35.0	CHEMBL3116	Homo sapiens	IC50	nM	35.0
327471	17706198	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3916775	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327472	17706199	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3934755	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327473	17706200	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3962241	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327474	17706201	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3965161	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327475	17706202	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3965161	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327476	17706203	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3927078	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327477	17706204	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3927078	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327478	17706205	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3962241	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327479	17706206	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3962241	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327480	17706207	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3960348	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327481	17706208	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3960348	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327482	17706209	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3960348	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327483	17706210	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N		CHEMBL3959283	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327484	17706211	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3976450	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327485	17706212	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3976450	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327486	17706213	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3976450	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327487	17706214	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3973367	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327488	17706215	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F		CHEMBL3897217	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327489	17706216	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F		CHEMBL3897217	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327490	17706217	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F		CHEMBL3897217	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327491	17706218	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3919796	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327492	17706219	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3946675	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327493	17706220	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3946675	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327494	17706221	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3946675	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327495	17706222	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=O)=NC#N)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3934141	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327496	17706223	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3960677	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327497	17706224	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3960677	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327498	17706225	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3960677	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327499	17706226	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3923419	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327500	17706227	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3959867	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327501	17706228	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3959867	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327502	17706229	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3959867	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327503	17706230	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)F)c2)ncc1F		CHEMBL3937866	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327504	17706231	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)F)c2)ncc1F		CHEMBL3905335	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327505	17706232	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=O)(Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N		CHEMBL3979266	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327506	17706233	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3917892	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327507	17706234	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3917892	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327508	17706235	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3917892	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327509	17706236	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)C(F)(F)F)c2)ncc1F		CHEMBL3984385	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
327510	17706237	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)C(F)(F)F)c2)ncc1F		CHEMBL3912866	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327511	17706238	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=O)(=NC#N)C3CC3)c2)ncc1F		CHEMBL3944304	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327512	17706239	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3921855	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
327513	17706240	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=O)(=NC#N)C3CC3)c2)ncc1F		CHEMBL3949630	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327514	17706241	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3934257	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327515	17706242	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3934257	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327516	17706243	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3934257	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327517	17706244	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCC4)n2)c1		CHEMBL3972796	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327518	17706245	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccc(F)cc3)n2)c1		CHEMBL3892881	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327519	17706246	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3967588	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327520	17706247	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3981911	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327521	17706248	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(C)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3953160	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327522	17706249	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115908	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327523	17706250	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115909	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327524	17706251	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115909	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327525	17706252	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115909	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327526	17706253	CHEMBL3887262	CDK9/CycT1 Kinase Assay: Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI Peptide Technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COCCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3932396	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327590	17706317	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3906489	=	IC50	nM	38.0	CHEMBL3116	Homo sapiens	IC50	nM	38.0
327591	17706318	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3965161	=	IC50	nM	248.0	CHEMBL3116	Homo sapiens	IC50	nM	248.0
327592	17706319	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3900262	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
327593	17706320	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3927078	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327594	17706321	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1		CHEMBL3949057	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	nM	14.0
327595	17706322	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCCC4)n2)c1		CHEMBL3978185	=	IC50	nM	67.0	CHEMBL3116	Homo sapiens	IC50	nM	67.0
327596	17706323	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1)=NC#N		CHEMBL3892285	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
327597	17706324	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3916775	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
327598	17706325	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3934755	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
327599	17706326	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3962241	=	IC50	nM	13.0	CHEMBL3116	Homo sapiens	IC50	nM	13.0
327600	17706327	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3965161	=	IC50	nM	95.0	CHEMBL3116	Homo sapiens	IC50	nM	95.0
327601	17706328	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3965161	=	IC50	nM	106.0	CHEMBL3116	Homo sapiens	IC50	nM	106.0
327602	17706329	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3927078	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327603	17706330	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccccc3)n2)c1		CHEMBL3927078	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327604	17706331	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3962241	=	IC50	nM	27.0	CHEMBL3116	Homo sapiens	IC50	nM	27.0
327605	17706332	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3962241	=	IC50	nM	37.0	CHEMBL3116	Homo sapiens	IC50	nM	37.0
327606	17706333	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3960348	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327607	17706334	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3960348	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327608	17706335	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3960348	=	IC50	nM	11.0	CHEMBL3116	Homo sapiens	IC50	nM	11.0
327609	17706336	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=O)(Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1)=NC#N		CHEMBL3959283	=	IC50	nM	9.0	CHEMBL3116	Homo sapiens	IC50	nM	9.0
327610	17706337	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3976450	=	IC50	nM	135.0	CHEMBL3116	Homo sapiens	IC50	nM	135.0
327611	17706338	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3976450	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	nM	96.0
327612	17706339	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3976450	=	IC50	nM	125.0	CHEMBL3116	Homo sapiens	IC50	nM	125.0
327613	17706340	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3973367	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327614	17706341	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F		CHEMBL3897217	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
327615	17706342	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F		CHEMBL3897217	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
327616	17706343	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)c(F)c(CS(C)(=N)=O)c2)ncc1F		CHEMBL3897217	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
327617	17706344	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3919796	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327618	17706345	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3946675	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327619	17706346	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3946675	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327620	17706347	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Br)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3946675	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327621	17706348	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=O)=NC#N)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3934141	=	IC50	nM	1.0	CHEMBL3116	Homo sapiens	IC50	nM	1.0
327622	17706349	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3960677	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327623	17706350	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3960677	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327624	17706351	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(CS(C)(=N)=O)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3960677	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327625	17706352	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3923419	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327626	17706353	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3959867	=	IC50	nM	60.0	CHEMBL3116	Homo sapiens	IC50	nM	60.0
327627	17706354	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3959867	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
327628	17706355	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3959867	=	IC50	nM	73.0	CHEMBL3116	Homo sapiens	IC50	nM	73.0
327629	17706356	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)F)c2)ncc1F		CHEMBL3937866	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327630	17706357	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)F)c2)ncc1F		CHEMBL3905335	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327632	17706358	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3917892	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
327633	17706359	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3917892	=	IC50	nM	35.0	CHEMBL3116	Homo sapiens	IC50	nM	35.0
327634	17706360	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCS(=N)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3917892	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
327635	17706361	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=O)=NC#N)cc(C(F)(F)C(F)(F)F)c2)ncc1F		CHEMBL3984385	=	IC50	nM	8.0	CHEMBL3116	Homo sapiens	IC50	nM	8.0
327636	17706362	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(CS(C)(=N)=O)cc(C(F)(F)C(F)(F)F)c2)ncc1F		CHEMBL3912866	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327637	17706363	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=O)(=NC#N)C3CC3)c2)ncc1F		CHEMBL3944304	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327638	17706364	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cccc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3921855	=	IC50	nM	279.0	CHEMBL3116	Homo sapiens	IC50	nM	279.0
327639	17706365	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=O)(=NC#N)C3CC3)c2)ncc1F		CHEMBL3949630	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327640	17706366	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3934257	=	IC50	nM	104.0	CHEMBL3116	Homo sapiens	IC50	nM	104.0
327641	17706367	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3934257	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
327642	17706368	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(F)cc(CS(=N)(=O)C3CC3)c2)ncc1F		CHEMBL3934257	=	IC50	nM	51.0	CHEMBL3116	Homo sapiens	IC50	nM	51.0
327643	17706369	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)N=S(C)(=O)Cc1cccc(Nc2ncc(F)c(-c3cccc4c3OCC4)n2)c1		CHEMBL3972796	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
327644	17706370	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=N)(=O)Cc1cccc(Nc2ncc(F)c(-c3ccc(F)cc3OCc3ccc(F)cc3)n2)c1		CHEMBL3892881	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
327645	17706371	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3967588	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327646	17706372	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(Cl)cc(CS(C)(=N)=O)c2)ncc1F		CHEMBL3981911	=	IC50	nM	7.0	CHEMBL3116	Homo sapiens	IC50	nM	7.0
327647	17706373	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cc(F)ccc1-c1nc(Nc2cc(C)cc(CS(C)(=O)=NC#N)c2)ncc1F		CHEMBL3953160	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
327648	17706374	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115908	=	IC50	nM	12.0	CHEMBL3116	Homo sapiens	IC50	nM	12.0
327649	17706375	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115909	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
327650	17706376	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115909	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
327651	17706377	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B			CHEMBL4115909	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
327652	17706378	CHEMBL3887264	CDK9/CycT1 : Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from Invitrogen (Cat. No PV4131). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany) For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of CDK9/CycT1 in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COCCOC(=O)N=S(C)(=O)Cc1cc(F)cc(Nc2ncc(F)c(-c3ccc(F)cc3OC)n2)c1		CHEMBL3932396	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
390881	17762991	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3950787	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	nM	21.0
390882	17762992	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C(=O)OC(C)(C)C)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3914748	=	IC50	nM	230.0	CHEMBL3116	Homo sapiens	IC50	nM	230.0
390883	17762993	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCOC(=O)NS(=O)(=O)N1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3984563	=	IC50	nM	47.0	CHEMBL3116	Homo sapiens	IC50	nM	47.0
390884	17762994	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3923769	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
390885	17762995	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CS(=O)(=O)N1CC=C(c2[nH]c3nccc4c3c2CNc2ccc(F)cc2-4)CC1		CHEMBL3899222	=	IC50	nM	62.0	CHEMBL3116	Homo sapiens	IC50	nM	62.0
390886	17762996	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCCN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3900378	=	IC50	nM	340.0	CHEMBL3116	Homo sapiens	IC50	nM	340.0
390887	17762997	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CS(=O)(=O)N1CC=C(c2[nH]c3nccc4c3c2CN(CC2CCOCC2)c2ccc(F)cc2-4)CC1		CHEMBL3971492	=	IC50	nM	800.0	CHEMBL3116	Homo sapiens	IC50	nM	800.0
390888	17762998	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCC1c2c(C3=CCN(C(=O)OC(C)(C)C)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3909386	=	IC50	nM	1400.0	CHEMBL3116	Homo sapiens	IC50	nM	1400.0
390889	17762999	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCC1c2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3976491	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	nM	48.0
390890	17763000	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1c2ccc(F)cc2-c2ccnc3[nH]c(C4=CCNCC4)c(c23)C1c1cnn(C)c1		CHEMBL3972845	=	IC50	nM	230.0	CHEMBL3116	Homo sapiens	IC50	nM	230.0
390891	17763001	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCC1c2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3894563	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
390892	17763002	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3914190	=	IC50	nM	51.0	CHEMBL3116	Homo sapiens	IC50	nM	51.0
390893	17763003	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)N1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3938690	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
390894	17763004	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	Fc1ccc2c(c1)-c1ccnc3[nH]c(C4=CCNCC4)c(c13)CO2		CHEMBL3901726	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
390895	17763005	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CS(=O)(=O)N1CC=C(c2[nH]c3nccc4c3c2COc2ccc(F)cc2-4)CC1		CHEMBL3929678	=	IC50	nM	94.0	CHEMBL3116	Homo sapiens	IC50	nM	94.0
390896	17763006	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3892764	=	IC50	nM	61.0	CHEMBL3116	Homo sapiens	IC50	nM	61.0
390897	17763007	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CCC[C@H]4CO)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3924254	=	IC50	nM	70.0	CHEMBL3116	Homo sapiens	IC50	nM	70.0
390898	17763008	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC(O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3985050	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
390899	17763009	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3915267	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	nM	48.0
390900	17763010	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC1c2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3922015	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
390901	17763011	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3946356	=	IC50	nM	400.0	CHEMBL3116	Homo sapiens	IC50	nM	400.0
390902	17763012	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3CCN(CC(=O)OC(C)(C)C)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3943802	=	IC50	nM	2800.0	CHEMBL3116	Homo sapiens	IC50	nM	2800.0
390903	17763013	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3CCN(CC(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3976471	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
390904	17763014	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N(C)C4CC(O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3938400	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	nM	40.0
390905	17763015	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNS(=O)(=O)CC(=O)N1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3967958	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
390906	17763016	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3CCN(CC(=O)N4CCC[C@H]4CO)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3967032	=	IC50	nM	93.0	CHEMBL3116	Homo sapiens	IC50	nM	93.0
390907	17763017	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1CCC(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3892247	=	IC50	nM	91.0	CHEMBL3116	Homo sapiens	IC50	nM	91.0
390908	17763018	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCOC(=O)C1c2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3952541	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
390909	17763019	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC(C)[C@@H](NC1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1)C(=O)O		CHEMBL3981309	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
390910	17763020	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	C[C@H](NC1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1)C(=O)O		CHEMBL3936047	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
390911	17763021	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(NCC(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3969174	=	IC50	nM	86.0	CHEMBL3116	Homo sapiens	IC50	nM	86.0
390912	17763022	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(N[C@H](C(=O)O)c4ccccc4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3976947	=	IC50	nM	56.0	CHEMBL3116	Homo sapiens	IC50	nM	56.0
390913	17763023	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1c2ccc(F)cc2-c2ccnc3[nH]c(C4=CCNCC4)c(c23)C1C(=O)O		CHEMBL3947668	=	IC50	nM	540.0	CHEMBL3116	Homo sapiens	IC50	nM	540.0
390914	17763024	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC(C)[C@H](NC1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1)C(=O)O		CHEMBL3985017	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
390915	17763025	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(N[C@@H](Cc4ccccc4)C(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3953020	=	IC50	nM	61.0	CHEMBL3116	Homo sapiens	IC50	nM	61.0
390916	17763026	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(N[C@H](C(=O)O)C(C)(C)C)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3932928	=	IC50	nM	64.0	CHEMBL3116	Homo sapiens	IC50	nM	64.0
390917	17763027	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(N4CCC[C@H]4C(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3961728	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	nM	160.0
390918	17763028	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(N[C@@H](CO)C(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3911825	=	IC50	nM	91.0	CHEMBL3116	Homo sapiens	IC50	nM	91.0
390919	17763029	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCC[C@H](NC1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1)C(=O)O		CHEMBL3975945	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
390920	17763030	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(N[C@@H](Cc4ccc(O)cc4)C(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3969672	=	IC50	nM	81.0	CHEMBL3116	Homo sapiens	IC50	nM	81.0
390921	17763031	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(C(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3940113	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
390922	17763032	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC[C@H](O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3971127	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	nM	48.0
390923	17763033	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3ccc(S(C)(=O)=O)cc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3899955	=	IC50	nM	66.0	CHEMBL3116	Homo sapiens	IC50	nM	66.0
390924	17763034	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3ccncc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3982411	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
390925	17763035	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3ccc(S(C)(=O)=O)nc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3909010	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
390926	17763036	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3cnc(N)nc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3954733	=	IC50	nM	3300.0	CHEMBL3116	Homo sapiens	IC50	nM	3300.0
390927	17763037	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3ccc(C(=O)O)cc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3983369	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
390928	17763038	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3960058	=	IC50	nM	27.0	CHEMBL3116	Homo sapiens	IC50	nM	27.0
390929	17763039	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C(=O)OC(C)(C)C)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3919798	=	IC50	nM	780.0	CHEMBL3116	Homo sapiens	IC50	nM	780.0
390930	17763040	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)C1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3961213	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
390931	17763041	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCC(C(=O)N4CC(O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3892232	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
390932	17763042	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)C1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3975721	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	nM	63.0
390933	17763043	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N(CCO)CCO)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3942947	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
390934	17763044	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC(F)(F)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3967245	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	nM	63.0
390935	17763045	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1[C@H]2CC[C@@H]1C=C(c1[nH]c3nccc4c3c1CN(C)c1ccc(F)cc1-4)C2		CHEMBL3937565	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	nM	160.0
390936	17763046	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4CC[C@@H](C3)N4S(C)(=O)=O)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3901001	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	nM	96.0
390937	17763047	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)N1[C@H]2CC[C@@H]1C=C(c1[nH]c3nccc4c3c1CN(C)c1ccc(F)cc1-4)C2		CHEMBL3966259	=	IC50	nM	200.0	CHEMBL3116	Homo sapiens	IC50	nM	200.0
390938	17763048	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4CC[C@@H](C3)N4CC(=O)O)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3980578	=	IC50	nM	170.0	CHEMBL3116	Homo sapiens	IC50	nM	170.0
390939	17763049	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CNCC4C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3951695	=	IC50	nM	88.0	CHEMBL3116	Homo sapiens	IC50	nM	88.0
390940	17763050	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3cccnc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3958055	=	IC50	nM	75.0	CHEMBL3116	Homo sapiens	IC50	nM	75.0
390941	17763051	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CCOC(=O)C1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3979619	=	IC50	nM	400.0	CHEMBL3116	Homo sapiens	IC50	nM	400.0
390942	17763052	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4CC[C@@H](C3)N4)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3975203	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
390943	17763053	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3900836	=	IC50	nM	38.0	CHEMBL3116	Homo sapiens	IC50	nM	38.0
390944	17763054	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CCC[C@@H]4CO)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3960860	=	IC50	nM	62.0	CHEMBL3116	Homo sapiens	IC50	nM	62.0
390945	17763055	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)OC(C)(C)C)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3952232	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
390946	17763056	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3ncc(F)c4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3952162	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
390947	17763057	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)O)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3984185	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	nM	48.0
390948	17763058	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3946855	=	IC50	nM	38.0	CHEMBL3116	Homo sapiens	IC50	nM	38.0
390949	17763059	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	COCCS(=O)(=O)N1CC2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2C1		CHEMBL3976153	=	IC50	nM	80.0	CHEMBL3116	Homo sapiens	IC50	nM	80.0
390950	17763060	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CCC[C@H]4CO)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3982110	=	IC50	nM	86.0	CHEMBL3116	Homo sapiens	IC50	nM	86.0
390951	17763061	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1CC=C(c2[nH]c3ncc(F)c4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3908656	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
390952	17763062	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC(O)C4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3899072	=	IC50	nM	79.0	CHEMBL3116	Homo sapiens	IC50	nM	79.0
390953	17763063	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC[C@H](O)C4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3970274	=	IC50	nM	52.0	CHEMBL3116	Homo sapiens	IC50	nM	52.0
390954	17763064	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC(CO)C4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3908119	=	IC50	nM	89.0	CHEMBL3116	Homo sapiens	IC50	nM	89.0
390955	17763065	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CCC[C@@H]4CO)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3981660	=	IC50	nM	51.0	CHEMBL3116	Homo sapiens	IC50	nM	51.0
390956	17763066	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)N1CC2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2C1		CHEMBL3982622	=	IC50	nM	41.0	CHEMBL3116	Homo sapiens	IC50	nM	41.0
390957	17763067	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2C1		CHEMBL3953940	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
390958	17763068	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CN(S(C)(=O)=O)CC4C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3914697	=	IC50	nM	62.0	CHEMBL3116	Homo sapiens	IC50	nM	62.0
390959	17763069	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4CC[C@@H](C3)N4CC(=O)N3CCC[C@H]3CO)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3959178	=	IC50	nM	72.0	CHEMBL3116	Homo sapiens	IC50	nM	72.0
390960	17763070	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4CC[C@@H](C3)N4CC(=O)N3CC(O)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3906898	=	IC50	nM	97.0	CHEMBL3116	Homo sapiens	IC50	nM	97.0
390961	17763071	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3ccc(CC(=O)O)cc3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3977523	=	IC50	nM	68.0	CHEMBL3116	Homo sapiens	IC50	nM	68.0
390962	17763072	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(-c3cccc(CC(=O)O)c3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3927646	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
390963	17763073	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1[C@H]2CC[C@@H]1C=C(c1[nH]c3nccc4c3c1CN(C)c1ccc(F)cc1-4)C2		CHEMBL3919423	=	IC50	nM	140.0	CHEMBL3116	Homo sapiens	IC50	nM	140.0
390964	17763074	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CN(CC(=O)N5CC(O)C5)CC4C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3933775	=	IC50	nM	94.0	CHEMBL3116	Homo sapiens	IC50	nM	94.0
390965	17763075	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1CC2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2C1		CHEMBL3986185	=	IC50	nM	99.0	CHEMBL3116	Homo sapiens	IC50	nM	99.0
390966	17763076	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1CC2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2C1		CHEMBL3959305	=	IC50	nM	43.0	CHEMBL3116	Homo sapiens	IC50	nM	43.0
390967	17763077	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3942621	=	IC50	nM	90.0	CHEMBL3116	Homo sapiens	IC50	nM	90.0
390968	17763078	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CCC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3927123	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
390969	17763079	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3951345	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
390970	17763080	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(CC(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3892477	=	IC50	nM	170.0	CHEMBL3116	Homo sapiens	IC50	nM	170.0
390971	17763081	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(CC(=O)N4CC(O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3920469	=	IC50	nM	180.0	CHEMBL3116	Homo sapiens	IC50	nM	180.0
390972	17763082	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3(C)C)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3915748	=	IC50	nM	420.0	CHEMBL3116	Homo sapiens	IC50	nM	420.0
390973	17763083	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCNC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3934364	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
390974	17763084	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CN(CC(=O)N(C)C5CC(O)C5)CC4C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3949735	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
390975	17763085	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(S(C)(=O)=O)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3921963	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
390976	17763086	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)N1CCC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)C1		CHEMBL3944411	=	IC50	nM	180.0	CHEMBL3116	Homo sapiens	IC50	nM	180.0
390977	17763087	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CCC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)C1		CHEMBL3941083	=	IC50	nM	420.0	CHEMBL3116	Homo sapiens	IC50	nM	420.0
390978	17763088	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4CC[C@@H](C3)N4CC(=O)N(C)C3CC(O)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL4113920	=	IC50	nM	73.0	CHEMBL3116	Homo sapiens	IC50	nM	73.0
390979	17763089	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CCCC(C3)N4S(C)(=O)=O)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3935574	=	IC50	nM	400.0	CHEMBL3116	Homo sapiens	IC50	nM	400.0
390980	17763090	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)N1C2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC1CCC2		CHEMBL3950866	=	IC50	nM	83.0	CHEMBL3116	Homo sapiens	IC50	nM	83.0
390981	17763091	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1C2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC1CCC2		CHEMBL3926650	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
390982	17763092	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CCCC(C3)N4C(=O)CC#N)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3903886	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	nM	44.0
390983	17763093	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1C2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC1CCC2		CHEMBL3907123	=	IC50	nM	86.0	CHEMBL3116	Homo sapiens	IC50	nM	86.0
390984	17763094	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CCCC(C3)N4CC(=O)N3CCC[C@H]3CO)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3969304	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
390985	17763095	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CCCC(C3)N4CC(=O)N3CC(O)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3941567	=	IC50	nM	98.0	CHEMBL3116	Homo sapiens	IC50	nM	98.0
390986	17763096	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CCCC(C3)N4CC(=O)N(C)C3CC(O)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3897049	=	IC50	nM	66.0	CHEMBL3116	Homo sapiens	IC50	nM	66.0
390987	17763097	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1C2C=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC1CCC2		CHEMBL3921585	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
390988	17763098	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CC4CCCC(C3)N4CC(=O)O)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3965251	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
390989	17763099	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N(C)C4CC(O)C4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3912612	=	IC50	nM	43.0	CHEMBL3116	Homo sapiens	IC50	nM	43.0
390990	17763100	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1CC=C(c2[nH]c3ncc(F)c4c3c2CN(C)c2ccc(F)cc2-4)CC1		CHEMBL3911547	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
390991	17763101	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)O)CC3(C)C)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3891725	=	IC50	nM	1600.0	CHEMBL3116	Homo sapiens	IC50	nM	1600.0
390992	17763102	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(CC(=O)O)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3900733	=	IC50	nM	240.0	CHEMBL3116	Homo sapiens	IC50	nM	240.0
390993	17763103	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3(C)C)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3978141	=	IC50	nM	650.0	CHEMBL3116	Homo sapiens	IC50	nM	650.0
390994	17763104	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)C(C)(C)C1		CHEMBL3952495	=	IC50	nM	870.0	CHEMBL3116	Homo sapiens	IC50	nM	870.0
390995	17763105	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CCC[C@H]4CO)CC3(C)C)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3960117	=	IC50	nM	950.0	CHEMBL3116	Homo sapiens	IC50	nM	950.0
390996	17763106	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)C(C)(C)C1		CHEMBL3922076	=	IC50	nM	890.0	CHEMBL3116	Homo sapiens	IC50	nM	890.0
390997	17763107	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC(O)C4)CC3(C)C)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3894072	=	IC50	nM	960.0	CHEMBL3116	Homo sapiens	IC50	nM	960.0
390998	17763108	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N(C)C4CC(O)C4)CC3(C)C)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3943576	=	IC50	nM	1200.0	CHEMBL3116	Homo sapiens	IC50	nM	1200.0
390999	17763109	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)C(C)(C)C1		CHEMBL3944510	=	IC50	nM	1300.0	CHEMBL3116	Homo sapiens	IC50	nM	1300.0
391000	17763110	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(CC(=O)N4CCC[C@H]4CO)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3963396	=	IC50	nM	480.0	CHEMBL3116	Homo sapiens	IC50	nM	480.0
391001	17763111	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(CC(=O)N4CC(O)C4)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3906050	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	nM	160.0
391002	17763112	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(CC(=O)N(C)C4CC(O)C4)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3969125	=	IC50	nM	420.0	CHEMBL3116	Homo sapiens	IC50	nM	420.0
391003	17763113	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CC(O)CO)C(=O)CN1CCC=C(c2[nH]c3nccc4c3c2CN(C)c2ccc(F)cc2-4)C1		CHEMBL3935996	=	IC50	nM	540.0	CHEMBL3116	Homo sapiens	IC50	nM	540.0
391004	17763114	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3958069	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	nM	48.0
391005	17763115	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@@H]4COC(=O)N4CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3930577	=	IC50	nM	54.0	CHEMBL3116	Homo sapiens	IC50	nM	54.0
391006	17763116	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H](CO)NCC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3982368	=	IC50	nM	58.0	CHEMBL3116	Homo sapiens	IC50	nM	58.0
391007	17763117	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1CCc2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3957008	=	IC50	nM	26.0	CHEMBL3116	Homo sapiens	IC50	nM	26.0
391008	17763118	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1CCc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3974363	=	IC50	nM	78.0	CHEMBL3116	Homo sapiens	IC50	nM	78.0
391009	17763119	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CCN(C)c2ccc(F)cc2-4)CC1		CHEMBL3944945	=	IC50	nM	67.0	CHEMBL3116	Homo sapiens	IC50	nM	67.0
391010	17763120	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3976427	=	IC50	nM	64.0	CHEMBL3116	Homo sapiens	IC50	nM	64.0
391011	17763121	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3973391	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	nM	36.0
391012	17763122	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2cc(F)c(F)cc2-4)CC1		CHEMBL3931677	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	nM	40.0
391013	17763123	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	COC(=O)CC1CCC(N2CC=C(c3[nH]c4nccc5c4c3CN(C)c3cc(F)c(F)cc3-5)CC2)CC1		CHEMBL3944130	=	IC50	nM	58.0	CHEMBL3116	Homo sapiens	IC50	nM	58.0
391014	17763124	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	COC(=O)CC1CCC(N2CC=C(c3[nH]c4nccc5c4c3CN(C)c3cc(F)c(F)cc3-5)CC2)CC1		CHEMBL3944130	=	IC50	nM	47.0	CHEMBL3116	Homo sapiens	IC50	nM	47.0
391015	17763125	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cccnc21		CHEMBL3970239	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	nM	63.0
391016	17763126	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3917273	=	IC50	nM	58.0	CHEMBL3116	Homo sapiens	IC50	nM	58.0
391017	17763127	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CC(O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3945173	=	IC50	nM	52.0	CHEMBL3116	Homo sapiens	IC50	nM	52.0
391018	17763128	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2cccnc21		CHEMBL3922725	=	IC50	nM	69.0	CHEMBL3116	Homo sapiens	IC50	nM	69.0
391019	17763129	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CNC(=O)N1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ncccc2-4)CC1		CHEMBL3953907	=	IC50	nM	94.0	CHEMBL3116	Homo sapiens	IC50	nM	94.0
391020	17763130	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CC(CC(=O)O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3923934	=	IC50	nM	42.0	CHEMBL3116	Homo sapiens	IC50	nM	42.0
391021	17763131	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3951638	=	IC50	nM	51.0	CHEMBL3116	Homo sapiens	IC50	nM	51.0
391022	17763132	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC[C@H]1c2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3923572	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
391023	17763133	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC[C@@H]1c2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3932161	=	IC50	nM	417.0	CHEMBL3116	Homo sapiens	IC50	nM	417.0
391024	17763134	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3970723	=	IC50	nM	29.0	CHEMBL3116	Homo sapiens	IC50	nM	29.0
391025	17763135	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)O)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3937675	=	IC50	nM	42.0	CHEMBL3116	Homo sapiens	IC50	nM	42.0
391026	17763136	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3975804	=	IC50	nM	82.0	CHEMBL3116	Homo sapiens	IC50	nM	82.0
391027	17763137	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N4CCC[C@H]4CO)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3946513	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
391028	17763138	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CC(=O)N(C)C4CC(O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3983849	=	IC50	nM	53.0	CHEMBL3116	Homo sapiens	IC50	nM	53.0
391029	17763139	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ncccc2-4)CC1		CHEMBL3958592	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
391030	17763140	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)c(F)cc21		CHEMBL3952127	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
391031	17763141	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@@H]4COC(=O)N4CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3924439	=	IC50	nM	37.0	CHEMBL3116	Homo sapiens	IC50	nM	37.0
391032	17763142	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H]4COC(=O)N4CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3905946	=	IC50	nM	41.0	CHEMBL3116	Homo sapiens	IC50	nM	41.0
391033	17763143	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN4C(=O)OC[C@H]4C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3937521	=	IC50	nM	66.0	CHEMBL3116	Homo sapiens	IC50	nM	66.0
391034	17763144	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@H](CO)NCC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3955479	=	IC50	nM	28.0	CHEMBL3116	Homo sapiens	IC50	nM	28.0
391035	17763145	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=C[C@@H](CO)NCC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3928730	=	IC50	nM	41.0	CHEMBL3116	Homo sapiens	IC50	nM	41.0
391036	17763146	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN[C@@H](CO)C3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3927462	=	IC50	nM	30.0	CHEMBL3116	Homo sapiens	IC50	nM	30.0
391037	17763147	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(CCO)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2cc(F)c(F)cc2-4)CC1		CHEMBL3951656	=	IC50	nM	46.0	CHEMBL3116	Homo sapiens	IC50	nM	46.0
391038	17763148	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3)[nH]c3nccc(c23)-c2ccccc21		CHEMBL3914925	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	nM	96.0
391039	17763149	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCNCC3)[nH]c3ncc(F)c(c23)-c2ccccc21		CHEMBL3942903	=	IC50	nM	34.0	CHEMBL3116	Homo sapiens	IC50	nM	34.0
391040	17763150	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3nccc(c23)-c2ccccc21		CHEMBL3898182	=	IC50	nM	85.0	CHEMBL3116	Homo sapiens	IC50	nM	85.0
391041	17763151	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(S(C)(=O)=O)CC3)[nH]c3ncc(F)c(c23)-c2ccccc21		CHEMBL3929697	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	nM	40.0
391042	17763152	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3nccc4c3c2CN(C)c2ccccc2-4)CC1		CHEMBL3933205	=	IC50	nM	115.0	CHEMBL3116	Homo sapiens	IC50	nM	115.0
391043	17763153	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN(C)C(=O)CN1CC=C(c2[nH]c3ncc(F)c4c3c2CN(C)c2ccccc2-4)CC1		CHEMBL3908787	=	IC50	nM	56.0	CHEMBL3116	Homo sapiens	IC50	nM	56.0
391044	17763154	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	OCC(O)CN1CC=C(c2[nH]c3nccc4c3c2COc2ccc(F)cc2-4)CC1		CHEMBL3924252	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
391045	17763155	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	O=C(O)CC1CCC(N2CC=C(c3[nH]c4nccc5c4c3COc3ccc(F)cc3-5)CC2)CC1		CHEMBL3896241	=	IC50	nM	390.0	CHEMBL3116	Homo sapiens	IC50	nM	390.0
391046	17763156	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3918837	=	IC50	nM	75.0	CHEMBL3116	Homo sapiens	IC50	nM	75.0
391047	17763157	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3915400	=	IC50	nM	67.0	CHEMBL3116	Homo sapiens	IC50	nM	67.0
391048	17763158	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC[C@H]1c2c(C3=CCN(CC(=O)N(C)C)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3937985	=	IC50	nM	60.0	CHEMBL3116	Homo sapiens	IC50	nM	60.0
391049	17763159	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2ccccc21		CHEMBL3910044	=	IC50	nM	90.0	CHEMBL3116	Homo sapiens	IC50	nM	90.0
391050	17763160	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2ccccc21		CHEMBL3925516	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
391051	17763161	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2ccccc21		CHEMBL3900994	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
391052	17763162	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CCC(C(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2ccccc21		CHEMBL3892893	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
391053	17763163	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CCC(=CC#N)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3920906	=	IC50	nM	45.0	CHEMBL3116	Homo sapiens	IC50	nM	45.0
391054	17763164	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	COC(=O)C(C)=C1CCC(N2CC=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2)CC1		CHEMBL3898302	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
391055	17763165	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CCC(=CC(=O)OC(C)(C)C)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3901731	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	nM	120.0
391056	17763166	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC(C(=O)O)=C1CCC(N2CC=C(c3[nH]c4nccc5c4c3CN(C)c3ccc(F)cc3-5)CC2)CC1		CHEMBL3977776	=	IC50	nM	84.0	CHEMBL3116	Homo sapiens	IC50	nM	84.0
391057	17763167	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CCC(=CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3907184	=	IC50	nM	58.0	CHEMBL3116	Homo sapiens	IC50	nM	58.0
391058	17763168	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CCS(=O)(=O)N(C)C)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3891660	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	nM	25.0
391059	17763169	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(CCS(N)(=O)=O)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3916153	=	IC50	nM	24.0	CHEMBL3116	Homo sapiens	IC50	nM	24.0
391060	17763170	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)[nH]c3ncc(F)c(c23)-c2ccccc21		CHEMBL3954215	=	IC50	nM	73.0	CHEMBL3116	Homo sapiens	IC50	nM	73.0
391061	17763171	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)[nH]c3ncc(F)c(c23)-c2ccccc21		CHEMBL3982885	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	nM	63.0
391062	17763172	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)[nH]c3ncc(F)c(c23)-c2ccccc21		CHEMBL3892177	=	IC50	nM	71.0	CHEMBL3116	Homo sapiens	IC50	nM	71.0
391063	17763173	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN([C@H]4CC[C@@H](C(=O)O)CC4)CC3)[nH]c3ncc(F)c(c23)-c2ccccc21		CHEMBL3961156	=	IC50	nM	80.0	CHEMBL3116	Homo sapiens	IC50	nM	80.0
391064	17763174	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCCN(C4CCC(=CC(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3901136	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
391065	17763175	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CCC(C(C)(C)C(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3975453	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	nM	130.0
391066	17763176	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC[C@H]1c2c(C3=CCN([C@H]4C[C@@H](C(=O)OC)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3976415	=	IC50	nM	64.0	CHEMBL3116	Homo sapiens	IC50	nM	64.0
391067	17763177	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC[C@H]1c2c(C3=CCN([C@H]4C[C@@H](C(=O)O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3947123	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
391068	17763178	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1CCc2c(C3=CCN([C@H]4C[C@@H](C(=O)O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3984474	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	nM	150.0
391069	17763179	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CC[C@H]1c2c(C3=CCN([C@H]4C[C@H](C(=O)O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc2N1C		CHEMBL3952466	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
391070	17763180	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1CCc2c(C3=CCN([C@H]4C[C@H](C(=O)O)C4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3899896	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	nM	160.0
391071	17763181	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CCC(C(C#N)C(=O)O)CC4)CC3)[nH]c3nccc(c23)-c2cc(F)ccc21		CHEMBL3971069	=	IC50	nM	88.0	CHEMBL3116	Homo sapiens	IC50	nM	88.0
391072	17763182	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CC(CC(=O)O)C4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3966523	=	IC50	nM	79.0	CHEMBL3116	Homo sapiens	IC50	nM	79.0
391073	17763183	CHEMBL3888351	LANCE ULight TR-FRET Kinase Assay : CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were diluted in 100% DMSO then diluted with 1:10 in serine/threonine kinase assay buffer containing 20 mM HEPES, 10 mM MgCl2, 100 mM Na3VO4, and 0.0075% Triton X-100. Equal volume of the compound dilutions was added to a final reaction mixture containing LANCE detection buffer (PerkinElmer CR97-100), 100 nM ULight MBP (PerkinElmer TRF0109M), 1000 μM ATP, and CDK9/Cyclin T1 (Carna Biosciences 04-110). The kinase reaction was carried out for 1 hour before addition of stopping buffer to a final of 20 mM EDTA and 0.5 nM of LANCE Ultra Europium anti-phospho-MBP antibody (PerkinElmer TRF0201M) in LANCE detection buffer. The reaction was incubated for 1 hour and the signal was read in Envision in TR-FRET mode (excitation at 320 nm and emission at 615/665 nm).	B	CN1Cc2c(C3=CCN(C4CC(C(=O)O)C4)CC3)[nH]c3ncc(F)c(c23)-c2cc(F)ccc21		CHEMBL3891658	=	IC50	nM	76.0	CHEMBL3116	Homo sapiens	IC50	nM	76.0
Inactive	17891154	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891155	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891156	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	81.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	81.0
Inactive	17891157	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891158	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891159	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891160	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891161	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891162	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891163	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891164	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891165	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891166	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	3609.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	3609.0
Inactive	17891167	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891168	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891169	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891170	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891171	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891172	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891173	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891174	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	3512.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	3512.0
Inactive	17891175	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891176	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891177	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891178	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	=	Kd	nM	28.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	28.0
Inactive	17891179	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891180	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891181	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891182	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891183	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891184	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891185	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891186	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891187	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	=	Kd	nM	988.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	988.0
Inactive	17891188	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891189	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	Kd	nM	34.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	34.0
Inactive	17891190	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891191	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891192	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891193	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891194	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891195	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891196	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891197	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891198	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891199	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891200	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Kd	nM	25.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	25.0
Active	17891201	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	Kd	nM	7.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	7.0
Inactive	17891202	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891203	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891204	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891205	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891206	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891207	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891208	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891209	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891210	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891211	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891212	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891213	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891214	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891215	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891216	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891217	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891218	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891219	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891220	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891221	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891222	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891223	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891224	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891225	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	9901.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	9901.0
Active	17891226	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	=	Kd	nM	1006.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1006.0
Inactive	17891227	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891228	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891229	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891230	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891231	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891232	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891233	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891234	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891235	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	Kd	nM	1.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1.0
Inactive	17891236	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891237	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891238	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891239	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	=	Kd	nM	7.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	7.0
Inactive	17891240	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891241	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17891242	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	=	Kd	nM	13279.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	13279.0
Inactive	17891243	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891244	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891245	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891246	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891247	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891248	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891249	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891250	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891251	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891252	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891253	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891254	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891255	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891256	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891257	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891258	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891259	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891260	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891261	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891262	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891263	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891264	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	=	Kd	nM	1870.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1870.0
Inactive	17891265	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891266	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891267	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891268	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891269	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891270	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891271	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891272	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	=	Kd	nM	320.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	320.0
Inactive	17891273	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891274	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891275	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891276	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891277	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891278	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891279	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891280	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891281	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891282	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891283	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891284	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891285	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891286	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	7.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	7.0
Inactive	17891287	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891288	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891289	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Kd	nM	174.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	174.0
Inactive	17891290	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891291	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891292	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891293	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891294	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891295	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891296	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891297	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891298	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891299	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891300	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891301	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891302	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891303	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891304	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891305	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	Kd	nM	9492.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	9492.0
Inactive	17891306	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891307	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891308	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891309	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891310	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891311	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891312	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891313	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	=	Kd	nM	3708.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	3708.0
Active	17891314	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Kd	nM	4251.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	4251.0
Inactive	17891315	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891316	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891317	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891318	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891319	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891320	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	Kd	nM	1355.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1355.0
Inactive	17891321	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891322	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891323	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891324	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	1640.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1640.0
Inactive	17891325	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891326	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891327	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891328	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891329	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Kd	nM	1790.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1790.0
Inactive	17891330	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891331	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891332	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891333	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891334	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891335	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891336	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891337	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891338	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891339	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891340	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891341	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	=	Kd	nM	33.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	33.0
Active	17891342	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	1354.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	1354.0
Inactive	17891343	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891344	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891345	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Kd	nM	4860.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	4860.0
Inactive	17891346	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891347	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891348	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891349	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891350	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891351	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891352	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891353	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	=	Kd	nM	741.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	741.0
Inactive	17891354	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891355	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891356	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891357	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891358	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891359	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891360	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891361	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891362	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891363	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891364	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891365	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Active	17891366	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	=	Kd	nM	218.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	218.0
Inactive	17891367	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891368	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891369	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891370	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891371	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891372	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891373	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891374	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891375	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891376	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891377	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891378	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891379	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891380	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891381	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891382	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891383	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891384	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891385	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891386	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891387	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891388	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891389	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891390	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891391	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891392	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891393	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891394	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891395	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17891396	CHEMBL3991663	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL3116	Homo sapiens	Kd apparent	nM	30000.0
	17964885	CHEMBL3994994	Inhibition of full length human CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	68.0	CHEMBL3116	Homo sapiens	Activity	%	68.0
	18031649	CHEMBL4007695	Inhibition of CDK9 (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	5330.0	CHEMBL3116	Homo sapiens	IC50	uM	5.33
	18031650	CHEMBL4007695	Inhibition of CDK9 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	18031651	CHEMBL4007695	Inhibition of CDK9 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	18031652	CHEMBL4007695	Inhibition of CDK9 (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	18031653	CHEMBL4007695	Inhibition of CDK9 (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	18064937	CHEMBL4014123	Inhibition of recombinant human CDK9 expressed in fall armyworm sf21 cells using PDKtide as substrate in presence of [gamma-32]-ATP	B	C[C@@H](c1ccc(F)cc1)n1nnc2cnc3ccc(-c4ccc5ocnc5c4)cc3c21		CHEMBL4083249	=	IC50	nM	1430.0	CHEMBL3116	Homo sapiens	IC50	nM	1430.0
Not Determined	18066727	CHEMBL4014537	Inhibition of human CDK9	B	COc1ccc(-c2cnc3scc(NC(=O)C4CCCCC4)c3c2)cc1OC		CHEMBL3334979		IC50			CHEMBL3116	Homo sapiens	IC50		
	18066728	CHEMBL4014537	Inhibition of human CDK9	B	O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21		CHEMBL490355	=	IC50	nM	2160.0	CHEMBL3116	Homo sapiens	IC50	uM	2.16
	18066729	CHEMBL4014538	Inhibition of human CDK9 at 10 uM relative to control	B	CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O		CHEMBL4105195	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	18066730	CHEMBL4014538	Inhibition of human CDK9 at 10 uM relative to control	B	COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2		CHEMBL4087337	<	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	18114435	CHEMBL4025059	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	99.0	CHEMBL3116	Homo sapiens	Activity	%	99.0
	18134355	CHEMBL4029555	Inhibition of CDK9 (unknown origin)	B	CSc1sc(C(N)=O)c2c1-c1sncc1CC2		CHEMBL4082469	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	18134356	CHEMBL4029555	Inhibition of CDK9 (unknown origin)	B	COCCNC(=O)c1ccc(Oc2sc(C(N)=O)c3c2-c2sncc2CC3)cn1		CHEMBL4066819	=	IC50	nM	270.0	CHEMBL3116	Homo sapiens	IC50	nM	270.0
	18134454	CHEMBL4029519	Inhibition of CDK9 (unknown origin) at 1 uM relative to control	B	COCCNC(=O)c1ccc(Oc2sc(C(N)=O)c3c2-c2sncc2CC3)cn1		CHEMBL4066819	=	Inhibition	%	83.0	CHEMBL3116	Homo sapiens	INH	%	83.0
	18134485	CHEMBL4029519	Inhibition of CDK9 (unknown origin) at 1 uM relative to control	B	CSc1sc(C(N)=O)c2c1-c1sncc1CC2		CHEMBL4082469	=	Inhibition	%	105.0	CHEMBL3116	Homo sapiens	INH	%	105.0
	18153118	CHEMBL4034296	Inhibition of CDK9 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	14.8	CHEMBL3116	Homo sapiens	INH	%	14.8
	18203583	CHEMBL4043870	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	97.0	CHEMBL3116	Homo sapiens	Activity	%	97.0
	18214072	CHEMBL4046601	Inhibition of CDK9 (unknown origin) at 70 nM relative to control	B	Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1		CHEMBL4076947	>	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	18214074	CHEMBL4046603	Inhibition of CDK9 (unknown origin)	B	Cc1cc(Nc2nccc3nc(-c4c(Cl)cc(C#N)cc4Cl)[nH]c23)ncn1		CHEMBL4076947	=	Ki	nM	108.0	CHEMBL3116	Homo sapiens	Ki	nM	108.0
	18221056	CHEMBL4047696	Inhibition of CDK9 (unknown origin)	B	Clc1ccnc2[nH]c(-c3ccc(N4CCNCC4)cc3)cc12		CHEMBL4084410	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	uM	0.02
	18221099	CHEMBL4047696	Inhibition of CDK9 (unknown origin)	B	Cn1c(-c2ccc(N3CCNCC3)cc2)cc2c(Cl)ccnc21		CHEMBL4102376	=	IC50	nM	5000.0	CHEMBL3116	Homo sapiens	IC50	uM	5.0
	18221100	CHEMBL4047696	Inhibition of CDK9 (unknown origin)	B	N#Cc1ccnc2[nH]c(-c3ccc(N4CCNCC4)cc3)cc12		CHEMBL4074103	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	uM	0.15
	18221101	CHEMBL4047696	Inhibition of CDK9 (unknown origin)	B	Cn1c(-c2ccc(N3CCNCC3)cc2)cc2c(C#N)ccnc21		CHEMBL4094627	=	IC50	nM	6100.0	CHEMBL3116	Homo sapiens	IC50	uM	6.1
	18253638	CHEMBL4055103	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	93.0	CHEMBL3116	Homo sapiens	Activity	%	93.0
	18253639	CHEMBL4055103	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	18265773	CHEMBL4057223	Inhibition of CDK9 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	9.3	CHEMBL3116	Homo sapiens	INH	%	9.3
	18266021	CHEMBL4057471	Inhibition of CDK9 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	2.3	CHEMBL3116	Homo sapiens	INH	%	2.3
	18282866	CHEMBL4120451	Inhibition of CDK9 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	9.3	CHEMBL3116	Homo sapiens	INH	%	9.3
	18283080	CHEMBL4120665	Inhibition of CDK9 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	-1.0	CHEMBL3116	Homo sapiens	INH	%	-1.0
	18283295	CHEMBL4120880	Inhibition of CDK9 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	0.0	CHEMBL3116	Homo sapiens	INH	%	0.0
	18299191	CHEMBL4124403	Inhibition of CDK9 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate after 1 hr by liquid scintillation counting analysis	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	18440125	CHEMBL4156949	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	99.0	CHEMBL3116	Homo sapiens	Activity	%	99.0
	18484565	CHEMBL4185728	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	97.0	CHEMBL3116	Homo sapiens	Activity	%	97.0
	18485056	CHEMBL4185728	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	97.0	CHEMBL3116	Homo sapiens	Activity	%	97.0
	18489577	CHEMBL4187318	Inhibition of wild-type human full length CDK9 expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	78.0	CHEMBL3116	Homo sapiens	Activity	%	78.0
	18526975	CHEMBL4194446	Inhibition of CDK9 (unknown origin)	B	CN1CCN(CCCCOc2c(OCc3ccc(C#N)cc3)cc(O)c3c(=O)cc(-c4ccccc4)oc23)CC1		CHEMBL4206957	=	IC50	nM	870.0	CHEMBL3116	Homo sapiens	IC50	uM	0.87
	18568714	CHEMBL4220232	Inhibition of CDK9 (unknown origin) in presence of [gamma33P]ATP by radiometric method	B	Cc1c(Br)c(Br)c2c3c1nc(N1CCNCC1)n3CCC2		CHEMBL4225966	=	IC50	nM	1070.0	CHEMBL3116	Homo sapiens	IC50	nM	1070.0
	18655607	CHEMBL4230628	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	18663775	CHEMBL4232879	Inhibition of full length human CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	87.0	CHEMBL3116	Homo sapiens	Activity	%	87.0
	18663992	CHEMBL4232976	Binding affinity to full length human CDK9 (M1 to F372 residues) expressed in bacterial expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL3116	Homo sapiens	Kd	uM	5.0
	18697621	CHEMBL4254294	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	91.0	CHEMBL3116	Homo sapiens	Activity	%	91.0
	18751686	CHEMBL4264217	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	0.9	CHEMBL3116	Homo sapiens	Activity	%	0.9
	18751961	CHEMBL4264058	Inhibition of CDK9 in human HL60 cells assessed as decrease in RNA polymerase 2 phosphorylation at Ser 2 residues in CTD domain after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	<	EC50	nM	100.0	CHEMBL3116	Homo sapiens	EC50	nM	100.0
	18751962	CHEMBL4264056	Inhibition of CDK9 in human MEC1 cells assessed as decrease in RNA polymerase 2 phosphorylation at Ser 2 residues in CTD domain after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	<	EC50	nM	100.0	CHEMBL3116	Homo sapiens	EC50	nM	100.0
	18751963	CHEMBL4264055	Inhibition of CDK9 in human MV4-11 cells assessed as decrease in RNA polymerase 2 phosphorylation at Ser 2 residues in CTD domain after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	<	EC50	nM	100.0	CHEMBL3116	Homo sapiens	EC50	nM	100.0
Dose-dependent effect	18751973	CHEMBL4264058	Inhibition of CDK9 in human HL60 cells assessed as decrease in RNA polymerase 2 phosphorylation at Ser 2 residues in CTD domain after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	18751974	CHEMBL4264056	Inhibition of CDK9 in human MEC1 cells assessed as decrease in RNA polymerase 2 phosphorylation at Ser 2 residues in CTD domain after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	18751975	CHEMBL4264055	Inhibition of CDK9 in human MV4-11 cells assessed as decrease in RNA polymerase 2 phosphorylation at Ser 2 residues in CTD domain after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	18751976	CHEMBL4264054	Inhibition of CDK9 in human HL60 cells assessed as decrease in phosphorylation at Thr 186 residues up to 3 uM after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	18751977	CHEMBL4264053	Inhibition of CDK9 in human MEC1 cells assessed as decrease in phosphorylation at Thr 186 residues up to 3 uM after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	18751978	CHEMBL4264052	Inhibition of CDK9 in human MV4-11 cells assessed as decrease in phosphorylation at Thr 186 residues up to 3 uM after 2 hrs by immunoblotting analysis	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	18762140	CHEMBL4266675	Inhibition of human full-length N-terminal GST-fused CDK9 (1 to 372 residues) expressed in baculovirus expression system using MBP as substrate after 100 mins by TR-FRET assay	B	CCOc1ccccc1CNc1nc(C)nc2[nH]cc(-c3ccnc(N)c3)c12		CHEMBL4294976	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
	18784876	CHEMBL4271327	Inhibition of CDK9 (unknown origin)	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	18784877	CHEMBL4271327	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
	18784878	CHEMBL4271327	Inhibition of CDK9 (unknown origin)	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
	18784879	CHEMBL4271327	Inhibition of CDK9 (unknown origin)	B	COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=N)=O)c2)n1		CHEMBL4286578	=	IC50	nM	385.0	CHEMBL3116	Homo sapiens	IC50	nM	385.0
	18784885	CHEMBL4271332	Inhibition of recombinant CDK9 (unknown origin) expressed in Sf9 cells using histone H1 derived biotinylated peptide and 33P-ATP incubated for 1 hr by liquid scintillation counting method	B	Cc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@@H]3CCO)nc12		CHEMBL4292930	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
Not Active	18847332	CHEMBL4304888	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	18857886	CHEMBL4307732	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
Not Active	18870772	CHEMBL4310025	Inhibition of CDK9 in human HCT116 cells assessed as induction of dephosphorylation of RNA polymerase 2 S2/S5 residues at at 250 to 500 nM after 24 hrs by Western blot analysis	B	Nc1cc(Nc2ccc(S(N)(=O)=O)cc2)ncn1		CHEMBL265964		Activity			CHEMBL3116	Homo sapiens	Activity		
Not Active	18871055	CHEMBL4310023	Inhibition of CDK9 in human HCT116 cells assessed as induction of dephosphorylation of RNA polymerase 2 S2/S5 residues at 0.5 to 1 uM after 24 hrs by Western blot analysis	B	OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL300389		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	18871073	CHEMBL4310025	Inhibition of CDK9 in human HCT116 cells assessed as induction of dephosphorylation of RNA polymerase 2 S2/S5 residues at at 250 to 500 nM after 24 hrs by Western blot analysis	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	18921630	CHEMBL4323533	Inhibition of CDK9 (unknown origin) at 1 uM relative to control	B	COC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnc4ccc(C#N)cc34)CC2)CC1		CHEMBL4455718	=	Inhibition	%	84.0	CHEMBL3116	Homo sapiens	INH	%	84.0
	18921841	CHEMBL4323546	Inhibition of CDK9 (unknown origin)	B	COC(=O)N1CCN([C@H]2CC[C@H](Nc3nc(Nc4cnn(C)c4)nc4ccc(CC#N)nc34)CC2)CC1		CHEMBL4582624	=	IC50	nM	13000.0	CHEMBL3116	Homo sapiens	IC50	uM	13.0
	18921842	CHEMBL4323546	Inhibition of CDK9 (unknown origin)	B	COC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnc4ccc(C#N)cc34)CC2)CC1		CHEMBL4455718	=	IC50	nM	370.0	CHEMBL3116	Homo sapiens	IC50	uM	0.37
	18934898	CHEMBL4326799	Inhibition of CDK9 (unknown origin)	B	O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CCC2)[nH]n1		CHEMBL4439395	=	IC50	nM	911.0	CHEMBL3116	Homo sapiens	IC50	nM	911.0
	18958804	CHEMBL4333323	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	83.0	CHEMBL3116	Homo sapiens	Activity	%	83.0
	18976125	CHEMBL4338272	Inhibition of CDK9 (unknown origin)	B	Cc1cc(=O)c2c(O)cc(O)c([C@@H]3CCN(C)C[C@@H]3O)c2o1		CHEMBL4521241	=	IC50	nM	300.0	CHEMBL3116	Homo sapiens	IC50	nM	300.0
	19016049	CHEMBL4346799	Inhibition of CDK9 (unknown origin)	B	Cc1cc(C)c(CNc2nc(N[C@@H](C)[C@@H](C)O)nc3c2ncn3C(C)C)cn1		CHEMBL4579344	=	IC50	nM	26.0	CHEMBL3116	Homo sapiens	IC50	nM	26.0
	19016061	CHEMBL4346792	Inhibition of recombinant CDK9 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H1 as substrate incubated for 1 hr in presence of cyclin by [33P]-ATP-based liquid scintillation counting method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	19027223	CHEMBL4348721	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
	19027224	CHEMBL4348721	Inhibition of CDK9 (unknown origin)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	230.0	CHEMBL3116	Homo sapiens	IC50	nM	230.0
	19027225	CHEMBL4348721	Inhibition of CDK9 (unknown origin)	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	IC50	nM	57.0	CHEMBL3116	Homo sapiens	IC50	nM	57.0
	19027229	CHEMBL4348725	Inhibition of recombinant CDK9 (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotinylated peptide as substrate after 1 hr in presence of [33P]ATP by TopCount scintillation counting method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	19059505	CHEMBL4357806	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	19090076	CHEMBL4365650	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
Dose-dependent effect	19092825	CHEMBL4366835	Inhibition of CDK9 in human MV4-11 cells assessed as inhibition of RNA polymerase 2 phosphorylation at S2 residue after 4 hrs by Western blot analysis	B	COc1cc(O)c2c(=O)cc(-c3ccc(N4CCN(C)CC4)cc3)oc2c1Oc1c(C)n[nH]c1C		CHEMBL4446230		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	19112086	CHEMBL4370707	Inhibition of human CDK9	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO		CHEMBL3905910	<	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
	19112087	CHEMBL4370707	Inhibition of human CDK9	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(/C=C/c4c(Cl)cccc4Cl)oc23)[C@H](O)C1		CHEMBL4079206	=	IC50	nM	1.9	CHEMBL3116	Homo sapiens	IC50	nM	1.9
	19133284	CHEMBL4375316	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system measured after 1 hr by kinomescan method	B	O=C(Nc1ccc2cc(C(=O)Nc3nccs3)ccc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL4445812	=	Kd	nM	8020.0	CHEMBL3116	Homo sapiens	Kd	uM	8.02
Active	19144549	CHEMBL4377568	Inhibition of CDK9 in human A549 cells assessed as reduction in phosphorylation of Rb at Ser 780 residue at 0.25 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144550	CHEMBL4377569	Inhibition of CDK9 in human H1299 cells assessed as reduction in phosphorylation of Rb at Ser 780 residue at 0.25 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144551	CHEMBL4377570	Inhibition of CDK9 in human A549 cells assessed as reduction in phosphorylation of RNA polymerase 2 CTD at Ser 2 residue at 0.25 to 1 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144552	CHEMBL4377571	Inhibition of CDK9 in human H1299 cells assessed as reduction in phosphorylation of RNA polymerase 2 CTD at Ser 2 residue at 0.25 to 1 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144553	CHEMBL4377572	Inhibition of CDK9 in human A549 cells assessed as reduction in phosphorylation of RNA polymerase 2 CTD at Ser 5 residue at 0.25 to 1 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144554	CHEMBL4377573	Inhibition of CDK9 in human H1299 cells assessed as reduction in phosphorylation of RNA polymerase 2 CTD at Ser 5 residue at 0.25 to 1 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144598	CHEMBL4377614	Inhibition of CDK9 in human A549 cells assessed as reduction in phosphorylation of Rb at Ser 807/811 residue at 0.25 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	19144599	CHEMBL4377615	Inhibition of CDK9 in human H1299 cells assessed as reduction in phosphorylation of Rb at Ser 807/811 residue at 0.25 uM after 24 hrs by Western blot analysis	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	19159333	CHEMBL4382437	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	80.0	CHEMBL3116	Homo sapiens	Activity	%	80.0
Tde	19176765	CHEMBL4386202	Inhibition of CDK9 in human Mino cells assessed as decrease in phosphorylation of RNA polymerase 2 C-terminal domain at Ser 2 residue at 12.5 nM by immunoblotting analysis	B	CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12		CHEMBL4540226		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Tde	19176766	CHEMBL4386203	Inhibition of CDK9 in human Mino cells assessed as decrease in phosphorylation of RNA polymerase 2 C-terminal domain at Ser 5 residue at 12.5 nM by immunoblotting analysis	B	CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12		CHEMBL4540226		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Tde	19176771	CHEMBL4386208	Inhibition of CDK9 in human Mino cells assessed as decrease in phosphorylation of Rb at Ser 608 residue at 12.5 nM by immunoblotting analysis	B	CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12		CHEMBL4540226		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Tde	19176772	CHEMBL4386209	Inhibition of CDK9 in human Mino cells assessed as decrease in phosphorylation of Rb at Ser 780 residue at 12.5 nM by immunoblotting analysis	B	CC(C)c1n[nH]c2c(NCc3ccc(-c4ccccn4)cc3)nc(SCCN)nc12		CHEMBL4540226		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	19191674	CHEMBL4389156	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	19191819	CHEMBL4389633	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	19199963	CHEMBL4391259	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	3.8	CHEMBL3116	Homo sapiens	Activity	%	3.8
	19258241	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
	19258248	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	1050.0	CHEMBL3116	Homo sapiens	IC50	nM	1050.0
	19258255	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	19258262	CHEMBL4403351	Inhibition of CDK9 (unknown origin) by luciferase reporter gene assay	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@@H]3CCNC[C@H]3O)nc12		CHEMBL4459754	=	IC50	nM	1100.0	CHEMBL3116	Homo sapiens	IC50	nM	1100.0
	19258283	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3N(C)C)nc(OC3CCN(C)CC3)nc12		CHEMBL4454044	=	IC50	nM	7450.0	CHEMBL3116	Homo sapiens	IC50	nM	7450.0
	19258289	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3-n3cccn3)nc(OC3CCCNC3)nc12		CHEMBL4562323	=	IC50	nM	1711.0	CHEMBL3116	Homo sapiens	IC50	nM	1711.0
	19258292	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3cccc4[nH]ncc34)nc(OC3CCCNC3)nc12		CHEMBL4552441	<	IC50	nM	50.0	CHEMBL3116	Homo sapiens	IC50	nM	50.0
	19258295	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3cccc4c3cnn4C)nc(OC3CCCNC3)nc12		CHEMBL4440386	<	IC50	nM	50.0	CHEMBL3116	Homo sapiens	IC50	nM	50.0
	19258298	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	Clc1cnc(N[C@H]2CCCNC2)nc1-c1c[nH]c2ccccc12		CHEMBL4555799	>	IC50	nM	200.0	CHEMBL3116	Homo sapiens	IC50	nM	200.0
	19258301	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	Clc1cnc(N[C@@H]2CCCNC2)nc1-c1c[nH]c2ccccc12		CHEMBL4533453	>	IC50	nM	200.0	CHEMBL3116	Homo sapiens	IC50	nM	200.0
	19258304	CHEMBL4403354	Inhibition of CDK9 (unknown origin) after 4 hrs	B	FC(F)(F)c1cnc(N[C@H]2CCCNC2)nc1-c1n[nH]c2ccccc12		CHEMBL4474655	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
	19258306	CHEMBL4403354	Inhibition of CDK9 (unknown origin) after 4 hrs	B	Clc1cnc(NC2CCCCC2)nc1-c1c[nH]c2cccnc12		CHEMBL4465061	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
	19258314	CHEMBL4403344	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1		CHEMBL4303287	=	IC50	nM	134.0	CHEMBL3116	Homo sapiens	IC50	nM	134.0
	19279520	CHEMBL4408761	Inhibition of CDK9 (unknown origin)	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530	<	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	19407431	CHEMBL4426791	Inhibition of CDK9 (unknown origin)	B	COC(=O)Nc1nc2cc(Sc3nnc4ccc(-c5ccc(F)cc5)nn34)ccc2[nH]1		CHEMBL4453878	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	uM	10.0
	19407438	CHEMBL4426791	Inhibition of CDK9 (unknown origin)	B	COCCNC(=O)Nc1nc2cc(OS(=O)(=O)c3c(F)cccc3F)ccc2[nH]1		CHEMBL4448572	=	IC50	nM	6.0	CHEMBL3116	Homo sapiens	IC50	nM	6.0
	19407439	CHEMBL4426791	Inhibition of CDK9 (unknown origin)	B	COC(=O)Nc1nc2cc(OS(=O)(=O)c3c(Cl)cccc3Cl)ccc2[nH]1		CHEMBL4538461	=	IC50	nM	1200.0	CHEMBL3116	Homo sapiens	IC50	nM	1200.0
Active	20606863	CHEMBL4605166	Inhibition of CDK9 in human MDA-MB-231 cells assessed as down regulation of cyclin T1 expression at 4 to 12 uM measured after 48 hrs by Western blot analysis	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1		CHEMBL4647703		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	20606864	CHEMBL4605165	Inhibition of CDK9 in human MDA-MB-231 cells assessed as down regulation of p-Pol II CTD S2 expression at 4 to 12 uM measured after 48 hrs by Western blot analysis	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1		CHEMBL4647703		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	20606865	CHEMBL4605164	Inhibition of CDK9 in human MDA-MB-231 cells assessed as reduction in c-Myc mRNA level at 4 to 12 uM by trizol reagent based qRT-PCR analysis	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1		CHEMBL4647703		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	20606866	CHEMBL4605163	Inhibition of CDK9 in human MDA-MB-231 cells assessed as reduction in Mcl-1 mRNA level at 4 to 12 uM by trizol reagent based qRT-PCR analysis	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1		CHEMBL4647703		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	20636334	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12		CHEMBL1801932	=	IC50	nM	4200.0	CHEMBL3116	Homo sapiens	IC50	nM	4200.0
	20636343	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12		CHEMBL4297488	=	IC50	nM	1200.0	CHEMBL3116	Homo sapiens	IC50	nM	1200.0
	20636352	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	Cc1cc(NC2CCN(C(=O)O[C@H]3CCN(C(=O)/C=C/CN(C)C)C3)CC2)n2ncc(C(C)C)c2n1		CHEMBL4635959	=	IC50	nM	6320.0	CHEMBL3116	Homo sapiens	IC50	uM	6.32
	20636356	CHEMBL4611867	Inhibition of CDK9 in human HCT116 cells assessed as inhibition of Ser2 phosphorylation	B	Cc1cc(NC2CCN(C(=O)O[C@H]3CCN(C(=O)/C=C/CN(C)C)C3)CC2)n2ncc(C(C)C)c2n1	Outside typical range	CHEMBL4635959	>	IC50	nM	20000000.0	CHEMBL3116	Homo sapiens	IC50	mM	20.0
	20636368	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N[C@@]2(C)CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)nc1		CHEMBL4582951	=	IC50	nM	914.0	CHEMBL3116	Homo sapiens	IC50	nM	914.0
	20636385	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)c1		CHEMBL4303287	=	IC50	nM	6830.0	CHEMBL3116	Homo sapiens	IC50	nM	6830.0
	20636392	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)cc1		CHEMBL4450322	>	IC50	nM	3020.0	CHEMBL3116	Homo sapiens	IC50	nM	3020.0
	20636396	CHEMBL4611863	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)Nc2cccc(Nc3n[nH]c4c3CN(C(=O)N[C@H](CN(C)C)c3ccccc3)C4(C)C)c2)cc1		CHEMBL4434871	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	20641530	CHEMBL4613415	Inhibition of CDK9 (unknown origin) in presence of high ATP	B	CCn1cnc2c(NCc3nc4ccc(F)c(F)c4[nH]3)nc(N3CCCC[C@H]3CCO)nc21		CHEMBL4649135	=	IC50	nM	1090.0	CHEMBL3116	Homo sapiens	IC50	uM	1.09
	20641537	CHEMBL4613417	Binding affinity to CDK9 (unknown origin)	B	Cn1ncc(-c2nc(N[C@H]3CC[C@H](N)CC3)ncc2F)c1CC1CC1		CHEMBL4632717	=	Kd	nM	5.4	CHEMBL3116	Homo sapiens	Kd	nM	5.4
	20641538	CHEMBL4613379	Inhibition of CDK9 (unknown origin)	B	CC[C@@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2n1		CHEMBL1615221	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	uM	0.11
	20641540	CHEMBL4613379	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCC[C@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1		CHEMBL4648857	=	IC50	nM	10500.0	CHEMBL3116	Homo sapiens	IC50	uM	10.5
	20641546	CHEMBL4613379	Inhibition of CDK9 (unknown origin)	B	NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL319467	=	IC50	nM	1100.0	CHEMBL3116	Homo sapiens	IC50	uM	1.1
	22441866	CHEMBL4678812	Reversible inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues preincubated for 6 hrs followed by compound washout and measured after 2 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530	>	IC50	nM	3000.0	CHEMBL3116	Homo sapiens	IC50	uM	3.0
	22441867	CHEMBL4678812	Reversible inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues preincubated for 6 hrs followed by compound washout and measured after 2 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(F)cn2)C1		CHEMBL4754081	>	IC50	nM	3000.0	CHEMBL3116	Homo sapiens	IC50	uM	3.0
	22441878	CHEMBL4678817	Reversible inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues preincubated for 6 hrs followed by compound washout and measured after 0.5 to 2 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)c(Cl)cn2)C1		CHEMBL4754399	>	IC50	nM	3000.0	CHEMBL3116	Homo sapiens	IC50	uM	3.0
Tde	22441888	CHEMBL4678827	Inhibition of CDK9 in human NOMO1 cells assessed as induction of caspase-3/7 activation incubated for 6 hrs by Western blot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	22441889	CHEMBL4678827	Inhibition of CDK9 in human NOMO1 cells assessed as induction of caspase-3/7 activation incubated for 6 hrs by Western blot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Tde	22441890	CHEMBL4678828	Inhibition of CDK9 in human NOMO1 cells assessed as depletion of Mcl-1 incubated for 6 hrs by Western blot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	22441891	CHEMBL4678828	Inhibition of CDK9 in human NOMO1 cells assessed as depletion of Mcl-1 incubated for 6 hrs by Western blot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Tde	22441892	CHEMBL4678829	Inhibition of CDK9 in human NOMO1 cells assessed as inhibition of RNA Polymerase 2 CTD phosphorylation at Ser2 residues incubated for 6 hrs by Western blot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	22441893	CHEMBL4678829	Inhibition of CDK9 in human NOMO1 cells assessed as inhibition of RNA Polymerase 2 CTD phosphorylation at Ser2 residues incubated for 6 hrs by Western blot analysis	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	22442171	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cn[nH]c3CC(C)(C)CO)c(Cl)cn2)C1		CHEMBL4792521	>	IC50	nM	2300.0	CHEMBL3116	Homo sapiens	IC50	uM	2.3
	22442172	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4O)c(Cl)cn2)C1		CHEMBL4747227	=	IC50	nM	170.0	CHEMBL3116	Homo sapiens	IC50	uM	0.17
	22442173	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cn[nH]c3CCCCO)c(Cl)cn2)C1		CHEMBL4777517	>	IC50	nM	2000.0	CHEMBL3116	Homo sapiens	IC50	uM	2.0
	22442174	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4O)c(Cl)cn2)C1		CHEMBL4750372	=	IC50	nM	720.0	CHEMBL3116	Homo sapiens	IC50	uM	0.72
	22442175	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC1(C)Cc2c(-c3cc(NC(=O)[C@H]4C[C@@H](O)C4)ncc3Cl)cnn2C1		CHEMBL4740254	=	IC50	nM	44.0	CHEMBL3116	Homo sapiens	IC50	uM	0.044000000000000004
	22442176	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4784117	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	uM	0.04
	22442177	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)NC1CCCC(C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4759074	=	IC50	nM	49.0	CHEMBL3116	Homo sapiens	IC50	uM	0.049
	22442178	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)NC1CCCC(C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4759074	=	IC50	nM	2400.0	CHEMBL3116	Homo sapiens	IC50	uM	2.4
	22442179	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@H]1CCC[C@@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4798156	=	IC50	nM	310.0	CHEMBL3116	Homo sapiens	IC50	uM	0.31
	22442180	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4n3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4749175	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	uM	0.036000000000000004
	22442181	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)C4)c(Cl)cn2)C1		CHEMBL4753256	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	uM	0.036000000000000004
	22442182	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)C4)c(Cl)cn2)C1		CHEMBL4753256	=	IC50	nM	77.0	CHEMBL3116	Homo sapiens	IC50	uM	0.077
	22442183	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(C)cn2)C1		CHEMBL4753076	=	IC50	nM	40.0	CHEMBL3116	Homo sapiens	IC50	uM	0.04
	22442184	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(C#N)cn2)C1		CHEMBL4784363	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	uM	0.15
	22442185	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530	=	IC50	nM	13.4	CHEMBL3116	Homo sapiens	IC50	uM	0.0134
	22442186	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(F)cn2)C1		CHEMBL4754081	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	uM	0.025
	22442187	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)ccn2)C1		CHEMBL4741063	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	uM	0.15
	22442188	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)CC4)c(F)cn2)C1		CHEMBL4752748	=	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	uM	0.01
	22442189	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)CC4)ccn2)C1		CHEMBL4785242	=	IC50	nM	48.0	CHEMBL3116	Homo sapiens	IC50	uM	0.048
	22442190	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3OCCC4)c(Cl)cn2)C1		CHEMBL4796500	=	IC50	nM	350.0	CHEMBL3116	Homo sapiens	IC50	uM	0.35
	22442191	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3NCCC4)c(Cl)cn2)C1		CHEMBL4750648	=	IC50	nM	860.0	CHEMBL3116	Homo sapiens	IC50	uM	0.86
	22442192	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CN(C)CC4)c(Cl)cn2)C1		CHEMBL4764361	=	IC50	nM	800.0	CHEMBL3116	Homo sapiens	IC50	uM	0.8
	22442193	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3COCC4)c(Cl)cn2)C1		CHEMBL4787309	=	IC50	nM	2100.0	CHEMBL3116	Homo sapiens	IC50	uM	2.1
	22442194	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCCC4)c(Cl)cn2)C1		CHEMBL4786995	=	IC50	nM	92.0	CHEMBL3116	Homo sapiens	IC50	uM	0.092
	22442195	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4n3CCC4)c(Cl)cn2)C1		CHEMBL4756050	=	IC50	nM	760.0	CHEMBL3116	Homo sapiens	IC50	uM	0.76
	22442196	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCC4)c(Cl)cn2)C1		CHEMBL4788016	=	IC50	nM	530.0	CHEMBL3116	Homo sapiens	IC50	uM	0.53
	22442197	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3nnn4ccccc34)c(Cl)cn2)C1		CHEMBL4764938	>	IC50	nM	2600.0	CHEMBL3116	Homo sapiens	IC50	uM	2.6
	22442198	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4ccccn34)c(Cl)cn2)C1		CHEMBL4765079	=	IC50	nM	1600.0	CHEMBL3116	Homo sapiens	IC50	uM	1.6
	22442199	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc(C)n3C)c(Cl)cn2)C1		CHEMBL4799201	>	IC50	nM	3000.0	CHEMBL3116	Homo sapiens	IC50	uM	3.0
	22442200	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4n3CCCC4)c(Cl)cn2)C1		CHEMBL4789009	=	IC50	nM	1200.0	CHEMBL3116	Homo sapiens	IC50	uM	1.2
	22442201	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4ccccc34)c(Cl)cn2)C1		CHEMBL4759053	=	IC50	nM	140.0	CHEMBL3116	Homo sapiens	IC50	uM	0.14
	22442202	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn(C)c3C)c(Cl)cn2)C1		CHEMBL4758821	=	IC50	nM	440.0	CHEMBL3116	Homo sapiens	IC50	uM	0.44
	22442203	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)c(Cl)cn2)C1		CHEMBL4754399	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	uM	0.11
	22442204	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)c(F)cn2)C1		CHEMBL4751230	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	uM	0.1
	22442205	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)ccn2)C1		CHEMBL4780912	=	IC50	nM	520.0	CHEMBL3116	Homo sapiens	IC50	uM	0.52
	22442206	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc(C)n3C(C)C)ccn2)C1		CHEMBL4760601	=	IC50	nM	920.0	CHEMBL3116	Homo sapiens	IC50	uM	0.92
	22442207	CHEMBL4678925	Inhibition of CDK9 in human MCF7 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues measured after 6 hrs by immunofluorescence assay	B	COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1		CHEMBL3673434	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	uM	0.13
	22442208	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC1(C)Cc2c(-c3cc(NC(=O)[C@H]4C[C@@H](O)C4)ncc3Cl)cnn2C1		CHEMBL4740254	=	EC50	nM	38.0	CHEMBL3116	Homo sapiens	EC50	uM	0.038
	22442209	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4784117	=	EC50	nM	15.0	CHEMBL3116	Homo sapiens	EC50	uM	0.015
	22442210	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)NC1CCCC(C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4759074	=	EC50	nM	68.0	CHEMBL3116	Homo sapiens	EC50	uM	0.068
	22442211	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)NC1CCCC(C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4759074	=	EC50	nM	4800.0	CHEMBL3116	Homo sapiens	EC50	uM	4.8
	22442212	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@H]1CCC[C@@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4798156	=	EC50	nM	420.0	CHEMBL3116	Homo sapiens	EC50	uM	0.42
	22442213	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4n3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4749175	=	EC50	nM	54.0	CHEMBL3116	Homo sapiens	EC50	uM	0.054000000000000006
	22442214	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)C4)c(Cl)cn2)C1		CHEMBL4753256	=	EC50	nM	92.0	CHEMBL3116	Homo sapiens	EC50	uM	0.092
	22442215	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)C4)c(Cl)cn2)C1		CHEMBL4753256	=	EC50	nM	77.0	CHEMBL3116	Homo sapiens	EC50	uM	0.077
	22442216	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(C)cn2)C1		CHEMBL4753076	=	EC50	nM	74.0	CHEMBL3116	Homo sapiens	EC50	uM	0.07400000000000001
	22442217	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(C#N)cn2)C1		CHEMBL4784363	=	EC50	nM	140.0	CHEMBL3116	Homo sapiens	EC50	uM	0.14
	22442218	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1		CHEMBL4462530	=	EC50	nM	13.7	CHEMBL3116	Homo sapiens	EC50	uM	0.0137
	22442219	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(F)cn2)C1		CHEMBL4754081	=	EC50	nM	29.0	CHEMBL3116	Homo sapiens	EC50	uM	0.028999999999999998
	22442220	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)ccn2)C1		CHEMBL4741063	=	EC50	nM	100.0	CHEMBL3116	Homo sapiens	EC50	uM	0.1
	22442221	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)CC4)c(F)cn2)C1		CHEMBL4752748	=	EC50	nM	15.0	CHEMBL3116	Homo sapiens	EC50	uM	0.015
	22442222	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)CC4)ccn2)C1		CHEMBL4785242	=	EC50	nM	39.0	CHEMBL3116	Homo sapiens	EC50	uM	0.039
	22442223	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3OCCC4)c(Cl)cn2)C1		CHEMBL4796500	=	EC50	nM	260.0	CHEMBL3116	Homo sapiens	EC50	uM	0.26
	22442224	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3NCCC4)c(Cl)cn2)C1		CHEMBL4750648	=	EC50	nM	670.0	CHEMBL3116	Homo sapiens	EC50	uM	0.67
	22442225	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CN(C)CC4)c(Cl)cn2)C1		CHEMBL4764361	=	EC50	nM	910.0	CHEMBL3116	Homo sapiens	EC50	uM	0.91
	22442226	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3COCC4)c(Cl)cn2)C1		CHEMBL4787309	=	EC50	nM	1900.0	CHEMBL3116	Homo sapiens	EC50	uM	1.9
	22442227	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCCC4)c(Cl)cn2)C1		CHEMBL4786995	=	EC50	nM	180.0	CHEMBL3116	Homo sapiens	EC50	uM	0.18
	22442228	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4n3CCC4)c(Cl)cn2)C1		CHEMBL4756050	=	EC50	nM	700.0	CHEMBL3116	Homo sapiens	EC50	uM	0.7
	22442229	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCC4)c(Cl)cn2)C1		CHEMBL4788016	=	EC50	nM	330.0	CHEMBL3116	Homo sapiens	EC50	uM	0.33
	22442230	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc4n3CCCC4)c(Cl)cn2)C1		CHEMBL4789009	=	EC50	nM	1200.0	CHEMBL3116	Homo sapiens	EC50	uM	1.2
	22442231	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4ccccc34)c(Cl)cn2)C1		CHEMBL4759053	=	EC50	nM	150.0	CHEMBL3116	Homo sapiens	EC50	uM	0.15
	22442232	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn(C)c3C)c(Cl)cn2)C1		CHEMBL4758821	=	EC50	nM	560.0	CHEMBL3116	Homo sapiens	EC50	uM	0.56
	22442233	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)c(Cl)cn2)C1		CHEMBL4754399	=	EC50	nM	130.0	CHEMBL3116	Homo sapiens	EC50	uM	0.13
	22442234	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)c(F)cn2)C1		CHEMBL4751230	=	EC50	nM	160.0	CHEMBL3116	Homo sapiens	EC50	uM	0.16
	22442235	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CCCC4)ccn2)C1		CHEMBL4780912	=	EC50	nM	440.0	CHEMBL3116	Homo sapiens	EC50	uM	0.44
	22442236	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnc(C)n3C(C)C)ccn2)C1		CHEMBL4760601	=	EC50	nM	660.0	CHEMBL3116	Homo sapiens	EC50	uM	0.66
	22442237	CHEMBL4678926	Inhibition of CDK9 in human MV4-11 cells assessed as induction of caspase-3/7 activation measured after 6 hrs followed by Caspase-glo reagent based assay	B	COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1		CHEMBL3673434	=	EC50	nM	220.0	CHEMBL3116	Homo sapiens	EC50	uM	0.22
Not Active	22443449	CHEMBL4679153	Inhibition of CDK9 (unknown origin) at 1 uM	B	O=C(Nc1ccccc1)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1Cc1ccccc1		CHEMBL4781000		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	22443515	CHEMBL4679181	Inhibition of CDK9 (unknown origin) at 1 uM relative to control	B	Cc1cc(C)nc(NS(=O)(=O)c2ccc(Nc3ncc4cc(C(=O)N(C)C)n(C5CCCC5)c4n3)cc2)n1		CHEMBL4746355	=	Inhibition	%	99.0	CHEMBL3116	Homo sapiens	INH	%	99.0
	22485840	CHEMBL4688588	Inhibition of CDK9 (unknown origin) by ATP competitive based analysis	B	NC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCC1CCN(Cc2ccc(F)cc2)CC1		CHEMBL4747992	=	IC50	nM	108.2	CHEMBL3116	Homo sapiens	IC50	nM	108.2
	22752698	CHEMBL4700171	Inhibition of human CDK9 by kinase-profiling analysis	B	C#Cc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc2[nH]cnc12		CHEMBL4074015	=	IC50	nM	41300.0	CHEMBL3116	Homo sapiens	IC50	uM	41.3
	22752746	CHEMBL4700196	Inhibition of human CDK9 at 1 uM by kinase-profiling analysis	B	C#Cc1nc(Nc2ccccc2)nc2[nH]cnc12		CHEMBL4094562	=	Inhibition	%	25.0	CHEMBL3116	Homo sapiens	INH	%	25.0
	22758190	CHEMBL4701381	Inhibition of CDK9 (unknown origin) assessed as reduction in RNA polymerase2 phosphorylation at serine 2 residue by cell based assay	B	COc1cc(F)ccc1-c1cc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)ncc1Cl		CHEMBL4755256	=	IC50	nM	96.0	CHEMBL3116	Homo sapiens	IC50	nM	96.0
	22758226	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
	22758227	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(OP(=O)(O)O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL4594423	=	IC50	nM	84.0	CHEMBL3116	Homo sapiens	IC50	nM	84.0
	22758228	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	C[C@H](CO)Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)ncc1Br		CHEMBL4741442	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
	22758229	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F		CHEMBL4442620	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
	22758230	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	COc1cc(F)ccc1-c1cc(Nc2cc(CS(C)(=N)=O)ccn2)ncc1F		CHEMBL4756595	=	IC50	nM	3.0	CHEMBL3116	Homo sapiens	IC50	nM	3.0
	22758231	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	COc1cc(F)ccc1-c1cc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)ncc1Cl		CHEMBL4755256	<	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
	22758232	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	Nc1nc(C[C@H]2CC3CCC2C3)sc1C(=O)c1ccccc1[N+](=O)[O-]		CHEMBL4761602	=	IC50	nM	5.0	CHEMBL3116	Homo sapiens	IC50	nM	5.0
	22758233	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	IC50	nM	230.0	CHEMBL3116	Homo sapiens	IC50	nM	230.0
	22758234	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	CC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)[C@@H](C)O		CHEMBL4764173	=	IC50	nM	26.0	CHEMBL3116	Homo sapiens	IC50	nM	26.0
	22758235	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	nM	4.0
	22758236	CHEMBL4701389	Inhibition of CDK9 (unknown origin)	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	<	IC50	nM	10.0	CHEMBL3116	Homo sapiens	IC50	nM	10.0
	22758260	CHEMBL4701411	Inhibition of human CDK9	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	IC50	nM	2.0	CHEMBL3116	Homo sapiens	IC50	nM	2.0
	22758307	CHEMBL4701442	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(O)CO)CC3)cc12		CHEMBL3668457	=	IC50	nM	1.2	CHEMBL3116	Homo sapiens	IC50	nM	1.2
	22758308	CHEMBL4701442	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12		CHEMBL4777981	=	IC50	nM	2.6	CHEMBL3116	Homo sapiens	IC50	nM	2.6
	22758333	CHEMBL4701455	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(O)CO)CC3)cc12		CHEMBL3668457	=	IC50	nM	27.6	CHEMBL3116	Homo sapiens	IC50	nM	27.6
	22758362	CHEMBL4701476	Binding affinity to wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system by Kinomescan method	B	Cn1ncc(-c2nc(N[C@H]3CC[C@H](N)CC3)ncc2Cl)c1CC1CC1		CHEMBL4754493	=	Kd	nM	4.0	CHEMBL3116	Homo sapiens	Kd	nM	4.0
	22887406	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccccc4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4748851	=	Inhibition	%	101.9	CHEMBL3116	Homo sapiens	INH	%	101.9
	22887407	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccncc4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4747650	=	Inhibition	%	98.0	CHEMBL3116	Homo sapiens	INH	%	98.0
	22887408	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	COc1ccccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4790090	=	Inhibition	%	103.5	CHEMBL3116	Homo sapiens	INH	%	103.5
	22887409	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(C#N)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4759451	=	Inhibition	%	71.8	CHEMBL3116	Homo sapiens	INH	%	71.8
	22887410	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3cccc(-c4ccccc4)c3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4780212	=	Inhibition	%	1.3	CHEMBL3116	Homo sapiens	INH	%	1.3
	22887411	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3cccc(-c4ccncc4)c3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4779338	=	Inhibition	%	0.7	CHEMBL3116	Homo sapiens	INH	%	0.7
	22887412	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	COc1ccccc1-c1cccc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)c1		CHEMBL4754662	=	Inhibition	%	3.8	CHEMBL3116	Homo sapiens	INH	%	3.8
	22887413	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3cccc(-c4cccc(C#N)c4)c3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4756378	=	Inhibition	%	-4.1	CHEMBL3116	Homo sapiens	INH	%	-4.1
	22887414	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	Cc1ccccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4779176	=	Inhibition	%	1.0	CHEMBL3116	Homo sapiens	INH	%	1.0
	22887415	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4c[nH]c5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4742663	=	Inhibition	%	58.6	CHEMBL3116	Homo sapiens	INH	%	58.6
	22887416	CHEMBL4728474	Inhibition of human CDK9 at 1 uM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(Nc5ccccc5)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4793601	=	Inhibition	%	47.8	CHEMBL3116	Homo sapiens	INH	%	47.8
	22887417	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccccc4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4748851	=	Inhibition	%	83.4	CHEMBL3116	Homo sapiens	INH	%	83.4
	22887418	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccncc4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4747650	=	Inhibition	%	94.5	CHEMBL3116	Homo sapiens	INH	%	94.5
	22887419	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	COc1ccccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4790090	=	Inhibition	%	67.9	CHEMBL3116	Homo sapiens	INH	%	67.9
	22887420	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(C#N)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4759451	=	Inhibition	%	25.2	CHEMBL3116	Homo sapiens	INH	%	25.2
	22887421	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3cccc(-c4ccccc4)c3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4780212	=	Inhibition	%	-6.1	CHEMBL3116	Homo sapiens	INH	%	-6.1
	22887422	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3cccc(-c4ccncc4)c3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4779338	=	Inhibition	%	2.2	CHEMBL3116	Homo sapiens	INH	%	2.2
	22887423	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	COc1ccccc1-c1cccc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)c1		CHEMBL4754662	=	Inhibition	%	-3.0	CHEMBL3116	Homo sapiens	INH	%	-3.0
	22887424	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3cccc(-c4cccc(C#N)c4)c3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4756378	=	Inhibition	%	2.0	CHEMBL3116	Homo sapiens	INH	%	2.0
	22887425	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	Cc1ccccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4779176	=	Inhibition	%	1.5	CHEMBL3116	Homo sapiens	INH	%	1.5
	22887426	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4c[nH]c5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4742663	=	Inhibition	%	7.6	CHEMBL3116	Homo sapiens	INH	%	7.6
	22887427	CHEMBL4728475	Inhibition of human CDK9 at 100 nM by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(Nc5ccccc5)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4793601	=	Inhibition	%	8.8	CHEMBL3116	Homo sapiens	INH	%	8.8
	22887476	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	COc1cccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)c1		CHEMBL4754326	=	IC50	nM	126.4	CHEMBL3116	Homo sapiens	IC50	nM	126.4
	22887477	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	COc1ccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)cc1		CHEMBL4796617	=	IC50	nM	31.7	CHEMBL3116	Homo sapiens	IC50	nM	31.7
	22887478	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	Cc1cccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)c1		CHEMBL4741061	=	IC50	nM	195.8	CHEMBL3116	Homo sapiens	IC50	nM	195.8
	22887479	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	Cc1ccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)cc1		CHEMBL4740156	=	IC50	nM	488.5	CHEMBL3116	Homo sapiens	IC50	nM	488.5
	22887480	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccccc4N)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4760844	=	IC50	nM	39.2	CHEMBL3116	Homo sapiens	IC50	nM	39.2
	22887481	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(N)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4755696	=	IC50	nM	5.9	CHEMBL3116	Homo sapiens	IC50	nM	5.9
	22887482	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccc(N)cc4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4740586	=	IC50	nM	48.9	CHEMBL3116	Homo sapiens	IC50	nM	48.9
	22887483	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	COc1cc(F)ccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4793212	=	IC50	nM	46.9	CHEMBL3116	Homo sapiens	IC50	nM	46.9
	22887484	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	Cc1cc(F)ccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4755816	=	IC50	nM	578.2	CHEMBL3116	Homo sapiens	IC50	nM	578.2
	22887485	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CNc1cccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)c1		CHEMBL4764023	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
	22887486	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CCNc1cccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)c1		CHEMBL4786023	=	IC50	nM	37.8	CHEMBL3116	Homo sapiens	IC50	nM	37.8
	22887487	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)Nc1cccc(-c2ccnc(Nc3ccc4c(c3)N(C(C)C)[C@H](C)C(=O)N4C)n2)c1		CHEMBL4745398	=	IC50	nM	50.9	CHEMBL3116	Homo sapiens	IC50	nM	50.9
	22887488	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(NC5CCCC5)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4798690	=	IC50	nM	121.9	CHEMBL3116	Homo sapiens	IC50	nM	121.9
	22887489	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc(NC5CCCCC5)c4)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4761833	=	IC50	nM	168.8	CHEMBL3116	Homo sapiens	IC50	nM	168.8
	22887490	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	Cc1c(N)cccc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4789072	=	IC50	nM	182.9	CHEMBL3116	Homo sapiens	IC50	nM	182.9
	22887491	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	Cc1ccc(N)cc1-c1ccnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)n1		CHEMBL4749819	=	IC50	nM	151.2	CHEMBL3116	Homo sapiens	IC50	nM	151.2
	22887492	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc5c4CCCN5)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4758996	=	IC50	nM	67.0	CHEMBL3116	Homo sapiens	IC50	nM	67.0
	22887493	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc5[nH]ccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4798556	=	IC50	nM	13.8	CHEMBL3116	Homo sapiens	IC50	nM	13.8
	22887494	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc5nn(C)cc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4747648	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	nM	110.0
	22887495	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc5cnccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4756594	=	IC50	nM	79.8	CHEMBL3116	Homo sapiens	IC50	nM	79.8
	22887496	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cccc5ncccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4752747	=	IC50	nM	81.6	CHEMBL3116	Homo sapiens	IC50	nM	81.6
	22887497	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4ccnc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4762677	=	IC50	nM	19.8	CHEMBL3116	Homo sapiens	IC50	nM	19.8
	22887498	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4742169	=	IC50	nM	22.4	CHEMBL3116	Homo sapiens	IC50	nM	22.4
	22887499	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3ncc(F)c(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4757918	=	IC50	nM	23.9	CHEMBL3116	Homo sapiens	IC50	nM	23.9
	22887500	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	CC(C)N1c2cc(Nc3ncc(Cl)c(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4783301	=	IC50	nM	23.0	CHEMBL3116	Homo sapiens	IC50	nM	23.0
	22887501	CHEMBL4728482	Inhibition of human CDK9 by mobility shift assay relative to control	B	Cc1cnc(Nc2ccc3c(c2)N(C(C)C)[C@H](C)C(=O)N3C)nc1-c1cncc2ccccc12		CHEMBL4800119	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	nM	100.0
Dose-dependent effect	22887511	CHEMBL4728491	Inhibition of CDK9 in human HCT-116 cells assessed as reduction in phosphorylation of RAP 2 protein expression at 50 to 500 nM after 24 hrs by Western blot analysis	B	CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4742169		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	22887512	CHEMBL4728491	Inhibition of CDK9 in human HCT-116 cells assessed as reduction in phosphorylation of RAP 2 protein expression at 50 to 500 nM after 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=N)=O)c2)n1		CHEMBL4286578		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	22887513	CHEMBL4728492	Inhibition of CDK9 in human HCT-116 cells assessed as reduction in phosphorylation of AR protein expression at 50 to 500 nM after 24 hrs by Western blot analysis	B	CC(C)N1c2cc(Nc3nccc(-c4cncc5ccccc45)n3)ccc2N(C)C(=O)[C@H]1C		CHEMBL4742169		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-dependent effect	22887514	CHEMBL4728492	Inhibition of CDK9 in human HCT-116 cells assessed as reduction in phosphorylation of AR protein expression at 50 to 500 nM after 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=N)=O)c2)n1		CHEMBL4286578		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	22889496	CHEMBL4729015	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	22908773	CHEMBL4733705	Inhibition of CDK9 (unknown origin) at 300 nM relative to control	B	CNC(=O)c1sc(-c2ccnc(NC(=O)C3CC3)c2)nc1OCCCCCCCCn1cc(COc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)nn1		CHEMBL4749204	=	Inhibition	%	3.27	CHEMBL3116	Homo sapiens	INH	%	3.27
	22922114	CHEMBL4736845	Inhibition of CDK9 (unknown origin) assessed as enzyme remaining activity at 5 uM relative to control	B	COc1ccc(-c2ccnc(N[C@H]3CO[C@@H]4[C@@H](NC(=O)Nc5ccc(C(C)=O)cc5)CO[C@H]34)n2)cc1		CHEMBL4758751	=	Activity	%	33.8	CHEMBL3116	Homo sapiens	Activity	%	33.8
	22930714	CHEMBL4738665	Inhibition of recombinant CDK9 (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated Histone H1 peptide as substrate incubated for 1 hr in presence of [33P]ATP by liquid scintillation counting method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	4.0	CHEMBL3116	Homo sapiens	IC50	uM	0.004
	22936214	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCOCC3)s2)c1		CHEMBL4777761	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936215	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(C)CC3)s2)c1		CHEMBL4790868	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936216	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(CC)CC3)s2)c1		CHEMBL4749580	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936217	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCN(C(=O)OC(C)(C)C)CC3)s2)c1		CHEMBL4763994	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936218	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)Nc2ncc(N3CCC(N(C)C)CC3)s2)c1		CHEMBL4743840	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936219	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4781539	=	IC50	nM	98.0	CHEMBL3116	Homo sapiens	IC50	nM	98.0
	22936220	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)NC1CCC(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)CC1		CHEMBL4793573	=	IC50	nM	22.0	CHEMBL3116	Homo sapiens	IC50	nM	22.0
	22936221	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)NC1CCN(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)CC1		CHEMBL4776271	=	IC50	nM	182.0	CHEMBL3116	Homo sapiens	IC50	nM	182.0
	22936222	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c(OC)c1		CHEMBL4746993	=	IC50	nM	164.0	CHEMBL3116	Homo sapiens	IC50	nM	164.0
	22936223	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4788401	=	IC50	nM	66.5	CHEMBL3116	Homo sapiens	IC50	nM	66.5
	22936224	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CNc4cc(C(F)(F)F)c(Cl)cn4)s3)C2)cc1		CHEMBL4763202	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936225	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(/C=C/c4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4753350	=	IC50	nM	15.1	CHEMBL3116	Homo sapiens	IC50	nM	15.1
	22936226	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4794338	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936227	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(COCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4764719	>	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	22936228	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(CNCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4781334	=	IC50	nM	7140.0	CHEMBL3116	Homo sapiens	IC50	nM	7140.0
	22936229	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(S(=O)(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4756935	=	IC50	nM	197.0	CHEMBL3116	Homo sapiens	IC50	nM	197.0
	22936230	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc([S+]([O-])N2CCCC(Nc3ncc(SCc4cccnc4)s3)C2)cc1		CHEMBL4786324	>	IC50	nM	1000.0	CHEMBL3116	Homo sapiens	IC50	nM	1000.0
	22936231	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ccccn4)s3)C2)cc1		CHEMBL4789890	=	IC50	nM	1000.0	CHEMBL3116	Homo sapiens	IC50	nM	1000.0
	22936232	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4cnc(C(F)(F)F)nc4)s3)C2)cc1		CHEMBL4789917	>	IC50	nM	1000.0	CHEMBL3116	Homo sapiens	IC50	nM	1000.0
	22936233	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)N1CCc2cc(S(=O)(=O)N3CCCC(Nc4ncc(SCc5ncc(C(C)(C)C)o5)s4)C3)ccc21		CHEMBL4744627	=	IC50	nM	1570.0	CHEMBL3116	Homo sapiens	IC50	nM	1570.0
	22936234	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c(C(F)(F)F)c1		CHEMBL4752238	=	IC50	nM	298.0	CHEMBL3116	Homo sapiens	IC50	nM	298.0
	22936235	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCC4CCOCC4)s3)C2)cc1		CHEMBL4643754	>	IC50	nM	1000.0	CHEMBL3116	Homo sapiens	IC50	nM	1000.0
	22936236	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCc4cncnc4)s3)C2)cc1		CHEMBL4797288	=	IC50	nM	7280.0	CHEMBL3116	Homo sapiens	IC50	nM	7280.0
	22936237	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4758168	=	IC50	nM	54.5	CHEMBL3116	Homo sapiens	IC50	nM	54.5
	22936238	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)N1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CC1		CHEMBL4777844	=	IC50	nM	0.495	CHEMBL3116	Homo sapiens	IC50	nM	0.495
	22936239	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)N1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CC1		CHEMBL4641226	=	IC50	nM	3.16	CHEMBL3116	Homo sapiens	IC50	nM	3.16
	22936240	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)CC/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4753717	=	IC50	nM	4.4	CHEMBL3116	Homo sapiens	IC50	nM	4.4
	22936241	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4644893	=	IC50	nM	1.79	CHEMBL3116	Homo sapiens	IC50	nM	1.79
	22936242	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)c1		CHEMBL4643057	=	IC50	nM	24.6	CHEMBL3116	Homo sapiens	IC50	nM	24.6
	22936243	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1cccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)c1		CHEMBL4786429	=	IC50	nM	10.7	CHEMBL3116	Homo sapiens	IC50	nM	10.7
	22936244	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1ccc(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)cc1		CHEMBL4756353	=	IC50	nM	8.9	CHEMBL3116	Homo sapiens	IC50	nM	8.9
	22936245	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1cccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c1		CHEMBL4797409	=	IC50	nM	198.0	CHEMBL3116	Homo sapiens	IC50	nM	198.0
	22936246	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1cccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)c1		CHEMBL4752989	=	IC50	nM	177.0	CHEMBL3116	Homo sapiens	IC50	nM	177.0
	22936247	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)Nc2cccc(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)c2)cc1		CHEMBL4761637	=	IC50	nM	23.7	CHEMBL3116	Homo sapiens	IC50	nM	23.7
	22936248	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4761001	=	IC50	nM	65.0	CHEMBL3116	Homo sapiens	IC50	nM	65.0
	22936249	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	CN(C)C/C=C/C(=O)Nc1ccc(S(=O)(=O)N2CCCC(Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4744850	=	IC50	nM	474.0	CHEMBL3116	Homo sapiens	IC50	nM	474.0
	22936250	CHEMBL4739785	Inhibition of CDK9 (unknown origin)	B	C=CC(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1		CHEMBL4788136	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	nM	33.0
	22960779	CHEMBL4768771	Inhibition of CDK9 (unknown origin) at 0.5 uM	B	Cc1ccc(N2CCN(C(=O)Nc3ncc(Cl)s3)CC2)cc1Cl		CHEMBL4788153	=	Inhibition	%	40.0	CHEMBL3116	Homo sapiens	INH	%	40.0
	22960780	CHEMBL4768771	Inhibition of CDK9 (unknown origin) at 0.5 uM	B	O=C(Nc1ncc(Cl)s1)N1CCN(c2cnc(Cl)c(Cl)c2)CC1		CHEMBL4777866	=	Inhibition	%	60.0	CHEMBL3116	Homo sapiens	INH	%	60.0
	22967931	CHEMBL4770022	Inhibition of CDK9 (unknown origin)	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	IC50	nM	20.0	CHEMBL3116	Homo sapiens	IC50	nM	20.0
Dose-dependent effect	22970588	CHEMBL4770561	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues incubated for 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1nc(Nc2ccc3c(N4CCOCC4)c(C(C)=O)c(=O)oc3c2)ncc1F		CHEMBL4788347		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	22970793	CHEMBL4770624	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in Mcl-1 expression level at 0.1 uM incubated for 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1nc(Nc2ccc3c(N4CCOCC4)c(C(C)=O)c(=O)oc3c2)ncc1F		CHEMBL4788347		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	22970794	CHEMBL4770625	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in c-Myc expression level at 0.1 uM incubated for 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1nc(Nc2ccc3c(N4CCOCC4)c(C(C)=O)c(=O)oc3c2)ncc1F		CHEMBL4788347		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	22970795	CHEMBL4770626	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in Mcl-1 expression level at 0.2 to 0.8 uM incubated for 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1nc(Nc2ccc3c(N4CCOCC4)c(C(C)=O)c(=O)oc3c2)ncc1F		CHEMBL4788347	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
	22970796	CHEMBL4770627	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in c-Myc expression level at 0.2 to 0.8 uM incubated for 24 hrs by Western blot analysis	B	COc1cc(F)ccc1-c1nc(Nc2ccc3c(N4CCOCC4)c(C(C)=O)c(=O)oc3c2)ncc1F		CHEMBL4788347	=	Inhibition	%	100.0	CHEMBL3116	Homo sapiens	INH	%	100.0
Active	22970797	CHEMBL4770628	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in RNA Polymerase 2 CTD phosphorylation at Ser2 residues at 0.8 uM incubated for 24 hrs by Western blot analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	22970798	CHEMBL4770629	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in Mcl-1 expression level at 0.8 uM incubated for 24 hrs by Western blot analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Active	22970799	CHEMBL4770630	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in c-Myc expression level at 0.8 uM incubated for 24 hrs by Western blot analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	23120289	CHEMBL4804362	Inhibition of CDK9 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	41100.0	CHEMBL3116	Homo sapiens	IC50	uM	41.1
	23120290	CHEMBL4804362	Inhibition of CDK9 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	28900.0	CHEMBL3116	Homo sapiens	IC50	uM	28.9
	23120291	CHEMBL4804362	Inhibition of CDK9 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	IC50	nM	65800.0	CHEMBL3116	Homo sapiens	IC50	uM	65.8
	23121331	CHEMBL4804544	Inhibition of CDK9 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	35.0	CHEMBL3116	Homo sapiens	INH	%	35.0
	23121332	CHEMBL4804544	Inhibition of CDK9 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL3116	Homo sapiens	INH	%	0.0
	23121333	CHEMBL4804544	Inhibition of CDK9 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	50.0	CHEMBL3116	Homo sapiens	INH	%	50.0
	23122491	CHEMBL4804842	Inhibition of human CDK9 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	97.0	CHEMBL3116	Homo sapiens	Activity	%	97.0
	23123186	CHEMBL4805430	Inhibition of human CDK9 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
	23123704	CHEMBL4805948	Inhibition of DNA-tagged human CDK9 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	84.0	CHEMBL3116	Homo sapiens	Activity	%	84.0
	23124205	CHEMBL4806304	Inhibition of CDK9 (unknown origin)	B	Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1		CHEMBL4877117	=	IC50	nM	10000.0	CHEMBL3116	Homo sapiens	IC50	nM	10000.0
	23124233	CHEMBL4806316	Inhibition of CDK9 (unknown origin) at 10 uM relative to control	B	Cn1cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)cn1		CHEMBL4852083	=	Inhibition	%	43.0	CHEMBL3116	Homo sapiens	INH	%	43.0
	23124234	CHEMBL4806316	Inhibition of CDK9 (unknown origin) at 10 uM relative to control	B	Fc1cccc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4211454	=	Inhibition	%	69.0	CHEMBL3116	Homo sapiens	INH	%	69.0
	23124235	CHEMBL4806316	Inhibition of CDK9 (unknown origin) at 10 uM relative to control	B	Cc1cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)no1		CHEMBL4847754	=	Inhibition	%	64.0	CHEMBL3116	Homo sapiens	INH	%	64.0
	23124462	CHEMBL4806447	Inhibition of human CDK9 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	66.0	CHEMBL3116	Homo sapiens	Activity	%	66.0
	23124463	CHEMBL4806447	Inhibition of human CDK9 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL3116	Homo sapiens	Activity	%	100.0
Not Active	23125689	CHEMBL4806997	Inhibition of CDK9 (unknown origin)	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ncnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4076837		Kd			CHEMBL3116	Homo sapiens	Kd		
	23196737	CHEMBL4819952	Inhibition of human full length recombinant CDK9 expressed in bacterial expression system assessed as remaining enzyme activity at 1 uM by competitive binding Kinome scan analysis	B	COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=O)=NC(=O)CCCCCCCC(=O)NCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)c2)n1		CHEMBL4854353	<	Activity	%	10.0	CHEMBL3116	Homo sapiens	Activity	%	10.0
Dose-Dependent Effect	23200689	CHEMBL4820776	Inhibition of CDK9 in human A2780 cells assessed as reduction in RNAP2 phosphorylation at ser2 residues after 24 hrs by Western blot analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCN5CCC4CC5)c3)ncc2C)s1		CHEMBL4860925		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Dose-Dependent Effect	23200690	CHEMBL4820777	Inhibition of CDK9 in human A2780 cells assessed as reduction in RNAP2 phosphorylation at ser5 residues after 24 hrs by Western blot analysis	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCN5CCC4CC5)c3)ncc2C)s1		CHEMBL4860925		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	23206410	CHEMBL4821740	Inhibition of CDK9 (unknown origin)	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(C(=O)CCl)CC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL4850687	=	IC50	nM	1834.0	CHEMBL3116	Homo sapiens	IC50	nM	1834.0
	23209020	CHEMBL4822305	Inhibition of CDK9 (unknown origin)	B	O=C(CCCOc1ccc(CC(=O)Nc2cc(C3CCC3)[nH]n2)cc1)NCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O		CHEMBL4864688	=	IC50	nM	530.0	CHEMBL3116	Homo sapiens	IC50	nM	530.0
	23209021	CHEMBL4822305	Inhibition of CDK9 (unknown origin)	B	COc1ccc(CC(=O)Nc2cc(C3CCC3)[nH]n2)cc1		CHEMBL4846069	=	IC50	nM	1080.0	CHEMBL3116	Homo sapiens	IC50	nM	1080.0
Not Active	23209023	CHEMBL4822307	Inhibition of CDK9 in human HEK293 cells assessed as reduction in CDK9 level at 10 uM incubated for 24 hrs by Western blot analysis	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	23209025	CHEMBL4822309	Inhibition of CDK9 in human HEK293 cells assessed as reduction in CDK9 level at 1 uM incubated for 24 hrs in presence of flavopiridol by Western blot analysis	B	O=C(CCCOc1ccc(CC(=O)Nc2cc(C3CCC3)[nH]n2)cc1)NCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O		CHEMBL4864688		Activity			CHEMBL3116	Homo sapiens	Activity		
	23209045	CHEMBL4822327	Binding affinity to CDK9 (unknown origin)	B	O=C(CCCOc1ccc(CC(=O)Nc2cc(C3CCC3)[nH]n2)cc1)NCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O		CHEMBL4864688	=	Kd	nM	1055.0	CHEMBL3116	Homo sapiens	Kd	nM	1055.0
	23209046	CHEMBL4822327	Binding affinity to CDK9 (unknown origin)	B	COc1ccc(CC(=O)Nc2cc(C3CCC3)[nH]n2)cc1		CHEMBL4846069	=	Kd	nM	1065.0	CHEMBL3116	Homo sapiens	Kd	nM	1065.0
	23234027	CHEMBL4827606	Inhibition of wild-type human full length CDK9 (M1 to F372 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	O=C(O)c1ccc(-c2ccnc3[nH]c(-c4ccccc4)nc23)cc1C1CCCC1		CHEMBL4870467	<	Activity	%	10.0	CHEMBL3116	Homo sapiens	Activity	%	10.0
Not Active	23256053	CHEMBL4832004	Inhibition of CDK9 (unknown origin) at 0.3 uM	B	O=C(Nc1cncc(OCC2CCN(Cc3ccc(F)cc3)CC2)c1)c1ccnc(NC(=O)C2CC2)c1		CHEMBL4873612		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
	23278722	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C(=O)NS(C)(=O)=O)CC3)cc12		CHEMBL4855187	=	IC50	nM	89.0	CHEMBL3116	Homo sapiens	IC50	uM	0.08900000000000001
	23278723	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C(=O)O)CC3)cc12		CHEMBL3668489	=	IC50	nM	75.0	CHEMBL3116	Homo sapiens	IC50	uM	0.075
	23278724	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)O)CC3)cc12		CHEMBL3668495	=	IC50	nM	33.0	CHEMBL3116	Homo sapiens	IC50	uM	0.033
	23278725	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	CNC(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668485	=	IC50	nM	21.0	CHEMBL3116	Homo sapiens	IC50	uM	0.021
	23278726	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCNCC3)cc12		CHEMBL3668361	=	IC50	nM	14.0	CHEMBL3116	Homo sapiens	IC50	uM	0.013999999999999999
	23278727	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)CO)CC3)cc12		CHEMBL3668374	=	IC50	nM	36.0	CHEMBL3116	Homo sapiens	IC50	uM	0.036000000000000004
	23278728	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)cc12		CHEMBL3668392	=	IC50	nM	43.0	CHEMBL3116	Homo sapiens	IC50	uM	0.043
	23278729	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	CCOC(=O)NS(=O)(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL4850143	=	IC50	nM	25.0	CHEMBL3116	Homo sapiens	IC50	uM	0.025
	23278730	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(NCC(=O)O)CC3)cc12		CHEMBL4872494	=	IC50	nM	63.0	CHEMBL3116	Homo sapiens	IC50	uM	0.063
	23278731	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N[C@@H](C(=O)O)C(C)C)CC3)cc12		CHEMBL3668508	=	IC50	nM	91.0	CHEMBL3116	Homo sapiens	IC50	uM	0.091
	23278732	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@@H](C(=O)O)CC4)CC3)cc12		CHEMBL4861217	=	IC50	nM	64.0	CHEMBL3116	Homo sapiens	IC50	uM	0.064
	23278733	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12		CHEMBL4855780	=	IC50	nM	83.0	CHEMBL3116	Homo sapiens	IC50	uM	0.083
	23278734	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)cc12		CHEMBL3668553	=	IC50	nM	80.0	CHEMBL3116	Homo sapiens	IC50	uM	0.08
	23278735	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)cc12		CHEMBL3668554	=	IC50	nM	200.0	CHEMBL3116	Homo sapiens	IC50	uM	0.2
	23278736	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@@H](C(=O)O)CC4)CC3)cc12		CHEMBL4851229	=	IC50	nM	81.0	CHEMBL3116	Homo sapiens	IC50	uM	0.081
	23278737	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12		CHEMBL4777981	=	IC50	nM	78.0	CHEMBL3116	Homo sapiens	IC50	uM	0.078
	23278738	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)cc12		CHEMBL4848653	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	uM	0.12
	23278739	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)cc12		CHEMBL4853678	=	IC50	nM	100.0	CHEMBL3116	Homo sapiens	IC50	uM	0.1
	23278740	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCC(C(=O)O)CC4)CC3)cc12		CHEMBL4878465	=	IC50	nM	120.0	CHEMBL3116	Homo sapiens	IC50	uM	0.12
	23278741	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCC(CC(=O)O)CC4)CC3)cc12		CHEMBL4865444	=	IC50	nM	86.0	CHEMBL3116	Homo sapiens	IC50	uM	0.086
	23278742	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C4CCN(CC(=O)O)CC4)CC3)cc12		CHEMBL4874984	=	IC50	nM	160.0	CHEMBL3116	Homo sapiens	IC50	uM	0.16
	23278743	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(c4ccc(CC(=O)O)cc4)CC3)cc12		CHEMBL4857987	=	IC50	nM	75.0	CHEMBL3116	Homo sapiens	IC50	uM	0.075
	23278744	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C4CCN(CC(=O)O)CC4)CC3)cc12		CHEMBL4870276	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	uM	0.11
	23278745	CHEMBL4836671	Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate measured after 1.5 hrs by TR-FRET LANCE method	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCN(CC(=O)O)CC4)CC3)cc12		CHEMBL4849746	=	IC50	nM	130.0	CHEMBL3116	Homo sapiens	IC50	uM	0.13
	23278770	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCNCC3)cc12		CHEMBL3668361	=	IC50	nM	18.0	CHEMBL3116	Homo sapiens	IC50	uM	0.018000000000000002
	23278771	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)cc12		CHEMBL3668392	=	IC50	nM	230.0	CHEMBL3116	Homo sapiens	IC50	uM	0.23
	23278772	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C(=O)CO)CC3)cc12		CHEMBL3668374	=	IC50	nM	72.0	CHEMBL3116	Homo sapiens	IC50	uM	0.07200000000000001
	23278773	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	CNC(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL3668485	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	uM	0.11
	23278774	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C(=O)O)CC3)cc12		CHEMBL3668489	=	IC50	nM	2100.0	CHEMBL3116	Homo sapiens	IC50	uM	2.1
	23278775	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(CC(=O)O)CC3)cc12		CHEMBL3668495	=	IC50	nM	87.0	CHEMBL3116	Homo sapiens	IC50	uM	0.087
	23278776	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C(=O)NS(C)(=O)=O)CC3)cc12		CHEMBL4855187	=	IC50	nM	660.0	CHEMBL3116	Homo sapiens	IC50	uM	0.66
	23278777	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	CCOC(=O)NS(=O)(=O)N1CC=C(c2cc3c(-c4cc(F)ccc4OC)ccnc3[nH]2)CC1		CHEMBL4850143	=	IC50	nM	210.0	CHEMBL3116	Homo sapiens	IC50	uM	0.21
	23278778	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(NCC(=O)O)CC3)cc12		CHEMBL4872494	=	IC50	nM	1500.0	CHEMBL3116	Homo sapiens	IC50	uM	1.5
	23278779	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N[C@@H](C(=O)O)C(C)C)CC3)cc12		CHEMBL3668508	=	IC50	nM	370.0	CHEMBL3116	Homo sapiens	IC50	uM	0.37
	23278780	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@@H](C(=O)O)CC4)CC3)cc12		CHEMBL4861217	=	IC50	nM	210.0	CHEMBL3116	Homo sapiens	IC50	uM	0.21
	23278781	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12		CHEMBL4855780	=	IC50	nM	270.0	CHEMBL3116	Homo sapiens	IC50	uM	0.27
	23278782	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)cc12		CHEMBL3668553	=	IC50	nM	220.0	CHEMBL3116	Homo sapiens	IC50	uM	0.22
	23278783	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)cc12		CHEMBL3668554	=	IC50	nM	350.0	CHEMBL3116	Homo sapiens	IC50	uM	0.35
	23278784	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@@H](C(=O)O)CC4)CC3)cc12		CHEMBL4851229	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	uM	0.11
	23278785	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](C(=O)O)CC4)CC3)cc12		CHEMBL4777981	=	IC50	nM	110.0	CHEMBL3116	Homo sapiens	IC50	uM	0.11
	23278786	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@@H](CC(=O)O)CC4)CC3)cc12		CHEMBL4848653	=	IC50	nM	180.0	CHEMBL3116	Homo sapiens	IC50	uM	0.18
	23278787	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1c(F)cnc2[nH]c(C3=CCN([C@H]4CC[C@H](CC(=O)O)CC4)CC3)cc12		CHEMBL4853678	=	IC50	nM	150.0	CHEMBL3116	Homo sapiens	IC50	uM	0.15
	23278788	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCC(C(=O)O)CC4)CC3)cc12		CHEMBL4878465	=	IC50	nM	680.0	CHEMBL3116	Homo sapiens	IC50	uM	0.68
	23278789	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCC(CC(=O)O)CC4)CC3)cc12		CHEMBL4865444	=	IC50	nM	980.0	CHEMBL3116	Homo sapiens	IC50	uM	0.98
	23278790	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(C4CCN(CC(=O)O)CC4)CC3)cc12		CHEMBL4874984	=	IC50	nM	2400.0	CHEMBL3116	Homo sapiens	IC50	uM	2.4
	23278791	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCN(C4CCN(CC(=O)O)CC4)CC3)cc12		CHEMBL4870276	=	IC50	nM	1200.0	CHEMBL3116	Homo sapiens	IC50	uM	1.2
	23278792	CHEMBL4836673	Inhibition of CDK9 in human A-431 cells assessed as reduction in RNA polymerase2 phosphorylation at C-terminal ser2 residue incubated for 4 hrs by In-cell Western analysis	B	COc1ccc(F)cc1-c1ccnc2[nH]c(C3=CCC(N4CCN(CC(=O)O)CC4)CC3)cc12		CHEMBL4849746	=	IC50	nM	640.0	CHEMBL3116	Homo sapiens	IC50	uM	0.64
	23297716	CHEMBL4841252	Inhibition of CDK9 (unknown origin) expressed in Sf9 insect cells using biotinylated peptide derived Histone H1 as substrate incubated for 1 hr in presence of [gamma33P]ATP by liquid scintillation counter method	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	=	IC50	nM	1.0	CHEMBL3116	Homo sapiens	IC50	nM	1.0
Not Active	23297835	CHEMBL4841303	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in RNAP2 phosphorylation at ser2 residues at 1 to 10 uM after 12 hrs by Western blot analysis	B	Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3Cl)cc12		CHEMBL4876497		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	23297836	CHEMBL4841304	Inhibition of CDK9 in human MV4-11 cells assessed as reduction in RNAP2 phosphorylation at ser5 residues at 1 to 10 uM after 12 hrs by Western blot analysis	B	Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3Cl)cc12		CHEMBL4876497		Inhibition	%		CHEMBL3116	Homo sapiens	INH		
Not Active	23317326	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	93.0	CHEMBL3116	Homo sapiens	% Control	%	93.0
Not Active	23317794	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	96.0	CHEMBL3116	Homo sapiens	% Control	%	96.0
Not Active	23318464	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23318944	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23319583	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23320056	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23320734	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23321202	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	97.0	CHEMBL3116	Homo sapiens	% Control	%	97.0
Not Active	23321832	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	88.0	CHEMBL3116	Homo sapiens	% Control	%	88.0
Not Active	23322300	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	87.0	CHEMBL3116	Homo sapiens	% Control	%	87.0
Not Active	23322989	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	89.0	CHEMBL3116	Homo sapiens	% Control	%	89.0
Not Active	23323457	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	78.0	CHEMBL3116	Homo sapiens	% Control	%	78.0
Not Active	23324311	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	96.9	CHEMBL3116	Homo sapiens	% Control	%	96.9
Not Active	23324946	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	72.0	CHEMBL3116	Homo sapiens	% Control	%	72.0
Not Active	23325414	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23326061	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	92.0	CHEMBL3116	Homo sapiens	% Control	%	92.0
Not Active	23326529	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	78.0	CHEMBL3116	Homo sapiens	% Control	%	78.0
Not Active	23327229	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23327697	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23328284	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	86.0	CHEMBL3116	Homo sapiens	% Control	%	86.0
Not Active	23328752	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23329698	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23330166	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	79.0	CHEMBL3116	Homo sapiens	% Control	%	79.0
Not Active	23330922	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23331390	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23331977	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	85.5	CHEMBL3116	Homo sapiens	% Control	%	85.5
Not Active	23332445	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23333161	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23333800	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23334268	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23335247	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	78.0	CHEMBL3116	Homo sapiens	% Control	%	78.0
Not Active	23335715	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23336342	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23336810	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23337543	CHEMBL4881914	CDK9CYCLIN Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	102.5	CHEMBL3116	Homo sapiens	% Ctrl	%	102.5
Not Active	23337891	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	96.0	CHEMBL3116	Homo sapiens	% Control	%	96.0
Not Active	23338359	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23338971	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23339439	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	78.0	CHEMBL3116	Homo sapiens	% Control	%	78.0
Not Active	23340076	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23340544	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23341201	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23341669	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	84.0	CHEMBL3116	Homo sapiens	% Control	%	84.0
Not Active	23342285	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	95.0	CHEMBL3116	Homo sapiens	% Control	%	95.0
Not Active	23342753	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23343383	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	97.0	CHEMBL3116	Homo sapiens	% Control	%	97.0
Not Active	23343851	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	82.0	CHEMBL3116	Homo sapiens	% Control	%	82.0
Not Active	23344489	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	97.0	CHEMBL3116	Homo sapiens	% Control	%	97.0
Not Active	23345062	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	83.0	CHEMBL3116	Homo sapiens	% Control	%	83.0
Not Active	23345530	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23346107	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23346576	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23347185	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	95.4	CHEMBL3116	Homo sapiens	% Control	%	95.4
Not Active	23347667	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23348246	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23348714	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23349301	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23349919	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	97.0	CHEMBL3116	Homo sapiens	% Control	%	97.0
Not Active	23350387	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23350992	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23351460	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23352484	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	80.0	CHEMBL3116	Homo sapiens	% Control	%	80.0
Not Active	23352952	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	84.0	CHEMBL3116	Homo sapiens	% Control	%	84.0
Not Active	23353834	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23354302	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23355034	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23355502	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23356138	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23356606	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23357215	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	89.0	CHEMBL3116	Homo sapiens	% Control	%	89.0
Not Active	23357862	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	93.0	CHEMBL3116	Homo sapiens	% Control	%	93.0
Not Active	23358330	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23358916	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	78.6	CHEMBL3116	Homo sapiens	% Control	%	78.6
Not Active	23359514	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	84.0	CHEMBL3116	Homo sapiens	% Control	%	84.0
Not Active	23359982	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23360567	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23361035	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23361608	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	87.0	CHEMBL3116	Homo sapiens	% Control	%	87.0
Not Active	23362144	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23362612	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23364254	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23364722	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23365461	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	94.0	CHEMBL3116	Homo sapiens	% Control	%	94.0
Not Active	23366004	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	99.0	CHEMBL3116	Homo sapiens	% Control	%	99.0
Not Active	23366594	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23367062	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23367509	CHEMBL4883862	CDK9/CycT ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	103.0	CHEMBL3116	Homo sapiens	% Residual activity with Skepinone-L	%	103.0
Not Active	23367940	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	93.0	CHEMBL3116	Homo sapiens	% Control	%	93.0
Not Active	23368408	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	87.0	CHEMBL3116	Homo sapiens	% Control	%	87.0
Not Active	23369007	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23369475	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23370443	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	94.0	CHEMBL3116	Homo sapiens	% Control	%	94.0
Not Active	23370911	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23371720	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23372188	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	87.0	CHEMBL3116	Homo sapiens	% Control	%	87.0
	23372696	CHEMBL4884661	CDK9(CDK9CGS1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL3116	Homo sapiens	pIC50		6.0
	23373105	CHEMBL4884952	CDK9(CDK9CGS1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL3116	Homo sapiens	pIC50		6.0
	23373466	CHEMBL4885243	CDK9(CDK9CGS1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL3116	Homo sapiens	pIC50		6.0
Not Active	23375615	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	97.0	CHEMBL3116	Homo sapiens	% Control	%	97.0
Not Active	23376083	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23376660	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	95.0	CHEMBL3116	Homo sapiens	% Control	%	95.0
Not Active	23377130	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23377988	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	85.0	CHEMBL3116	Homo sapiens	% Control	%	85.0
Not Active	23378456	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	91.0	CHEMBL3116	Homo sapiens	% Control	%	91.0
Not Active	23379623	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	99.0	CHEMBL3116	Homo sapiens	% Control	%	99.0
Not Active	23380091	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	88.0	CHEMBL3116	Homo sapiens	% Control	%	88.0
Not Active	23380785	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23381433	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23381901	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
Not Active	23382525	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	86.0	CHEMBL3116	Homo sapiens	% Control	%	86.0
Not Active	23382993	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	84.0	CHEMBL3116	Homo sapiens	% Control	%	84.0
Not Active	23383604	CHEMBL4887264	CDK9 (INACTIVE) Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	91.0	CHEMBL3116	Homo sapiens	% Ctrl	%	91.0
Not Active	23383732	CHEMBL4887380	CDK9CYCLIN Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	86.0	CHEMBL3116	Homo sapiens	% Ctrl	%	86.0
Not Active	23384908	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	85.0	CHEMBL3116	Homo sapiens	% Control	%	85.0
Not Active	23385375	CHEMBL4879632	KinomeScan assay: inhibition of CDK9	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL3116	Homo sapiens	% Control	%	100.0
